Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Razelle Kurzrock MD

Razelle Kurzrock MD profile photo picture

Center Associate Director, Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Hematology

Member of the Cancer Center


Leadership Positions

  • Associate Director of Clinical Research, Cancer Center
  • Associate Director of Clinical Research, GSPMC
  • Publications (936)

  • Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies (Gupta D, Kurzrock R, Lee S, Okamura R, Lim HJ, Kim KH, Sicklick JK, Kato S) npj Precision Oncology December 2022;6(1) SCOPUS ID: 2-s2.0-85127279352 12/01/2022       1 Citation
  • Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting. (Kato S, Li B, Adashek JJ, Cha SW, Bianchi-Frias D, Qian D, Kim L, So TW, Mitchell M, Kamei N, Hoiness R, Hoo J, Gray PN, Iyama T, Kashiwagi M, Lu HM, Kurzrock R) Oncoimmunology 2022;11(1):2052410 PMID: 35371621 PMCID: PMC8966985 SCOPUS ID: 2-s2.0-85127471090 04/05/2022    
  • A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. (Solomon B, Callejo A, Bar J, Berchem G, Bazhenova L, Saintigny P, Wunder F, Raynaud J, Girard N, Lee JJ, Sulaiman R, Prouse B, Bresson C, Ventura H, Magidi S, Rubin E, Young B, Onn A, Leyland-Jones B, Schilsky RL, Lazar V, Felip E, Kurzrock R) Cancer Med 2022 Mar 20 PMID: 35307972 SCOPUS ID: 2-s2.0-85126533919 03/22/2022    
  • Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy (Magbanua MJM, Gumusay O, Kurzrock R, van ‘t Veer LJ, Rugo HS) Frontiers in Oncology 15 March 2022;12 SCOPUS ID: 2-s2.0-85127474955 03/15/2022    
  • Precision medicine-based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience. (Louie BH, Kato S, Kim KH, Lim HJ, Lee S, Okamura R, Fanta PT, Kurzrock R) Mol Oncol 2022 Mar 03 PMID: 35238467 SCOPUS ID: 2-s2.0-85127555414 03/04/2022    
  • Association of differential expression of immunoregulatory molecules and presence of targetable mutations may inform rational design of clinical trials. (Szeto CW, Kurzrock R, Kato S, Goloubev A, Veerapaneni S, Preble A, Reddy SK, Adashek JJ) ESMO Open 2022 02;7(1):100396 PMID: 35158206 PMCID: PMC8850727 SCOPUS ID: 2-s2.0-85124383503 02/15/2022       1 Citation
  • Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench. (Subbiah V, Kurzrock R) Oncotarget 2022;13:13-15 PMID: 35018215 PMCID: PMC8730288 01/13/2022    
  • Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine. (Charo LM, Eskander RN, Sicklick J, Kim KH, Lim HJ, Okamura R, Lee S, Subramanian R, Schwab R, Shatsky R, Plaxe S, Kato S, Kurzrock R) JCO Precis Oncol 2022 01;6:e2000508 PMID: 35005995 PMCID: PMC8769125 SCOPUS ID: 2-s2.0-85124303205 01/11/2022    
  • Hyperprogression in Gastric Cancer: Is MDM2 Amplification the Dark Horse? (Dayyani F, Kato S, Kurzrock R) JCO Precis Oncol 2021 11;5:931-932 PMID: 34994620 SCOPUS ID: 2-s2.0-85108545311 01/08/2022       1 Citation
  • Progression-free survival 2: Is it ready for prime time? (George B, Kurzrock R) Cancer 2022 04 01;128(7):1361-1362 PMID: 34985767 SCOPUS ID: 2-s2.0-85122309248 01/06/2022    
  • Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench (Subbiah V, Kurzrock R) Oncotarget 2022;13:13-15 SCOPUS ID: 2-s2.0-85125711902 01/01/2022    
  • Cutaneous perivascular epithelioid cell tumor (PEComa): case report and world literature review of clinical and molecular characteristics (Cohen PR, Kato SM, Erickson CP, Calame A, Kurzrock R) Dermatology Online Journal 2022;28(1) SCOPUS ID: 2-s2.0-85129208467 01/01/2022    
  • Analysis of CDK12 alterations in a pan-cancer database. (Pan E, Cabal A, Javier-DesLoges J, Patel D, Panian J, Lee S, Shaya J, Nonato T, Xu X, Stewart T, Rose B, Shabaik A, Cohen E, Kurzrock R, Tamayo P, McKay RR) Cancer Med 2022 02;11(3):753-763 PMID: 34898046 PMCID: PMC8817093 SCOPUS ID: 2-s2.0-85120979954 12/14/2021    
  • Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. (Friedman CF, Hainsworth JD, Kurzrock R, Spigel DR, Burris HA, Sweeney CJ, Meric-Bernstam F, Wang Y, Levy J, Grindheim J, Shames DS, Schulze K, Patel A, Swanton C) Cancer Discov 2022 03 01;12(3):654-669 PMID: 34876409 SCOPUS ID: 2-s2.0-85125964453 12/09/2021       2 Citations
  • Therapeutic implications of cancer gene amplifications without mRNA overexpression: silence may not be golden. (Boichard A, Lippman SM, Kurzrock R) J Hematol Oncol 2021 12 02;14(1):201 PMID: 34857015 PMCID: PMC8638100 SCOPUS ID: 2-s2.0-85120746940 12/04/2021    
  • Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary. (Kato S, Weipert C, Gumas S, Okamura R, Lee S, Sicklick JK, Saam J, Kurzrock R) JCO Precis Oncol 2021;5 PMID: 34778692 PMCID: PMC8585281 11/16/2021    
  • A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609). (Adams S, Othus M, Patel SP, Miller KD, Chugh R, Schuetze SM, Chamberlin MD, Haley BJ, Storniolo AMV, Reddy MP, Anderson SA, Zimmerman CT, O'Dea AP, Mirshahidi HR, Ahnert JR, Brescia FJ, Hahn O, Raymond JM, Biggs DD, Connolly RM, Sharon E, Korde LA, Gray RJ, Mayerson E, Plets M, Blanke CD, Chae YK, Kurzrock R) Clin Cancer Res 2022 01 15;28(2):271-278 PMID: 34716198 PMCID: PMC8776596 SCOPUS ID: 2-s2.0-85123369221 10/31/2021       1 Citation
  • Assessing CAR T-Cell Therapy Response Using Genome-Wide Sequencing of Cell-Free DNA in Patients With B-Cell Lymphomas. (Goodman AM, Holden KA, Jeong AR, Kim L, Fitzgerald KD, Almasri E, McLennan G, Eisenberg M, Jahromi AH, Hoh C, Hurley M, Mulroney C, Tzachanis D, Ball ED, Jensen TJ, Kurzrock R) Transplant Cell Ther 2022 01;28(1):30.e1-30.e7 PMID: 34655803 SCOPUS ID: 2-s2.0-85119147439 10/17/2021       1 Citation
  • SMARCA4: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy. (Mardinian K, Adashek JJ, Botta GP, Kato S, Kurzrock R) Mol Cancer Ther 2021 12;20(12):2341-2351 PMID: 34642211 PMCID: PMC8643328 SCOPUS ID: 2-s2.0-85120778693 10/14/2021       3 Citations
  • Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers. (Pham TV, Goodman AM, Sivakumar S, Frampton G, Kurzrock R) Genome Med 2021 10 12;13(1):159 PMID: 34641956 PMCID: PMC8513181 SCOPUS ID: 2-s2.0-85117302727 10/14/2021       2 Citations
  • Targeting ARID1A mutations in cancer. (Mullen J, Kato S, Sicklick JK, Kurzrock R) Cancer Treat Rev 2021 Nov;100:102287 PMID: 34619527 SCOPUS ID: 2-s2.0-85116342891 10/08/2021       2 Citations
  • Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study. (Sicklick JK, Kato S, Okamura R, Patel H, Nikanjam M, Fanta PT, Hahn ME, De P, Williams C, Guido J, Solomon BM, McKay RR, Krie A, Boles SG, Ross JS, Lee JJ, Leyland-Jones B, Lippman SM, Kurzrock R) Genome Med 2021 10 04;13(1):155 PMID: 34607609 PMCID: PMC8491393 SCOPUS ID: 2-s2.0-85116352781 10/06/2021       5 Citations
  • Variant allele fraction of genomic alterations in circulating tumor DNA (%ctDNA) correlates with SUVmax in PET scan. (Haghighat Jahromi A, Zabel M, Okamura R, Hoh CK, Kurzrock R) Am J Nucl Med Mol Imaging 2021;11(4):307-312 PMID: 34513284 PMCID: PMC8414395 09/14/2021    
  • Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not Feasible. (Jensen TJ, Goodman AM, Ellison CK, Holden KA, Kato S, Kim L, Daniels GA, Fitzgerald K, McCarthy E, Nakashe P, Mazloom AR, Almasri E, McLennan G, Grosu DS, Eisenberg M, Kurzrock R) Mol Cancer Ther 2021 11;20(11):2274-2279 PMID: 34465593 SCOPUS ID: 2-s2.0-85119045480 09/02/2021       1 Citation
  • Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease. (Goodman AM, Jeong AR, Phillips A, Wang HY, Sokol ES, Cohen PR, Sicklick J, Fajgenbaum DC, Kurzrock R) Eur J Haematol 2021 Dec;107(6):642-649 PMID: 34431136 SCOPUS ID: 2-s2.0-85115257192 08/26/2021       1 Citation
  • Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response. (Yebra M, Bhargava S, Kumar A, Burgoyne AM, Tang CM, Yoon H, Banerjee S, Aguilera J, Cordes T, Sheth V, Noh S, Ustoy R, Li S, Advani SJ, Corless CL, Heinrich MC, Kurzrock R, Lippman SM, Fanta PT, Harismendy O, Metallo C, Sicklick JK) Clin Cancer Res 2022 01 01;28(1):187-200 PMID: 34426440 PMCID: PMC8738129 SCOPUS ID: 2-s2.0-85122921894 08/25/2021       3 Citations
  • Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer. (Tsimberidou AM, Shaw JV, Juric D, Verschraegen C, Weise AM, Sarantopoulos J, Lopes G, Nemunaitis J, Mita M, Park H, Ellers-Lenz B, Tian H, Xiong W, Kaleta R, Kurzrock R) J Hematol Oncol 2021 08 18;14(1):127 PMID: 34407844 PMCID: PMC8371902 SCOPUS ID: 2-s2.0-85112781061 08/20/2021       4 Citations
  • Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). (Wagner MJ, Othus M, Patel SP, Ryan C, Sangal A, Powers B, Budd GT, Victor AI, Hsueh CT, Chugh R, Nair S, Leu KM, Agulnik M, Sharon E, Mayerson E, Plets M, Blanke C, Streicher H, Chae YK, Kurzrock R) J Immunother Cancer 2021 08;9(8) PMID: 34380663 PMCID: PMC8330584 SCOPUS ID: 2-s2.0-85114117626 08/13/2021       15 Citations
  • SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. (Botta GP, Kato S, Patel H, Fanta P, Lee S, Okamura R, Kurzrock R) JCI Insight 2021 09 22;6(18) PMID: 34375311 PMCID: PMC8492298 SCOPUS ID: 2-s2.0-85115979107 08/11/2021       4 Citations
  • Missing the target in cancer therapy. (Adashek JJ, Goloubev A, Kato S, Kurzrock R) Nat Cancer 2021 04;2:369-371 PMID: 34368781 PMCID: PMC8336921 SCOPUS ID: 2-s2.0-85104144709 08/10/2021       2 Citations
  • Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. (Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, Hainsworth J, Meric-Bernstam F, Swanton C, Sweeney CJ, Friedman CF, Bose R, Spigel DR, Wang Y, Levy J, Schulze K, Cuchelkar V, Patel A, Burris H) Lancet Oncol 2021 09;22(9):1290-1300 PMID: 34339623 SCOPUS ID: 2-s2.0-85113412076 08/03/2021       33 Citations
  • The Impact of COVID-19 on Cancer Clinical Trials Conducted by NCI-Designated Comprehensive Cancer Centers. (Gupta D, Kato S, Kurzrock R) J Immunother Precis Oncol 2021 May;4(2):56-63 PMID: 34337550 PMCID: PMC8320380 08/03/2021    
  • Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening. (Adashek JJ, Janku F, Kurzrock R) Cancers (Basel) 2021 Jul 18;13(14) PMID: 34298813 PMCID: PMC8306582 SCOPUS ID: 2-s2.0-85110160476 07/25/2021       6 Citations
  • Comparative Genomic Analysis of Intrahepatic Cholangiocarcinoma: Biopsy Type, Ancestry, and Testing Patterns. (Israel MA, Danziger N, McGregor KA, Murugesan K, Gjoerup O, Sokol ES, Tukachinsky H, Kurzrock R, Kato S, Sicklick JK, Nimeiri HS, Oxnard GR, Ross JS) Oncologist 2021 09;26(9):787-796 PMID: 34080753 PMCID: PMC8417854 SCOPUS ID: 2-s2.0-85108120634 06/04/2021       2 Citations
  • Moving Beyond 3+3: The Future of Clinical Trial Design. (Kurzrock R, Lin CC, Wu TC, Hobbs BP, Pestana RC MD, Hong DS) Am Soc Clin Oncol Educ Book 2021 Jun;41:e133-e144 PMID: 34061563 06/02/2021    
  • Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. (Lazar V, Magidi S, Girard N, Savignoni A, Martini JF, Massimini G, Bresson C, Berger R, Onn A, Raynaud J, Wunder F, Berindan-Neagoe I, Sekacheva M, Braña I, Tabernero J, Felip E, Porgador A, Kleinman C, Batist G, Solomon B, Tsimberidou AM, Soria JC, Rubin E, Kurzrock R, Schilsky RL) NPJ Precis Oncol 2021 Apr 28;5(1):33 PMID: 33911192 PMCID: PMC8080819 SCOPUS ID: 2-s2.0-85116954646 04/30/2021    
  • A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort. (Patel SP, Mayerson E, Chae YK, Strosberg J, Wang J, Konda B, Hayward J, McLeod CM, Chen HX, Sharon E, Othus M, Ryan CW, Plets M, Blanke CD, Kurzrock R) Cancer 2021 09 01;127(17):3194-3201 PMID: 33882143 PMCID: PMC8606104 SCOPUS ID: 2-s2.0-85104640638 04/22/2021       8 Citations
  • Functional measurement of mitogen-activated protein kinase pathway activation predicts responsiveness of RAS-mutant cancers to MEK inhibitors. (Kato S, Porter R, Okamura R, Lee S, Zelichov O, Tarcic G, Vidne M, Kurzrock R) Eur J Cancer 2021 05;149:184-192 PMID: 33865203 SCOPUS ID: 2-s2.0-85104075728 04/18/2021    
  • Tumor Lysis Syndrome: Introduction of a Cutaneous Variant and a New Classification System. (Cohen PR, Prieto VG, Kurzrock R) Cureus 2021 Mar 11;13(3):e13816 PMID: 33859885 PMCID: PMC8038896 04/17/2021    
  • Synthetic lethality-mediated precision oncology via the tumor transcriptome. (Lee JS, Nair NU, Dinstag G, Chapman L, Chung Y, Wang K, Sinha S, Cha H, Kim D, Schperberg AV, Srinivasan A, Lazar V, Rubin E, Hwang S, Berger R, Beker T, Ronai Z, Hannenhalli S, Gilbert MR, Kurzrock R, Lee SH, Aldape K, Ruppin E) Cell 2021 04 29;184(9):2487-2502.e13 PMID: 33857424 SCOPUS ID: 2-s2.0-85104146184 04/16/2021       7 Citations
  • Maternal to fetal transmission of cancer: implications for molecular tumor testing, immune regulation, and pediatric malignancies. (Eskander RN, Kurzrock R) Med (N Y) 2021 03 12;2(3):211-213 PMID: 33855310 PMCID: PMC8040028 SCOPUS ID: 2-s2.0-85122974985 04/16/2021    
  • Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker. (Fountzilas E, Kurzrock R, Hiep Vo H, Tsimberidou AM) J Natl Cancer Inst 2021 Apr 06 PMID: 33823006 04/07/2021    
  • STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications. (Krishnamurthy N, Goodman AM, Barkauskas DA, Kurzrock R) Eur J Cancer 2021 05;148:215-229 PMID: 33744718 SCOPUS ID: 2-s2.0-85102865132 03/22/2021       5 Citations
  • BRAF V600E/V600K Mutations versus Nonstandard Alterations: Prognostic Implications and Therapeutic Outcomes. (Nikanjam M, Tinajero J, Barkauskas DA, Kurzrock R) Mol Cancer Ther 2021 06;20(6):1072-1079 PMID: 33722853 SCOPUS ID: 2-s2.0-85107007438 03/17/2021       3 Citations
  • A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. (Ribrag V, Lee ST, Rizzieri D, Dyer MJS, Fayad L, Kurzrock R, Andritsos L, Bouabdallah R, Hayat A, Bacon L, Jiang Y, Miah K, Delafont B, Hamid O, Anyanwu S, Martinez P, Hess B) Clin Lymphoma Myeloma Leuk 2021 05;21(5):309-317.e3 PMID: 33632668 SCOPUS ID: 2-s2.0-85101261976 02/27/2021       4 Citations
  • Cutaneous Metastatic Cancer: Carcinoma Hemorrhagiectoides Presenting as the Shield Sign. (Cohen PR, Kurzrock R) Cureus 2021 Jan 11;13(1):e12627 PMID: 33585116 PMCID: PMC7872488 02/16/2021    
  • Immune profiling and immunotherapeutic targets in pancreatic cancer. (Lenzo FL, Kato S, Pabla S, DePietro P, Nesline MK, Conroy JM, Burgher B, Glenn ST, Kuvshinoff B, Kurzrock R, Morrison C) Ann Transl Med 2021 Jan;9(2):119 PMID: 33569421 PMCID: PMC7867882 02/12/2021    
  • Bilateral Postprocedural Rhinitis After Intravenous Sedation With Supplemental Nasal Oxygen (PRAISE SNOG) After Cataract Surgery. (Cohen PR, Coden DJ, Kurzrock R) Cureus 2021 Jan 03;13(1):e12452 PMID: 33552770 PMCID: PMC7853694 02/09/2021    
  • Balancing clinical evidence in the context of a pandemic. (Adashek JJ, Kurzrock R) Nat Biotechnol 2021 03;39(3):270-274 PMID: 33547424 SCOPUS ID: 2-s2.0-85100502862 02/07/2021    
  • KRAS-Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery. (Kato S, McFall T, Takahashi K, Bamel K, Ikeda S, Eskander RN, Plaxe S, Parker B, Stites E, Kurzrock R) Oncologist 2021 04;26(4):e530-e536 PMID: 33528846 PMCID: PMC8018312 SCOPUS ID: 2-s2.0-85101866994 02/03/2021       3 Citations
  • Landscape of Cyclin Pathway Genomic Alterations Across 5,356 Prostate Cancers: Implications for Targeted Therapeutics. (Jardim DL, Millis SZ, Ross JS, Woo MS, Ali SM, Kurzrock R) Oncologist 2021 04;26(4):e715-e718 PMID: 33522043 PMCID: PMC8018295 SCOPUS ID: 2-s2.0-85100903779 02/02/2021    
  • Cancer of Unknown Primary in the Molecular Era. (Kato S, Alsafar A, Walavalkar V, Hainsworth J, Kurzrock R) Trends Cancer 2021 05;7(5):465-477 PMID: 33516660 PMCID: PMC8062281 SCOPUS ID: 2-s2.0-85100033256 02/01/2021       3 Citations
  • High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment. (Okamura R, Piccioni DE, Boichard A, Lee S, Jimenez RE, Sicklick JK, Kato S, Kurzrock R) Int J Cancer 2021 06 01;148(11):2839-2847 PMID: 33497479 PMCID: PMC8048515 SCOPUS ID: 2-s2.0-85100514305 01/27/2021       2 Citations
  • Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics. (Kato S, Adashek JJ, Shaya J, Okamura R, Jimenez RE, Lee S, Sicklick JK, Kurzrock R) Clin Cancer Res 2021 05 15;27(10):2792-2797 PMID: 33472910 SCOPUS ID: 2-s2.0-85102781995 01/22/2021       4 Citations
  • Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor-based regimens. (Kato S, Okamura R, Adashek JJ, Khalid N, Lee S, Nguyen V, Sicklick JK, Kurzrock R) JCI Insight 2021 01 11;6(1) PMID: 33427211 PMCID: PMC7821594 SCOPUS ID: 2-s2.0-85099304467 01/12/2021       6 Citations
  • The impact of COVID-19 on cancer clinical trials conducted by nci-designated comprehensive cancer centers (Gupta D, Kato S, Kurzrock R) Journal of Immunotherapy and Precision Oncology 2021;4(2):56-63 SCOPUS ID: 2-s2.0-85107201900 01/01/2021       3 Citations
  • Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients. (Haghighat Jahromi A, Barkauskas DA, Zabel M, Goodman AM, Frampton G, Nikanjam M, Hoh CK, Kurzrock R) EJNMMI Res 2020 Dec 09;10(1):150 PMID: 33296034 PMCID: PMC7726049 SCOPUS ID: 2-s2.0-85097423621 12/10/2020       2 Citations
  • International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. (van Rhee F, Oksenhendler E, Srkalovic G, Voorhees P, Lim M, Dispenzieri A, Ide M, Parente S, Schey S, Streetly M, Wong R, Wu D, Maillard I, Brandstadter J, Munshi N, Bowne W, Elenitoba-Johnson KS, Fössa A, Lechowicz MJ, Chandrakasan S, Pierson SK, Greenway A, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Chadburn A, Fajgenbaum DC) Blood Adv 2020 12 08;4(23):6039-6050 PMID: 33284946 PMCID: PMC7724917 SCOPUS ID: 2-s2.0-85098082934 12/08/2020       21 Citations
  • Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden. (Gong J, Patel S, Adashek JJ, Frishberg D, Guan M, Placencio-Hickok VR, Gangi A, Gresham G, Tuli R, Chae YK, Kurzrock R, Hendifar AE) JCO Precis Oncol 2020;4 PMID: 33215052 PMCID: PMC7670562 SCOPUS ID: 2-s2.0-85086177081 11/21/2020    
  • Standardized uptake value (SUVmax) in 18F-FDG PET/CT is correlated with the total number of main oncogenic anomalies in cancer patients. (Haghighat Jahromi A, Chang G, Kurzrock R, Hoh CK) Cancer Biol Ther 2020 11 01;21(11):1067-1071 PMID: 33131408 PMCID: PMC7678945 SCOPUS ID: 2-s2.0-85094911689 11/03/2020       1 Citation
  • The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. (Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R) Cancer Cell 2021 02 08;39(2):154-173 PMID: 33125859 PMCID: PMC7878292 SCOPUS ID: 2-s2.0-85095988063 10/31/2020       64 Citations
  • Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. (Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA) Clin Cancer Res 2020 11 01;26(21):5579-5587 PMID: 33055173 SCOPUS ID: 2-s2.0-85100892622 10/16/2020       7 Citations
  • Unique Genomic Landscape of High-Grade Neuroendocrine Cervical Carcinoma: Implications for Rethinking Current Treatment Paradigms. (Eskander RN, Elvin J, Gay L, Ross JS, Miller VA, Kurzrock R) JCO Precis Oncol 2020;4 PMID: 33015532 PMCID: PMC7529537 SCOPUS ID: 2-s2.0-85092691697 10/06/2020       6 Citations
  • Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. (Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, Kuo DJ, Eskander RN, Goodman A, Galanina N, Fanta PT, Schwab RB, Shatsky R, Plaxe SC, Sharabi A, Stites E, Adashek JJ, Okamura R, Lee S, Lippman SM, Sicklick JK, Kurzrock R) Nat Commun 2020 10 02;11(1):4965 PMID: 33009371 PMCID: PMC7532150 SCOPUS ID: 2-s2.0-85091838131 10/04/2020       53 Citations
  • From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm. (Adashek JJ, Subbiah V, Kurzrock R) Trends Cancer 2021 01;7(1):15-28 PMID: 33008795 SCOPUS ID: 2-s2.0-85091803111 10/04/2020       24 Citations
  • Survival Implications of the Relationship between Tissue versus Circulating Tumor DNA TP53 Mutations-A Perspective from a Real-World Precision Medicine Cohort. (Rosenberg S, Okamura R, Kato S, Soussi T, Kurzrock R) Mol Cancer Ther 2020 12;19(12):2612-2620 PMID: 32999047 SCOPUS ID: 2-s2.0-85100512510 10/02/2020       2 Citations
  • Transcriptomics and solid tumors: The next frontier in precision cancer medicine. (Tsimberidou AM, Fountzilas E, Bleris L, Kurzrock R) Semin Cancer Biol 2020 Sep 17 PMID: 32950605 SCOPUS ID: 2-s2.0-85092169088 09/21/2020       14 Citations
  • Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT Experience. (Bohan SS, Sicklick JK, Kato S, Okamura R, Miller VA, Leyland-Jones B, Lippman SM, Kurzrock R) Oncologist 2020 11;25(11):e1803-e1806 PMID: 32949172 PMCID: PMC7648352 SCOPUS ID: 2-s2.0-85091863651 09/20/2020       2 Citations
  • Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients. (Zhang T, Pabla S, Lenzo FL, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Giamo V, Andreas J, Wang Y, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Gupta R, Zhu J, Labriola M, McCall S, George DJ, Ghatalia P, Dayyani F, Edwards R, Park MS, Singh R, Jacob R, George S, Xu B, Zibelman M, Kurzrock R, Morrison C) Oncoimmunology 2020 06 10;9(1):1773200 PMID: 32923131 PMCID: PMC7458647 SCOPUS ID: 2-s2.0-85087017373 09/15/2020       6 Citations
  • Total Number of Alterations in Liquid Biopsies Is an Independent Predictor of Survival in Patients With Advanced Cancers. (Vu P, Khagi Y, Riviere P, Goodman A, Kurzrock R) JCO Precis Oncol 2020;4 PMID: 32923910 PMCID: PMC7450932 SCOPUS ID: 2-s2.0-85086463706 09/15/2020       5 Citations
  • Tumor mutational burden is not predictive of cytotoxic chemotherapy response. (Nikanjam M, Riviere P, Goodman A, Barkauskas DA, Frampton G, Kurzrock R) Oncoimmunology 2020 06 24;9(1):1781997 PMID: 32923144 PMCID: PMC7458654 SCOPUS ID: 2-s2.0-85087501507 09/15/2020       1 Citation
  • Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large-Scale Data to Inform Therapeutic Directions. (Jardim DL, Millis SZ, Ross JS, Woo MS, Ali SM, Kurzrock R) Oncologist 2021 01;26(1):e78-e89 PMID: 32885893 PMCID: PMC7794175 SCOPUS ID: 2-s2.0-85090938872 09/05/2020       6 Citations
  • Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients. (Charo LM, Eskander RN, Okamura R, Patel SP, Nikanjam M, Lanman RB, Piccioni DE, Kato S, McHale MT, Kurzrock R) Mol Oncol 2021 01;15(1):67-79 PMID: 32881280 PMCID: PMC7782073 SCOPUS ID: 2-s2.0-85090996729 09/04/2020       9 Citations
  • BAP1: Not just a BRCA1-associated protein. (Louie BH, Kurzrock R) Cancer Treat Rev 2020 Nov;90:102091 PMID: 32877777 PMCID: PMC7655689 SCOPUS ID: 2-s2.0-85089944563 09/03/2020       33 Citations
  • Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer. (Adashek JJ, Arroyo-Martinez Y, Menta AK, Kurzrock R, Kato S) Front Oncol 2020;10:1312 PMID: 32850413 PMCID: PMC7418523 SCOPUS ID: 2-s2.0-85089820827 08/28/2020       6 Citations
  • Selpercatinib Aimed at RET-Altered Cancers. (Kurzrock R) N Engl J Med 2020 08 27;383(9):868-869 PMID: 32846067 SCOPUS ID: 2-s2.0-85089977563 08/28/2020       7 Citations
  • Letter responds to comment on "intention-to-treat analysis in precision oncology: A cautious interpretation". (Sicklick J, Kato S, Kurzrock R) Eur J Cancer 2020 10;138:228 PMID: 32839070 SCOPUS ID: 2-s2.0-85090167022 08/26/2020    
  • Circulating Tumor Cells: From the Laboratory to the Cancer Clinic. (Agashe R, Kurzrock R) Cancers (Basel) 2020 Aug 21;12(9) PMID: 32825548 PMCID: PMC7564158 SCOPUS ID: 2-s2.0-85090543373 08/23/2020       10 Citations
  • The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians. (Subbiah V, Solit DB, Chan TA, Kurzrock R) Ann Oncol 2020 09;31(9):1115-1118 PMID: 32771306 SCOPUS ID: 2-s2.0-85089498915 08/11/2020       62 Citations
  • Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases. (Baumgartner JM, Riviere P, Lanman RB, Kelly KJ, Veerapong J, Lowy AM, Kurzrock R) Ann Surg Oncol 2020 Sep;27(9):3259-3267 PMID: 32767050 PMCID: PMC7470602 SCOPUS ID: 2-s2.0-85089118363 08/09/2020       4 Citations
  • Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy. (Cohen PR, Nikanjam M, Kato S, Goodman AM, Kurzrock R) Cureus 2020 Jul 02;12(7):e8967 PMID: 32766009 PMCID: PMC7398726 08/09/2020    
  • High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers. (Riviere P, Goodman AM, Okamura R, Barkauskas DA, Whitchurch TJ, Lee S, Khalid N, Collier R, Mareboina M, Frampton GM, Fabrizio D, Sharabi AB, Kato S, Kurzrock R) Mol Cancer Ther 2020 10;19(10):2139-2145 PMID: 32747422 PMCID: PMC7541603 SCOPUS ID: 2-s2.0-85092500317 08/05/2020       18 Citations
  • Machine learning model to predict oncologic outcomes for drugs in randomized clinical trials. (Schperberg AV, Boichard A, Tsigelny IF, Richard SB, Kurzrock R) Int J Cancer 2020 11 01;147(9):2537-2549 PMID: 32745254 SCOPUS ID: 2-s2.0-85089666955 08/04/2020       1 Citation
  • Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. (Okamura R, Kurzrock R, Mallory RJ, Fanta PT, Burgoyne AM, Clary BM, Kato S, Sicklick JK) Int J Cancer 2021 02 01;148(3):702-712 PMID: 32700810 PMCID: PMC7739197 SCOPUS ID: 2-s2.0-85089978472 07/24/2020       13 Citations
  • Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing. (Boichard A, Wagner MJ, Kurzrock R) Genome Med 2020 07 09;12(1):61 PMID: 32646514 PMCID: PMC7350570 SCOPUS ID: 2-s2.0-85087804311 07/11/2020       13 Citations
  • IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. (Amin HM, Morani AC, Daw NC, Lamhamedi-Cherradi SE, Subbiah V, Menegaz BA, Vishwamitra D, Eskandari G, George B, Benjamin RS, Patel S, Song J, Lazar AJ, Wang WL, Kurzrock R, Pappo A, Anderson PM, Schwartz GK, Araujo D, Cuglievan B, Ratan R, McCall D, Mohiuddin S, Livingston JA, Molina ER, Naing A, Ludwig JA) Cancers (Basel) 2020 Jul 02;12(7) PMID: 32630797 PMCID: PMC7408058 SCOPUS ID: 2-s2.0-85087414605 07/08/2020       12 Citations
  • Reply to "Effective therapy for advanced basal cell carcinoma". (Cohen PR, Kurzrock R) J Am Acad Dermatol 2022 03;86(3):e109 PMID: 32615156 SCOPUS ID: 2-s2.0-85089992251 07/03/2020       1 Citation
  • Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy. (Pham TV, Boichard A, Goodman A, Riviere P, Yeerna H, Tamayo P, Kurzrock R) Mol Oncol 2020 08;14(8):1680-1694 PMID: 32530570 PMCID: PMC7400787 SCOPUS ID: 2-s2.0-85087573711 06/13/2020       10 Citations
  • Transcriptomic silencing as a potential mechanism of treatment resistance. (Adashek JJ, Kato S, Parulkar R, Szeto CW, Sanborn JZ, Vaske CJ, Benz SC, Reddy SK, Kurzrock R) JCI Insight 2020 06 04;5(11) PMID: 32493840 PMCID: PMC7308055 SCOPUS ID: 2-s2.0-85086008367 06/05/2020       14 Citations
  • New therapeutic approaches to overcoming resistant EGFR exon 20 alterations. (Li AM, Boichard A, Felip E, Kurzrock R) Crit Rev Oncol Hematol 2020 Jul;151:102990 PMID: 32485428 PMCID: PMC7416421 SCOPUS ID: 2-s2.0-85085564380 06/03/2020       4 Citations
  • MHC-I genotype and tumor mutational burden predict response to immunotherapy. (Goodman AM, Castro A, Pyke RM, Okamura R, Kato S, Riviere P, Frampton G, Sokol E, Zhang X, Ball ED, Carter H, Kurzrock R) Genome Med 2020 05 19;12(1):45 PMID: 32430031 PMCID: PMC7236948 SCOPUS ID: 2-s2.0-85084962181 05/21/2020       30 Citations
  • Precision oncology: the intention-to-treat analysis fallacy. (Sicklick JK, Kato S, Okamura R, Kurzrock R) Eur J Cancer 2020 07;133:25-28 PMID: 32422506 PMCID: PMC7786388 SCOPUS ID: 2-s2.0-85084462817 05/19/2020       3 Citations
  • Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response. (Patel SP, Othus M, Chae YK, Kurzrock R, S1609 Team) Clin Cancer Res 2020 05 15;26(10):2434 PMID: 32414761 SCOPUS ID: 2-s2.0-85084785711 05/18/2020       1 Citation
  • Are Cancer Patients at Higher Risk of Death With COVID-19? (Adashek JJ, Hajjar J, Chemaly RF, Kurzrock R) J Immunother Precis Oncol 2020 May;3(2):49-51 PMID: 34532715 PMCID: PMC8442944 05/01/2020    
  • Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. (Subbiah V, Dumbrava EI, Jiang Y, Thein KZ, Naing A, Hong DS, Fu S, Piha-Paul SA, Tsimberidou AM, Janku F, Meric-Bernstam F, Kurzrock R, Falchook G) Exp Hematol Oncol 2020;9:7 PMID: 32337094 PMCID: PMC7171918 SCOPUS ID: 2-s2.0-85084392612 04/28/2020       7 Citations
  • ASO Author Reflections: Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases. (Baumgartner JM, Riviere P, Kurzrock R) Ann Surg Oncol 2020 Sep;27(9):3268-3269 PMID: 32303875 SCOPUS ID: 2-s2.0-85083564939 04/19/2020    
  • Review of precision cancer medicine: Evolution of the treatment paradigm. (Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R) Cancer Treat Rev 2020 Jun;86:102019 PMID: 32251926 PMCID: PMC7272286 SCOPUS ID: 2-s2.0-85082664741 04/07/2020       67 Citations
  • Snapshot: Trial Types in Precision Medicine. (Dickson D, Johnson J, Bergan R, Owens R, Subbiah V, Kurzrock R) Cell 2020 04 02;181(1):208-208.e1 PMID: 32243791 SCOPUS ID: 2-s2.0-85082412574 04/04/2020       4 Citations
  • Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden. (Bieg-Bourne CC, Okamura R, Kurzrock R) Mol Oncol 2020 06;14(6):1242-1251 PMID: 32187847 PMCID: PMC7266274 SCOPUS ID: 2-s2.0-85082967068 03/19/2020       7 Citations
  • Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. (Kato S, Okamura R, Kumaki Y, Ikeda S, Nikanjam M, Eskander R, Goodman A, Lee S, Glenn ST, Dressman D, Papanicolau-Sengos A, Lenzo FL, Morrison C, Kurzrock R) Oncoimmunology 2020;9(1):1708065 PMID: 32117584 PMCID: PMC7028323 SCOPUS ID: 2-s2.0-85079718496 03/03/2020       22 Citations
  • ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy. (Okamura R, Kato S, Lee S, Jimenez RE, Sicklick JK, Kurzrock R) J Immunother Cancer 2020 02;8(1) PMID: 32111729 PMCID: PMC7057434 SCOPUS ID: 2-s2.0-85081073370 03/01/2020       52 Citations
  • Basal cell carcinoma: Management of advanced or metastatic cancer with checkpoint inhibitors and concurrent paradoxical development of new superficial tumors. (Cohen PR, Kurzrock R) J Am Acad Dermatol 2020 06;82(6):e253-e254 PMID: 32109540 SCOPUS ID: 2-s2.0-85084370572 02/29/2020       5 Citations
  • Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. (Kurzrock R, Bowles DW, Kang H, Meric-Bernstam F, Hainsworth J, Spigel DR, Bose R, Burris H, Sweeney CJ, Beattie MS, Blotner S, Schulze K, Cuchelkar V, Swanton C) Ann Oncol 2020 03;31(3):412-421 PMID: 32067683 SCOPUS ID: 2-s2.0-85078335328 02/19/2020       39 Citations
  • The paradox of cancer genes in non-malignant conditions: implications for precision medicine. (Adashek JJ, Kato S, Lippman SM, Kurzrock R) Genome Med 2020 02 17;12(1):16 PMID: 32066498 PMCID: PMC7027240 SCOPUS ID: 2-s2.0-85079668519 02/19/2020       13 Citations
  • Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. (Tolcher AW, Kurzrock R, Valero V, Gonzalez R, Heist RS, Tan AR, Means-Powell J, Werner TL, Becerra C, Wang C, Leonowens C, Kalyana-Sundaram S, Kleha JF, Gauvin J, D'Amelio AM Jr, Ellis C, Ibrahim N, Yan L) Cancer Chemother Pharmacol 2020 04;85(4):673-683 PMID: 32062691 SCOPUS ID: 2-s2.0-85079720073 02/18/2020       19 Citations
  • Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress? (Adashek JJ, Kato S, Ferrara R, Lo Russo G, Kurzrock R) Oncologist 2020 02;25(2):94-98 PMID: 32043794 PMCID: PMC7011624 SCOPUS ID: 2-s2.0-85075390401 02/12/2020       26 Citations
  • Real-World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim-Chester Disease. (Saunders IM, Goodman AM, Kurzrock R) Oncologist 2020 02;25(2):e386-e390 PMID: 32043767 PMCID: PMC7011668 SCOPUS ID: 2-s2.0-85075299733 02/12/2020       7 Citations
  • Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. (van Rhee F, Casper C, Voorhees PM, Fayad LE, Gibson D, Kanhai K, Kurzrock R) Lancet Haematol 2020 Mar;7(3):e209-e217 PMID: 32027862 SCOPUS ID: 2-s2.0-85080079856 02/07/2020       17 Citations
  • New drug approvals in oncology. (Kurzrock R, Kantarjian HM, Kesselheim AS, Sigal EV) Nat Rev Clin Oncol 2020 03;17(3):140-146 PMID: 32020042 SCOPUS ID: 2-s2.0-85079116824 02/06/2020       14 Citations
  • Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. (Jardim DL, De Melo Gagliato D, Nikanjam M, Barkauskas DA, Kurzrock R) Oncoimmunology 2020;9(1):1710052 PMID: 32002305 PMCID: PMC6959453 SCOPUS ID: 2-s2.0-85078579289 02/01/2020       7 Citations
  • A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. (Patel SP, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A, Baghdadi TA, Matrana M, Gatalica Z, Korn WM, Hayward J, McLeod C, Chen HX, Sharon E, Mayerson E, Ryan CW, Plets M, Blanke CD, Kurzrock R) Clin Cancer Res 2020 05 15;26(10):2290-2296 PMID: 31969335 PMCID: PMC7231627 SCOPUS ID: 2-s2.0-85081687211 01/24/2020       97 Citations
  • The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine. (Dickson D, Johnson J, Bergan R, Owens R, Subbiah V, Kurzrock R) Cell 2020 01 09;180(1):9-14 PMID: 31951522 SCOPUS ID: 2-s2.0-85077474489 01/18/2020       20 Citations
  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments. (Boichard A, Richard SB, Kurzrock R) Cancers (Basel) 2020 Jan 09;12(1) PMID: 31936627 PMCID: PMC7017109 SCOPUS ID: 2-s2.0-85077905665 01/16/2020       5 Citations
  • Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. (Tsimberidou AM, Hong DS, Wheler JJ, Falchook GS, Janku F, Naing A, Fu S, Piha-Paul S, Cartwright C, Broaddus RR, Nogueras Gonzalez GM, Hwu P, Kurzrock R) J Hematol Oncol 2019 12 30;12(1):145 PMID: 31888672 PMCID: PMC6937824 SCOPUS ID: 2-s2.0-85077235900 01/01/2020       16 Citations
  • Repurposing Interleukin-6 Inhibitors to Combat COVID-19. (Kato S, Kurzrock R) J Immunother Precis Oncol 2020;3(2):52-55 PMID: 34169296 PMCID: PMC8221576 01/01/2020    
  • Are cancer patients at higher risk of death with covid-19? (Adashek JJ, Hajjar J, Chemaly RF, Kurzrock R) Journal of Immunotherapy and Precision Oncology 2020;3(2):49-51 SCOPUS ID: 2-s2.0-85102867194 01/01/2020       6 Citations
  • Repurposing interleukin-6 inhibitors to combat covid-19 (Kato S, Kurzrock R) Journal of Immunotherapy and Precision Oncology 2020;3(2):52-55 SCOPUS ID: 2-s2.0-85090670871 01/01/2020       2 Citations
  • First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. (Falchook GS, Kurzrock R, Amin HM, Xiong W, Fu S, Piha-Paul SA, Janku F, Eskandari G, Catenacci DV, Klevesath M, Bruns R, Stammberger U, Johne A, Bladt F, Friese-Hamim M, Girard P, El Bawab S, Hong DS) Clin Cancer Res 2020 03 15;26(6):1237-1246 PMID: 31822497 SCOPUS ID: 2-s2.0-85081944035 12/12/2019       41 Citations
  • Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. (Patel H, Okamura R, Fanta P, Patel C, Lanman RB, Raymond VM, Kato S, Kurzrock R) J Hematol Oncol 2019 12 04;12(1):130 PMID: 31801585 PMCID: PMC6894333 SCOPUS ID: 2-s2.0-85076053435 12/06/2019       37 Citations
  • Targeting fusions for improved outcomes in oncology treatment. (Nikanjam M, Okamura R, Barkauskas DA, Kurzrock R) Cancer 2020 03 15;126(6):1315-1321 PMID: 31794076 PMCID: PMC7050395 SCOPUS ID: 2-s2.0-85076090969 12/04/2019       4 Citations
  • Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies. (Kato S, Okamura R, Sicklick JK, Daniels GA, Hong DS, Goodman A, Weihe E, Lee S, Khalid N, Collier R, Mareboina M, Riviere P, Whitchurch TJ, Fanta PT, Lippman SM, Kurzrock R) Int J Cancer 2020 06 15;146(12):3450-3460 PMID: 31782524 SCOPUS ID: 2-s2.0-85078788986 11/30/2019       7 Citations
  • Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress? (Adashek JJ, Kato S, Ferrara R, Lo Russo G, Kurzrock R) Oncologist 2019 Nov 20 PMID: 31748338 SCOPUS ID: 2-s2.0-85075390401 11/22/2019       26 Citations
  • Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues. (Li AM, Boichard A, Kurzrock R) Cancer Biol Ther 2020;21(1):95-100 PMID: 31564192 PMCID: PMC7012180 SCOPUS ID: 2-s2.0-85073987308 10/01/2019       16 Citations
  • Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. (Falchook G, Rosen S, LoRusso P, Watts J, Gupta S, Coombs CC, Talpaz M, Kurzrock R, Mita M, Cassaday R, Harb W, Peguero J, Smith DC, Piha-Paul SA, Szmulewitz R, Noel MS, Yeleswaram S, Liu P, Switzky J, Zhou G, Zheng F, Mehta A) Clin Cancer Res 2020 03 15;26(6):1247-1257 PMID: 31527168 PMCID: PMC7528620 SCOPUS ID: 2-s2.0-85081941841 09/19/2019       31 Citations
  • Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. (Nikanjam M, Arguello D, Gatalica Z, Swensen J, Barkauskas DA, Kurzrock R) Int J Cancer 2020 06 01;146(11):3087-3097 PMID: 31479512 PMCID: PMC7051881 SCOPUS ID: 2-s2.0-85074461579 09/04/2019       12 Citations
  • Phase I trials as valid therapeutic options for patients with cancer. (Adashek JJ, LoRusso PM, Hong DS, Kurzrock R) Nat Rev Clin Oncol 2019 12;16(12):773-778 PMID: 31477881 PMCID: PMC6868302 SCOPUS ID: 2-s2.0-85072113183 09/04/2019       35 Citations
  • Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics. (Nikanjam M, Cohen PR, Kato S, Sicklick JK, Kurzrock R) Ann Oncol 2019 10 01;30(10):1675 PMID: 31408092 PMCID: PMC6857610 SCOPUS ID: 2-s2.0-85075094983 08/14/2019       2 Citations
  • Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. (Goodman AM, Sokol ES, Frampton GM, Lippman SM, Kurzrock R) Cancer Immunol Res 2019 10;7(10):1570-1573 PMID: 31405947 PMCID: PMC6774837 SCOPUS ID: 2-s2.0-85072849285 08/14/2019       83 Citations
  • Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals. (Kurzrock R, Gurski LA, Carlson RW, Ettinger DS, Horwitz SM, Kumar SK, Million L, von Mehren M, Benson AB 3rd) Ann Oncol 2019 10 01;30(10):1647-1652 PMID: 31373348 PMCID: PMC6857604 SCOPUS ID: 2-s2.0-85074436608 08/03/2019       7 Citations
  • Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. (Kaseb AO, Sánchez NS, Sen S, Kelley RK, Tan B, Bocobo AG, Lim KH, Abdel-Wahab R, Uemura M, Pestana RC, Qiao W, Xiao L, Morris J, Amin HM, Hassan MM, Rashid A, Banks KC, Lanman RB, Talasaz A, Mills-Shaw KR, George B, Haque A, Raghav KPS, Wolff RA, Yao JC, Meric-Bernstam F, Ikeda S, Kurzrock R) Clin Cancer Res 2019 10 15;25(20):6107-6118 PMID: 31363003 SCOPUS ID: 2-s2.0-85072574769 08/01/2019       37 Citations
  • Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics. (Choi IS, Kato S, Fanta PT, Leichman L, Okamura R, Raymond VM, Lanman RB, Lippman SM, Kurzrock R) Mol Cancer Ther 2019 10;18(10):1852-1862 PMID: 31320401 SCOPUS ID: 2-s2.0-85072849095 07/20/2019       15 Citations
  • Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. (Ang C, Klempner SJ, Ali SM, Madison R, Ross JS, Severson EA, Fabrizio D, Goodman A, Kurzrock R, Suh J, Millis SZ) Oncotarget 2019 Jun 18;10(40):4018-4025 PMID: 31258846 PMCID: PMC6592287 07/02/2019    
  • Temporal and spatial effects and survival outcomes associated with concordance between tissue and blood KRAS alterations in the pan-cancer setting. (Mardinian K, Okamura R, Kato S, Kurzrock R) Int J Cancer 2020 01 15;146(2):566-576 PMID: 31199507 PMCID: PMC6874714 SCOPUS ID: 2-s2.0-85068474243 06/15/2019       12 Citations
  • A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. (Kurzrock R, Ball DW, Zahurak ML, Nelkin BD, Subbiah V, Ahmed S, O'Connor A, Karunsena E, Parkinson RM, Bishop JA, Ha Y, Sharma R, Gocke CD, Zinner R, Rudek MA, Sherman SI, Azad NS) Clin Cancer Res 2019 09 15;25(18):5475-5484 PMID: 31186313 PMCID: PMC7038784 SCOPUS ID: 2-s2.0-85068791268 06/13/2019       10 Citations
  • Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma (Ang C, Klempner SJ, Ali SM, Madison R, Ross JS, Severson EA, Fabrizio D, Goodman A, Kurzrock R, Suh J, Millis SZ) Oncotarget 1 June 2019;10(40):4018-4025 SCOPUS ID: 2-s2.0-85068135070 06/01/2019       58 Citations
  • Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer. (Adashek JJ, Junior PNA, Galanina N, Kurzrock R) J Immunother Cancer 2019 05 22;7(1):130 PMID: 31113482 PMCID: PMC6530036 SCOPUS ID: 2-s2.0-85066497099 05/23/2019       7 Citations
  • Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. (Kato S, Okamura R, Mareboina M, Lee S, Goodman A, Patel SP, Fanta PT, Schwab RB, Vu P, Raymond VM, Lanman RB, Sicklick JK, Lippman SM, Kurzrock R) JCO Precis Oncol 2019;3 PMID: 31058253 PMCID: PMC6497417 SCOPUS ID: 2-s2.0-85071986930 05/07/2019       28 Citations
  • Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival. (Kato S, Schwaederlé MC, Fanta PT, Okamura R, Leichman L, Lippman SM, Lanman RB, Raymond VM, Talasaz A, Kurzrock R) JCO Precis Oncol 2019;3 PMID: 31032472 PMCID: PMC6484865 SCOPUS ID: 2-s2.0-85071153093 04/30/2019       28 Citations
  • Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. (Janku F, Diamond EL, Goodman AM, Raghavan VK, Barnes TG, Kato S, Abdel-Wahab O, Durham BH, Meric-Bernstam F, Kurzrock R) Mol Cancer Ther 2019 06;18(6):1149-1157 PMID: 31015311 PMCID: PMC6548628 SCOPUS ID: 2-s2.0-85067217817 04/25/2019       17 Citations
  • Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. (Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P, Krie A, Piccioni DE, Miller VA, Ross JS, Benson A, Webster J, Stephens PJ, Lee JJ, Fanta PT, Lippman SM, Leyland-Jones B, Kurzrock R) Nat Med 2019 05;25(5):744-750 PMID: 31011206 PMCID: PMC6553618 SCOPUS ID: 2-s2.0-85064759962 04/24/2019       236 Citations
  • Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. (Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, Tsimberidou A, Saintigny P, Ackerstein A, Braña I, Loriot Y, Afshar M, Miller V, Wunder F, Bresson C, Martini JF, Raynaud J, Mendelsohn J, Batist G, Onn A, Tabernero J, Schilsky RL, Lazar V, Lee JJ, Kurzrock R) Nat Med 2019 05;25(5):751-758 PMID: 31011205 PMCID: PMC6599610 SCOPUS ID: 2-s2.0-85064740607 04/24/2019       195 Citations
  • Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness. (Goodman AM, Kato S, Chattopadhyay R, Okamura R, Saunders IM, Montesion M, Frampton GM, Miller VA, Daniels GA, Kurzrock R) Cancer Immunol Res 2019 06;7(6):866-873 PMID: 31003990 PMCID: PMC6548620 SCOPUS ID: 2-s2.0-85067219850 04/21/2019       14 Citations
  • Schnitzler syndrome associated with MYD88 L265P mutation. (Goodman AM, Cohen PR, Li A, Hinds B, Kurzrock R) JAAD Case Rep 2019 Apr;5(4):312-316 PMID: 30989098 PMCID: PMC6446129 SCOPUS ID: 2-s2.0-85063626757 04/17/2019       3 Citations
  • Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies. (Shatsky R, Parker BA, Bui NQ, Helsten T, Schwab RB, Boles SG, Kurzrock R) Mol Cancer Ther 2019 05;18(5):1001-1011 PMID: 30926636 SCOPUS ID: 2-s2.0-85065511969 03/31/2019       24 Citations
  • Immune Escape of AML Cells after Transplantation. (Goodman AM, Kurzrock R) N Engl J Med 2019 03 28;380(13):1289 PMID: 30917272 SCOPUS ID: 2-s2.0-85063920487 03/28/2019       1 Citation
  • Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. (Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, Schulze K, Cuchelkar V, Hainsworth J) Lancet Oncol 2019 04;20(4):518-530 PMID: 30857956 PMCID: PMC6781620 SCOPUS ID: 2-s2.0-85063595326 03/13/2019       182 Citations
  • Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer. (Kurzrock R, Hickish T, Wyrwicz L, Saunders M, Wu Q, Stecher M, Mohanty P, Dinarello CA, Simard J) Oncoimmunology 2019;8(3):1551651 PMID: 30723583 PMCID: PMC6350690 SCOPUS ID: 2-s2.0-85058490309 02/07/2019       22 Citations
  • APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy. (Boichard A, Pham TV, Yeerna H, Goodman A, Tamayo P, Lippman S, Frampton GM, Tsigelny IF, Kurzrock R) Oncoimmunology 2019;8(3):1550341 PMID: 30723579 PMCID: PMC6350681 SCOPUS ID: 2-s2.0-85059079482 02/07/2019       20 Citations
  • Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. (Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Yirong W, Dy GK, Yau E, Early A, Chen H, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Marin D, Zhu J, Clarke J, Labriola M, McCall S, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Dressler L, Steciuk M, Binns O, Kasuganti D, Shah N, Ernstoff M, Odunsi K, Kurzrock R, Gardner M, Galluzzi L, Morrison C) J Immunother Cancer 2019 02 01;7(1):27 PMID: 30709424 PMCID: PMC6359802 SCOPUS ID: 2-s2.0-85060929943 02/03/2019       31 Citations
  • Dosing Oncology Therapeutics in Combination Therapy for Renal Dysfunction: The University of California San Diego Study of Personalized Cancer Therapy to Determine Response and Toxicity (UCSD-PREDICT) Experience. (Nikanjam M, Wing J, Capparelli E, Kurzrock R) Cureus 2018 Nov 26;10(11):e3634 PMID: 30705793 PMCID: PMC6349570 02/02/2019    
  • Novel patterns of response under immunotherapy. (Borcoman E, Kanjanapan Y, Champiat S, Kato S, Servois V, Kurzrock R, Goel S, Bedard P, Le Tourneau C) Ann Oncol 2019 03 01;30(3):385-396 PMID: 30657859 SCOPUS ID: 2-s2.0-85064114046 01/19/2019       194 Citations
  • Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. (Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R) JCO Precis Oncol 2018;2018 PMID: 30637364 PMCID: PMC6329466 SCOPUS ID: 2-s2.0-85077480919 01/15/2019       150 Citations
  • Identification of targets for prostate cancer immunotherapy. (Papanicolau-Sengos A, Yang Y, Pabla S, Lenzo FL, Kato S, Kurzrock R, DePietro P, Nesline M, Conroy J, Glenn S, Chatta G, Morrison C) Prostate 2019 04;79(5):498-505 PMID: 30614027 SCOPUS ID: 2-s2.0-85059549968 01/08/2019       18 Citations
  • Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes. (Tray N, Taff J, Singh B, Suh J, Ngo N, Kwa M, Troxel AB, Chae YK, Kurzrock R, Patel SP, Sharon E, Denkert C, Ross JS, Adams S) Breast 2019 Apr;44:29-32 PMID: 30609392 SCOPUS ID: 2-s2.0-85059581979 01/05/2019       26 Citations
  • In the era of immune checkpoint inhibitor therapy, can we safely expand to patients with immunodeficiency? (Bilen MA, Kurzrock R) Journal of Immunotherapy and Precision Oncology 2019;2(4):129 SCOPUS ID: 2-s2.0-85102851773 01/01/2019    
  • Pancreas Cancer-Associated Weight Loss. (Hendifar AE, Petzel MQB, Zimmers TA, Denlinger CS, Matrisian LM, Picozzi VJ, Rahib L, Precision Promise Consortium) Oncologist 2019 05;24(5):691-701 PMID: 30591550 PMCID: PMC6516128 SCOPUS ID: 2-s2.0-85059139109 12/29/2018       50 Citations
  • Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities. (Millis SZ, Jardim DL, Albacker L, Ross JS, Miller VA, Ali SM, Kurzrock R) Cancer 2019 04 01;125(7):1185-1199 PMID: 30582752 PMCID: PMC6433468 SCOPUS ID: 2-s2.0-85059038877 12/26/2018       25 Citations
  • Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials. (Galanina N, Bejar R, Choi M, Goodman A, Wieduwilt M, Mulroney C, Kim L, Yeerna H, Tamayo P, Vergilio JA, Mughal TI, Miller V, Jamieson C, Kurzrock R) Cancers (Basel) 2018 Dec 21;11(1) PMID: 30583461 PMCID: PMC6356731 SCOPUS ID: 2-s2.0-85061902473 12/26/2018       16 Citations
  • Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients. (Jensen TJ, Goodman AM, Kato S, Ellison CK, Daniels GA, Kim L, Nakashe P, McCarthy E, Mazloom AR, McLennan G, Grosu DS, Ehrich M, Kurzrock R) Mol Cancer Ther 2019 02;18(2):448-458 PMID: 30523049 SCOPUS ID: 2-s2.0-85061039583 12/14/2018       43 Citations
  • STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. (Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Curran M, Liu Q, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MVP, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR, Hong DS) J Immunother Cancer 2018 11 16;6(1):119 PMID: 30446007 PMCID: PMC6240242 SCOPUS ID: 2-s2.0-85056740625 11/18/2018       100 Citations
  • ASO Author Reflections: Circulating Tumor DNA in Peritoneal Carcinomatosis. (Baumgartner JM, Kurzrock R) Ann Surg Oncol 2018 12;25(Suppl 3):772-773 PMID: 30421042 SCOPUS ID: 2-s2.0-85056375664 11/14/2018    
  • An avatar for precision cancer therapy. (Kato S, Kurzrock R) Nat Biotechnol 2018 11 09;36(11):1053-1055 PMID: 30412185 SCOPUS ID: 2-s2.0-85056356153 11/10/2018       6 Citations
  • Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response. (Guram K, Nunez M, Einck J, Mell LK, Cohen E, Sanders PD, Miyauchi S, Weihe E, Kurzrock R, Boles S, Sharabi AB) Front Oncol 2018;8:435 PMID: 30386736 PMCID: PMC6199376 SCOPUS ID: 2-s2.0-85055316697 11/06/2018       8 Citations
  • Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. (Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F) Cancer 2019 02 01;125(3):463-472 PMID: 30383888 PMCID: PMC6340722 SCOPUS ID: 2-s2.0-85055952073 11/02/2018       7 Citations
  • The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match. (Subbiah V, Kurzrock R) Oncologist 2019 01;24(1):1-3 PMID: 30352943 PMCID: PMC6324623 SCOPUS ID: 2-s2.0-85055431168 10/26/2018       15 Citations
  • Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma. (Kato S, Okamura R, Baumgartner JM, Patel H, Leichman L, Kelly K, Sicklick JK, Fanta PT, Lippman SM, Kurzrock R) Clin Cancer Res 2018 12 15;24(24):6248-6256 PMID: 30348637 PMCID: PMC6384095 SCOPUS ID: 2-s2.0-85058443864 10/24/2018       52 Citations
  • Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial. (Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R, Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrishnan K, Zhou X, Leonard EJ, Schilder RJ) JAMA Oncol 2019 01 01;5(1):e183773 PMID: 30347019 PMCID: PMC6439781 SCOPUS ID: 2-s2.0-85055291610 10/23/2018       41 Citations
  • Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. (Ikeda S, Elkin SK, Tomson BN, Carter JL, Kurzrock R) Cancer Biol Ther 2019;20(2):219-226 PMID: 30339521 PMCID: PMC6343723 SCOPUS ID: 2-s2.0-85055533585 10/20/2018       12 Citations
  • Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. (Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Tsang KWK, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek MF, Lilly M, Sonpavde G, Lee CE, Lanman RB, Meric-Bernstam F, Kurzrock R, Weitzel JN) J Clin Oncol 2018 Oct 19:JCO1800328 PMID: 30339520 PMCID: PMC6286162 SCOPUS ID: 2-s2.0-85058209440 10/20/2018       46 Citations
  • Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL). (Galanina N, Kurzrock R) Cancer Biol Ther 2019;20(3):247-251 PMID: 30307363 PMCID: PMC6370366 SCOPUS ID: 2-s2.0-85054873374 10/12/2018       1 Citation
  • Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology. (Jardim DL, de Melo Gagliato D, Kurzrock R) Integr Cancer Ther 2018 12;17(4):1012-1015 PMID: 30229677 PMCID: PMC6247554 SCOPUS ID: 2-s2.0-85065266106 09/20/2018       4 Citations
  • Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics. (Nikanjam M, Cohen PR, Kato S, Sicklick JK, Kurzrock R) Ann Oncol 2018 11 01;29(11):2192-2199 PMID: 30219896 PMCID: PMC6290882 SCOPUS ID: 2-s2.0-85056732329 09/17/2018       20 Citations
  • GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers. (Parish AJ, Nguyen V, Goodman AM, Murugesan K, Frampton GM, Kurzrock R) Cancer 2018 10 15;124(20):4080-4089 PMID: 30204251 PMCID: PMC6234097 SCOPUS ID: 2-s2.0-85053374147 09/12/2018       20 Citations
  • Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade. (Galanina N, Goodman AM, Cohen PR, Frampton GM, Kurzrock R) Cancer Immunol Res 2018 10;6(10):1129-1135 PMID: 30194084 PMCID: PMC6248326 SCOPUS ID: 2-s2.0-85054410945 09/09/2018       49 Citations
  • International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. (van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC) Blood 2018 11 15;132(20):2115-2124 PMID: 30181172 PMCID: PMC6238190 SCOPUS ID: 2-s2.0-85056614930 09/06/2018       115 Citations
  • Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies. (Kato S, Ross JS, Gay L, Dayyani F, Roszik J, Subbiah V, Kurzrock R) JCO Precis Oncol 2018;2018 PMID: 30148248 PMCID: PMC6106866 SCOPUS ID: 2-s2.0-85065171977 08/28/2018       29 Citations
  • Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. (Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL) Oncologist 2018 11;23(11):1300-1309 PMID: 30139837 PMCID: PMC6291334 SCOPUS ID: 2-s2.0-85053222766 08/25/2018       26 Citations
  • Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. (Subbiah IM, Tang C, Rao A, Falchook GS, Subbiah V, Tsimberidou AM, Karp D, Kurzrock R, Hong DS) Oncotarget 2018 Jun 22;9(48):28842-28848 PMID: 29989021 PMCID: PMC6034739 SCOPUS ID: 2-s2.0-85048935169 07/11/2018       2 Citations
  • Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival. (Baumgartner JM, Raymond VM, Lanman RB, Tran L, Kelly KJ, Lowy AM, Kurzrock R) Ann Surg Oncol 2018 Aug;25(8):2400-2408 PMID: 29948422 PMCID: PMC6044413 SCOPUS ID: 2-s2.0-85048540497 06/28/2018       29 Citations
  • Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. (Goodman AM, Piccioni D, Kato S, Boichard A, Wang HY, Frampton G, Lippman SM, Connelly C, Fabrizio D, Miller V, Sicklick JK, Kurzrock R) JAMA Oncol 2018 09 01;4(9):1237-1244 PMID: 29902298 PMCID: PMC6139049 SCOPUS ID: 2-s2.0-85051649522 06/15/2018       135 Citations
  • MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis. (Ikeda S, Schwaederle M, Mohindra M, Fontes Jardim DL, Kurzrock R) J Hematol Oncol 2018 06 04;11(1):76 PMID: 29866143 PMCID: PMC5987577 SCOPUS ID: 2-s2.0-85048018924 06/06/2018       26 Citations
  • Reply to J.J. Tao et al. (Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R) J Clin Oncol 2018 08 10;36(23):2451 PMID: 29856693 SCOPUS ID: 2-s2.0-85052704705 06/02/2018    
  • Cancer research in the United States: A critical review of current status and proposal for alternative models. (Kantarjian HM, Prat F, Steensma DP, Kurzrock R, Stewart DJ, Sekeres MA, Leveque J) Cancer 2018 07 15;124(14):2881-2889 PMID: 29757456 SCOPUS ID: 2-s2.0-85047548974 05/15/2018       11 Citations
  • Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. (Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D) Br J Cancer 2018 05;118(11):1419-1424 PMID: 29695765 PMCID: PMC5988803 SCOPUS ID: 2-s2.0-85046021462 04/27/2018       4 Citations
  • Razelle Kurzrock and Shumei Kato on Immunotherapy and Hyperprogression of Disease. (Kurzrock R, Kato S) Oncology (Williston Park) 2018 04 15;32(4):150-1, 163 PMID: 29684227 SCOPUS ID: 2-s2.0-85050432542 04/24/2018       1 Citation
  • The importance of greater speed in drug development for advanced malignancies. (Stewart DJ, Stewart AA, Wheatley-Price P, Batist G, Kantarjian HM, Schiller J, Clemons M, Bradford JP, Gillespie L, Kurzrock R) Cancer Med 2018 05;7(5):1824-1836 PMID: 29601671 PMCID: PMC5943431 SCOPUS ID: 2-s2.0-85044610663 03/31/2018       14 Citations
  • TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [18F] fluorodeoxyglucose (18F-FDG PET). (Chang GH, Kurzrock R, Tran L, Schwaederle M, Hoh CK) Oncotarget 2018 Mar 06;9(18):14306-14310 PMID: 29581845 PMCID: PMC5865671 SCOPUS ID: 2-s2.0-85042923358 03/28/2018       4 Citations
  • JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis. (Choi MY, Kato S, Wang HY, Lin JH, Lanman RB, Kurzrock R) Cancer Biol Ther 2018 08 03;19(8):664-668 PMID: 29565699 PMCID: PMC6067874 SCOPUS ID: 2-s2.0-85050400905 03/23/2018    
  • Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. (Maitland ML, Piha-Paul S, Falchook G, Kurzrock R, Nguyen L, Janisch L, Karovic S, McKee M, Hoening E, Wong S, Munasinghe W, Palma J, Donawho C, Lian GK, Ansell P, Ratain MJ, Hong D) Br J Cancer 2018 04;118(8):1042-1050 PMID: 29551775 PMCID: PMC5931107 SCOPUS ID: 2-s2.0-85044072216 03/20/2018       8 Citations
  • Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. (Ikeda S, Tsigelny IF, Skjevik ÅA, Kono Y, Mendler M, Kuo A, Sicklick JK, Heestand G, Banks KC, Talasaz A, Lanman RB, Lippman S, Kurzrock R) Oncologist 2018 05;23(5):586-593 PMID: 29487225 PMCID: PMC5947459 SCOPUS ID: 2-s2.0-85042618999 03/01/2018       43 Citations
  • Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics. (Ikeda S, Lim JS, Kurzrock R) Mol Cancer Ther 2018 05;17(5):1114-1122 PMID: 29483209 PMCID: PMC5932233 SCOPUS ID: 2-s2.0-85047623285 02/28/2018       30 Citations
  • Challenging Standard-of-Care Paradigms in the Precision Oncology Era. (Subbiah V, Kurzrock R) Trends Cancer 2018 02;4(2):101-109 PMID: 29458960 PMCID: PMC5822744 SCOPUS ID: 2-s2.0-85040447227 02/21/2018       26 Citations
  • Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies. (Goodman AM, Kato S, Cohen PR, Boichard A, Frampton G, Miller V, Stephens PJ, Daniels GA, Kurzrock R) Oncoimmunology 2018;7(3):e1404217 PMID: 29399405 PMCID: PMC5790366 SCOPUS ID: 2-s2.0-85038875231 02/06/2018       31 Citations
  • Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. (Schrock AB, Pavlick D, Klempner SJ, Chung JH, Forcier B, Welsh A, Young L, Leyland-Jones B, Bordoni R, Carvajal RD, Chao J, Kurzrock R, Sicklick JK, Ross JS, Stephens PJ, Devoe C, Braiteh F, Ali SM, Miller VA) Clin Cancer Res 2018 04 15;24(8):1881-1890 PMID: 29363525 PMCID: PMC6076990 SCOPUS ID: 2-s2.0-85046659151 01/25/2018       33 Citations
  • Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. (Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R) J Clin Oncol 2018 02 20;36(6):536-542 PMID: 29320312 SCOPUS ID: 2-s2.0-85041996976 01/11/2018       227 Citations
  • Preface (Patel SP, Kurzrock R) Current Cancer Research 2018:v-ix SCOPUS ID: 2-s2.0-85111808980 01/01/2018    
  • Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials (Patel M, Patel SP, Kurzrock R) Current Cancer Research 2018:243-280 SCOPUS ID: 2-s2.0-85111801203 01/01/2018    
  • New rationales and designs for clinical trials in the era of precision medicine (Nikanjam M, Kurzrock R) Encyclopedia of Cancer 1 January 2018:30-43 SCOPUS ID: 2-s2.0-85079112339 01/01/2018    
  • Proteins Flexibility as a Criterion for Elucidation of Activating Mutants in Personalized Cancer Medicine (Tsigelny IF, Kurzrock R, Skjevik ÅA, Kouznetsova VL, Boichard A, Ikeda S) Advances in Intelligent Systems and Computing 2018;676:75-82 SCOPUS ID: 2-s2.0-85033731072 01/01/2018    
  • Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors. (Jardim DL, de Melo Gagliato D, Giles FJ, Kurzrock R) Clin Cancer Res 2018 04 15;24(8):1785-1794 PMID: 29212781 PMCID: PMC5899646 SCOPUS ID: 2-s2.0-85047857372 12/08/2017       31 Citations
  • Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients. (Schwaederle M, Krishnamurthy N, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Patel SP, Parker BA, Kurzrock R) Cancer 2018 03 15;124(6):1288-1296 PMID: 29211306 PMCID: PMC5839978 SCOPUS ID: 2-s2.0-85043316625 12/07/2017       18 Citations
  • Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support. (Chae YK, Pan AP, Davis AA, Patel SP, Carneiro BA, Kurzrock R, Giles FJ) Mol Cancer Ther 2017 Dec;16(12):2645-2655 PMID: 29203694 SCOPUS ID: 2-s2.0-85038555334 12/06/2017       38 Citations
  • Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors. (Krishnamurthy N, Kurzrock R) Cancer Treat Rev 2018 Jan;62:50-60 PMID: 29169144 PMCID: PMC5745276 SCOPUS ID: 2-s2.0-85034639136 11/24/2017       482 Citations
  • Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-stakeholder Consensus. (Conley RB, Dickson D, Zenklusen JC, Al Naber J, Messner DA, Atasoy A, Chaihorsky L, Collyar D, Compton C, Ferguson M, Khozin S, Klein RD, Kotte S, Kurzrock R, Lin CJ, Liu F, Marino I, McDonough R, McNeal A, Miller V, Schilsky RL, Wang LI) Cell 2017 Nov 16;171(5):982-986 PMID: 29149611 SCOPUS ID: 2-s2.0-85034103971 11/18/2017       10 Citations
  • Molecular Tumor Boards: Realizing Precision Oncology Therapy. (Patel M, Kato SM, Kurzrock R) Clin Pharmacol Ther 2018 02;103(2):206-209 PMID: 29134641 PMCID: PMC5760337 SCOPUS ID: 2-s2.0-85033678654 11/15/2017       17 Citations
  • The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA. (Riviere P, Fanta PT, Ikeda S, Baumgartner J, Heestand GM, Kurzrock R) Mol Cancer Ther 2018 01;17(1):297-305 PMID: 29133621 PMCID: PMC5752585 SCOPUS ID: 2-s2.0-85040026371 11/15/2017       22 Citations
  • Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. (Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul S, Janku F, Meric-Bernstam F, Hwu P, Kee B, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R) JCO Precis Oncol 2017;2017 PMID: 29082359 PMCID: PMC5659750 SCOPUS ID: 2-s2.0-85039861105 10/31/2017       81 Citations
  • Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. (Schöffski P, Gordon M, Smith DC, Kurzrock R, Daud A, Vogelzang NJ, Lee Y, Scheffold C, Shapiro GI) Eur J Cancer 2017 11;86:296-304 PMID: 29059635 SCOPUS ID: 2-s2.0-85031818140 10/24/2017       46 Citations
  • Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach. (Kato S, Kurasaki K, Ikeda S, Kurzrock R) Oncologist 2018 02;23(2):171-178 PMID: 29038235 PMCID: PMC5813742 SCOPUS ID: 2-s2.0-85038262363 10/19/2017       20 Citations
  • Genomics of Immunotherapy-Associated Hyperprogressors-Response. (Kato S, Kurzrock R) Clin Cancer Res 2017 10 15;23(20):6376 PMID: 29030333 SCOPUS ID: 2-s2.0-85031497018 10/17/2017       8 Citations
  • Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities. (Costa R, Costa RB, Talamantes SM, Helenoswki I, Carneiro BA, Chae YK, Gradishar WJ, Kurzrock R, Giles FJ) Oncotarget 2017 Sep 15;8(40):67782-67789 PMID: 28978071 PMCID: PMC5620211 10/06/2017    
  • Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. (Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, Bazhenova LA, Kurzrock R) Clin Cancer Res 2017 Oct 01;23(19):5729-5736 PMID: 28972084 PMCID: PMC5678984 SCOPUS ID: 2-s2.0-85032026566 10/04/2017       129 Citations
  • Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability. (Bieg-Bourne CC, Millis SZ, Piccioni DE, Fanta PT, Goldberg ME, Chmielecki J, Parker BA, Kurzrock R) Cancer Res 2017 11 15;77(22):6313-6320 PMID: 28939679 PMCID: PMC5690871 SCOPUS ID: 2-s2.0-85033778348 09/25/2017       19 Citations
  • Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns. (Nikanjam M, Patel H, Kurzrock R) Oncoimmunology 2017;6(8):e1338997 PMID: 28920006 PMCID: PMC5593707 SCOPUS ID: 2-s2.0-85023748608 09/19/2017       21 Citations
  • The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. (Khemlina G, Ikeda S, Kurzrock R) Mol Cancer 2017 08 30;16(1):149 PMID: 28854942 PMCID: PMC5577674 SCOPUS ID: 2-s2.0-85028505271 09/01/2017       166 Citations
  • Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. (Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R) Mol Cancer Ther 2017 11;16(11):2598-2608 PMID: 28835386 PMCID: PMC5670009 SCOPUS ID: 2-s2.0-85032796880 08/25/2017       1100 Citations
  • BRAF mutation as a novel driver of eosinophilic cystitis. (Choi MY, Tsigelny IF, Boichard A, Skjevik ÅA, Shabaik A, Kurzrock R) Cancer Biol Ther 2017 Sep 02;18(9):655-659 PMID: 28829677 PMCID: PMC5663411 SCOPUS ID: 2-s2.0-85029457275 08/23/2017       3 Citations
  • Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing. (Schwaederle M, Chattopadhyay R, Kato S, Fanta PT, Banks KC, Choi IS, Piccioni DE, Ikeda S, Talasaz A, Lanman RB, Bazhenova L, Kurzrock R) Cancer Res 2017 10 01;77(19):5419-5427 PMID: 28807936 PMCID: PMC5626633 SCOPUS ID: 2-s2.0-85031426857 08/16/2017       64 Citations
  • Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease. (Cohen PR, Kato S, Goodman AM, Ikeda S, Kurzrock R) Int J Mol Sci 2017 Jul 31;18(8) PMID: 28788102 PMCID: PMC5578053 SCOPUS ID: 2-s2.0-85026746325 08/10/2017       25 Citations
  • A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma. (Vergote IB, Smith DC, Berger R, Kurzrock R, Vogelzang NJ, Sella A, Wheler J, Lee Y, Foster PG, Weitzman R, Buckanovich RJ) Eur J Cancer 2017 09;83:229-236 PMID: 28755607 SCOPUS ID: 2-s2.0-85026307586 07/30/2017       19 Citations
  • Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. (Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Hong DS) Clin Cancer Res 2017 Aug 01;23(15):4155-4162 PMID: 28729355 PMCID: PMC5902668 SCOPUS ID: 2-s2.0-85027126578 07/22/2017       3 Citations
  • Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients. (Heestand GM, Schwaederle M, Gatalica Z, Arguello D, Kurzrock R) Eur J Cancer 2017 09;83:80-87 PMID: 28728050 PMCID: PMC5613945 SCOPUS ID: 2-s2.0-85024106522 07/21/2017       36 Citations
  • Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit. (Kato S, Subbiah V, Kurzrock R) J Natl Compr Canc Netw 2017 07;15(7):863-866 PMID: 28687573 PMCID: PMC6317845 SCOPUS ID: 2-s2.0-85022323410 07/09/2017       16 Citations
  • Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies. (Goodman AM, Choi M, Wieduwilt M, Mulroney C, Costello C, Frampton G, Miller V, Kurzrock R) JCO Precis Oncol 2017 06;1 PMID: 28681041 PMCID: PMC5495179 SCOPUS ID: 2-s2.0-85054881173 07/07/2017       16 Citations
  • Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary. (Kato S, Krishnamurthy N, Banks KC, De P, Williams K, Williams C, Leyland-Jones B, Lippman SM, Lanman RB, Kurzrock R) Cancer Res 2017 08 15;77(16):4238-4246 PMID: 28642281 PMCID: PMC5729906 SCOPUS ID: 2-s2.0-85028298499 06/24/2017       62 Citations
  • Polycystic ovary syndrome in men. (Cohen PR, Kurzrock R) Med Hypotheses 2017 06;103:64 PMID: 28571814 SCOPUS ID: 2-s2.0-85018648440 06/03/2017       4 Citations
  • Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. (Sharabi A, Kim SS, Kato S, Sanders PD, Patel SP, Sanghvi P, Weihe E, Kurzrock R) Oncologist 2017 06;22(6):631-637 PMID: 28550027 PMCID: PMC5469598 SCOPUS ID: 2-s2.0-85020933301 05/28/2017       58 Citations
  • Debunking the Delusion That Precision Oncology Is an Illusion. (Subbiah V, Kurzrock R) Oncologist 2017 08;22(8):881-882 PMID: 28550030 PMCID: PMC5553950 SCOPUS ID: 2-s2.0-85027363308 05/28/2017       15 Citations
  • Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma. (Schwaederlé MC, Patel SP, Husain H, Ikeda M, Lanman RB, Banks KC, Talasaz A, Bazhenova L, Kurzrock R) Clin Cancer Res 2017 Sep 01;23(17):5101-5111 PMID: 28539465 PMCID: PMC5581668 SCOPUS ID: 2-s2.0-85027511861 05/26/2017       93 Citations
  • Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology. (Husain H, Nykin D, Bui N, Quan D, Gomez G, Woodward B, Venkatapathy S, Duttagupta R, Fung E, Lippman SM, Kurzrock R) Mol Cancer Ther 2017 05;16(5):948-955 PMID: 28468865 SCOPUS ID: 2-s2.0-85020053681 05/05/2017       58 Citations
  • Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients. (Nikanjam M, Liu S, Yang J, Kurzrock R) Oncologist 2017 05;22(5):576-584 PMID: 28424323 PMCID: PMC5423521 SCOPUS ID: 2-s2.0-85019061076 04/21/2017       23 Citations
  • Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine. (Husain H, Melnikova VO, Kosco K, Woodward B, More S, Pingle SC, Weihe E, Park BH, Tewari M, Erlander MG, Cohen E, Lippman SM, Kurzrock R) Clin Cancer Res 2017 Aug 15;23(16):4716-4723 PMID: 28420725 PMCID: PMC5737735 SCOPUS ID: 2-s2.0-85028040404 04/20/2017       70 Citations
  • High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations. (Boichard A, Tsigelny IF, Kurzrock R) Oncoimmunology 2017;6(3):e1284719 PMID: 28405512 PMCID: PMC5384346 SCOPUS ID: 2-s2.0-85015145636 04/14/2017       40 Citations
  • Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma. (Subbiah V, Meyer C, Zinner R, Meric-Bernstam F, Zahurak ML, O'Connor A, Roszik J, Shaw K, Ludwig JA, Kurzrock R, Azad NA) Clin Cancer Res 2017 08 01;23(15):4027-4034 PMID: 28377484 PMCID: PMC5754188 SCOPUS ID: 2-s2.0-85027275432 04/06/2017       25 Citations
  • Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. (Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R) Clin Cancer Res 2017 Aug 01;23(15):4242-4250 PMID: 28351930 PMCID: PMC5647162 SCOPUS ID: 2-s2.0-85026810566 03/30/2017       523 Citations
  • Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasis. (Costa R, Gill N, Rademaker AW, Carneiro BA, Chae YK, Kumthekar P, Gradishar WJ, Kurzrock R, Giles FJ) Cancer Treat Rev 2017 Apr;55:10-15 PMID: 28279895 SCOPUS ID: 2-s2.0-85014578132 03/11/2017       13 Citations
  • JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease. (Patel M, Ikeda S, Pilat SR, Kurzrock R) JAMA Dermatol 2017 05 01;153(5):449-452 PMID: 28241173 PMCID: PMC5470416 SCOPUS ID: 2-s2.0-85019165731 02/28/2017       8 Citations
  • Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors. (Mita M, Fu S, Piha-Paul SA, Janku F, Mita A, Natale R, Guo W, Zhao C, Kurzrock R, Naing A) Invest New Drugs 2017 10;35(5):616-626 PMID: 28194539 PMCID: PMC5935457 SCOPUS ID: 2-s2.0-85012284794 02/15/2017       20 Citations
  • Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer. (Husain H, Scur M, Murtuza A, Bui N, Woodward B, Kurzrock R) Mol Cancer Ther 2017 02;16(2):265-272 PMID: 28159915 SCOPUS ID: 2-s2.0-85011697899 02/06/2017       24 Citations
  • Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. (Daud A, Kluger HM, Kurzrock R, Schimmoller F, Weitzman AL, Samuel TA, Moussa AH, Gordon MS, Shapiro GI) Br J Cancer 2017 Feb 14;116(4):432-440 PMID: 28103611 PMCID: PMC5318966 SCOPUS ID: 2-s2.0-85010021960 01/20/2017       44 Citations
  • International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. (Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, Simpson D, Liu AY, Menke D, Chandrakasan S, Lechowicz MJ, Wong RS, Pierson S, Paessler M, Rossi JF, Ide M, Ruth J, Croglio M, Suarez A, Krymskaya V, Chadburn A, Colleoni G, Nasta S, Jayanthan R, Nabel CS, Casper C, Dispenzieri A, Fosså A, Kelleher D, Kurzrock R, Voorhees P, Dogan A, Yoshizaki K, van Rhee F, Oksenhendler E, Jaffe ES, Elenitoba-Johnson KS, Lim MS) Blood 2017 Mar 23;129(12):1646-1657 PMID: 28087540 PMCID: PMC5364342 SCOPUS ID: 2-s2.0-85016255188 01/15/2017       218 Citations
  • FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors. (Shi E, Chmielecki J, Tang CM, Wang K, Heinrich MC, Kang G, Corless CL, Hong D, Fero KE, Murphy JD, Fanta PT, Ali SM, De Siena M, Burgoyne AM, Movva S, Madlensky L, Heestand GM, Trent JC, Kurzrock R, Morosini D, Ross JS, Harismendy O, Sicklick JK) J Transl Med 2016 12 14;14(1):339 PMID: 27974047 PMCID: PMC5157084 SCOPUS ID: 2-s2.0-85005987227 12/16/2016       122 Citations
  • Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. (Ikeda S, Goodman AM, Cohen PR, Jensen TJ, Ellison CK, Frampton G, Miller V, Patel SP, Kurzrock R) NPJ Genom Med 2016;1 PMID: 27942391 PMCID: PMC5142752 SCOPUS ID: 2-s2.0-85015695943 12/13/2016       86 Citations
  • Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients. (Kurzrock R, Stewart DJ) Clin Cancer Res 2017 Mar 01;23(5):1137-1148 PMID: 27940520 SCOPUS ID: 2-s2.0-85014628645 12/13/2016       23 Citations
  • Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. (Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL 3rd, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL) JAMA Oncol 2017 Apr 01;3(4):509-515 PMID: 27893038 SCOPUS ID: 2-s2.0-85018594183 11/29/2016       97 Citations
  • Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review. (Jardim DL, Groves ES, Breitfeld PP, Kurzrock R) Cancer Treat Rev 2017 Jan;52:12-21 PMID: 27883925 SCOPUS ID: 2-s2.0-84998678876 11/25/2016       54 Citations
  • Next generation predictive biomarkers for immune checkpoint inhibition. (Khagi Y, Kurzrock R, Patel SP) Cancer Metastasis Rev 2017 03;36(1):179-190 PMID: 27873079 PMCID: PMC5385298 SCOPUS ID: 2-s2.0-84996551878 11/23/2016       65 Citations
  • Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual. (Tang C, Hess KR, Sanders D, Davis SE, Buzdar AU, Kurzrock R, Lee JJ, Meric-Bernstam F, Hong DS) Clin Cancer Res 2017 Mar 15;23(6):1407-1413 PMID: 27852698 PMCID: PMC5872813 SCOPUS ID: 2-s2.0-85016149657 11/18/2016       6 Citations
  • PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. (Goodman A, Patel SP, Kurzrock R) Nat Rev Clin Oncol 2017 04;14(4):203-220 PMID: 27805626 SCOPUS ID: 2-s2.0-84994120928 11/03/2016       247 Citations
  • Targeted therapies: What have we learned from SHIVA? (Le Tourneau C, Kurzrock R) Nat Rev Clin Oncol 2016 12;13(12):719-720 PMID: 27725677 SCOPUS ID: 2-s2.0-84991030334 11/03/2016       15 Citations
  • Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER. (Subbiah IM, Wheler JJ, Hess KR, Hong DS, Naing A, Fu S, Kurzrock R, Tsimberidou AM) Int J Cancer 2017 Jan 01;140(1):208-215 PMID: 27599876 SCOPUS ID: 2-s2.0-84994410804 10/18/2016       7 Citations
  • RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. (Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL, Kurzrock R) Clin Cancer Res 2017 04 15;23(8):1988-1997 PMID: 27683183 SCOPUS ID: 2-s2.0-85018802020 09/30/2016       121 Citations
  • Bringing Blood-Based Molecular Testing to the Clinic. (Janku F, Kurzrock R) Clin Cancer Res 2016 Nov 15;22(22):5400-5402 PMID: 27663595 SCOPUS ID: 2-s2.0-84995874954 09/25/2016       7 Citations
  • Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. (Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku F) Oncotarget 2016 Oct 11;7(41):67521-67531 PMID: 27589687 PMCID: PMC5341894 SCOPUS ID: 2-s2.0-84993984510 09/03/2016       34 Citations
  • An 84-Year-Old Woman With an Indolent B-Cell Lymphoma. (Goodman AM, Choi M, Wang L, Kurzrock R) Oncology (Williston Park) 2016 08 15;30(8):705-8, 710, 712 PMID: 27535668 SCOPUS ID: 2-s2.0-85049227515 08/19/2016    
  • Genomic Landscape of Malignant Mesotheliomas. (Kato S, Tomson BN, Buys TP, Elkin SK, Carter JL, Kurzrock R) Mol Cancer Ther 2016 10;15(10):2498-2507 PMID: 27507853 SCOPUS ID: 2-s2.0-84990973713 08/11/2016       43 Citations
  • Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors. (Wheler JJ, Atkins JT, Janku F, Moulder SL, Stephens PJ, Yelensky R, Valero V, Miller V, Kurzrock R, Meric-Bernstam F) Oncoscience 2016;3(5-6):164-72 PMID: 27489863 PMCID: PMC4965259 SCOPUS ID: 2-s2.0-84978280182 08/05/2016       32 Citations
  • Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. (Livingston JA, Hess KR, Naing A, Hong DS, Patel S, Benjamin RS, Ludwig JA, Conley A, Herzog CE, Anderson P, Meric-Bernstam F, Kurzrock R, Subbiah V) Oncotarget 2016 Sep 27;7(39):64421-64430 PMID: 27486883 PMCID: PMC5325454 SCOPUS ID: 2-s2.0-84993982633 08/04/2016       12 Citations
  • TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. (Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong D, Kurzrock R) Mol Cancer Ther 2016 10;15(10):2475-2485 PMID: 27466356 SCOPUS ID: 2-s2.0-84990927257 07/29/2016       53 Citations
  • An appraisal of drug development timelines in the Era of precision oncology. (Jardim DL, Schwaederle M, Hong DS, Kurzrock R) Oncotarget 2016 Aug 16;7(33):53037-53046 PMID: 27419632 PMCID: PMC5288167 SCOPUS ID: 2-s2.0-84982296374 07/16/2016       24 Citations
  • ATM Mutations in Cancer: Therapeutic Implications. (Choi M, Kipps T, Kurzrock R) Mol Cancer Ther 2016 08;15(8):1781-91 PMID: 27413114 SCOPUS ID: 2-s2.0-84985914250 07/15/2016       220 Citations
  • Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013. (Nikanjam M, Liu S, Kurzrock R) Int J Cancer 2016 Nov 01;139(9):2135-41 PMID: 27389805 PMCID: PMC5096042 SCOPUS ID: 2-s2.0-84983084682 07/09/2016       22 Citations
  • Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors. (Millis SZ, Ikeda S, Reddy S, Gatalica Z, Kurzrock R) JAMA Oncol 2016 Dec 01;2(12):1565-1573 PMID: 27388585 SCOPUS ID: 2-s2.0-85013149379 07/09/2016       142 Citations
  • Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib. (Lam LH, Capparelli EV, Kurzrock R) Cancer Chemother Pharmacol 2016 Aug;78(2):427-32 PMID: 27372908 PMCID: PMC4967016 SCOPUS ID: 2-s2.0-84976487009 07/04/2016       18 Citations
  • My personal experiences at the BEST Medical Center: A day in the clinic-the afternoon. (Cohen PR, Kurzrock R) Clin Dermatol 2016 Jul-Aug;34(4):517-20 PMID: 27343967 SCOPUS ID: 2-s2.0-84991073165 06/28/2016       1 Citation
  • Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. (Schwaederle M, Zhao M, Lee JJ, Lazar V, Leyland-Jones B, Schilsky RL, Mendelsohn J, Kurzrock R) JAMA Oncol 2016 Nov 01;2(11):1452-1459 PMID: 27273579 SCOPUS ID: 2-s2.0-84992138510 06/09/2016       178 Citations
  • My personal experiences at the BEST Medical Center: A day in the clinic-the morning. (Cohen PR, Kurzrock R) Clin Dermatol 2016 May-Jun;34(3):422-5 PMID: 27265082 SCOPUS ID: 2-s2.0-84971477037 06/07/2016       3 Citations
  • Health policy: The right to try is embodied in the right to die. (Cohen-Kurzrock BA, Cohen PR, Kurzrock R) Nat Rev Clin Oncol 2016 07;13(7):399-400 PMID: 27217273 SCOPUS ID: 2-s2.0-84969961304 05/25/2016       8 Citations
  • BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. (Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F) Mol Cancer Ther 2016 06;15(6):1397-404 PMID: 27207774 SCOPUS ID: 2-s2.0-84971516426 05/22/2016       59 Citations
  • Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. (Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong DS, Kurzrock R) Cancer Res 2016 07 01;76(13):3690-701 PMID: 27197177 SCOPUS ID: 2-s2.0-84977530459 05/20/2016       157 Citations
  • Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics. (Helsten T, Kato S, Schwaederle M, Tomson BN, Buys TP, Elkin SK, Carter JL, Kurzrock R) Mol Cancer Ther 2016 07;15(7):1682-90 PMID: 27196769 SCOPUS ID: 2-s2.0-84979642830 05/20/2016       24 Citations
  • Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. (Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Patel SP, Harismendy O, Ikeda M, Parker BA, Kurzrock R) Clin Cancer Res 2016 Nov 15;22(22):5497-5505 PMID: 27185373 SCOPUS ID: 2-s2.0-84995670109 05/18/2016       92 Citations
  • Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitors. (Falchook GS, Rady P, Konopinski JC, Busaidy N, Hess K, Hymes S, Nguyen HP, Prieto VG, Bustinza-Linares E, Lin Q, Parkhurst KL, Hong DS, Sherman S, Tyring SK, Kurzrock R) Arch Dermatol Res 2016 Jul;308(5):357-65 PMID: 27098388 SCOPUS ID: 2-s2.0-84964344812 04/22/2016       7 Citations
  • Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. (Said R, Kakadiaris E, Piha-Paul S, Fu S, Falchook G, Janku F, Wheler JJ, Zinner R, Hong DS, Kurzrock R, Tsimberidou AM) Cancer Chemother Pharmacol 2016 05;77(5):1097-102 PMID: 27085994 SCOPUS ID: 2-s2.0-84963757334 04/18/2016       3 Citations
  • Universal Genomic Testing Needed to Win the War Against Cancer: Genomics IS the Diagnosis. (Subbiah V, Kurzrock R) JAMA Oncol 2016 Jun 01;2(6):719-20 PMID: 27078832 SCOPUS ID: 2-s2.0-85010302953 04/15/2016       25 Citations
  • Idiopathic multicentric Castleman's disease: a systematic literature review. (Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, Krymskaya VP, Kelleher D, Rubenstein AH, Fajgenbaum DC) Lancet Haematol 2016 Apr;3(4):e163-75 PMID: 27063975 SCOPUS ID: 2-s2.0-84961223908 04/12/2016       149 Citations
  • The Conundrum of Genetic "Drivers" in Benign Conditions. (Kato S, Lippman SM, Flaherty KT, Kurzrock R) J Natl Cancer Inst 2016 08;108(8) PMID: 27059373 PMCID: PMC5017937 SCOPUS ID: 2-s2.0-84989964975 04/10/2016       81 Citations
  • Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. (Hong D, Infante J, Janku F, Jones S, Nguyen LM, Burris H, Naing A, Bauer TM, Piha-Paul S, Johnson FM, Kurzrock R, Golden L, Hynes S, Lin J, Lin AB, Bendell J) J Clin Oncol 2016 05 20;34(15):1764-71 PMID: 27044938 PMCID: PMC5321045 SCOPUS ID: 2-s2.0-84969584672 04/06/2016       106 Citations
  • Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm. (Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R) Mol Cancer Ther 2016 04;15(4):533-47 PMID: 27009213 SCOPUS ID: 2-s2.0-84964334401 03/25/2016       46 Citations
  • Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. (Fu S, Culotta KS, Falchook GS, Hong DS, Myers AL, Zhang YP, Naing A, Janku F, Hou MM, Kurzrock R) Cancer Chemother Pharmacol 2016 Apr;77(4):881 PMID: 26994910 SCOPUS ID: 2-s2.0-84961201335 03/21/2016       2 Citations
  • Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics. (Cohen PR, Tomson BN, Elkin SK, Marchlik E, Carter JL, Kurzrock R) Oncotarget 2016 Apr 26;7(17):23454-67 PMID: 26981779 PMCID: PMC5029639 SCOPUS ID: 2-s2.0-84966681514 03/17/2016       28 Citations
  • The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer. (Parsons HA, Baracos VE, Hong DS, Abbruzzese J, Bruera E, Kurzrock R) Oncotarget 2016 Apr 12;7(15):20293-304 PMID: 26934122 PMCID: PMC4991455 SCOPUS ID: 2-s2.0-84964706580 03/05/2016       16 Citations
  • Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. (Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA) Oncotarget 2016 Apr 26;7(17):23227-38 PMID: 26933802 PMCID: PMC5029622 SCOPUS ID: 2-s2.0-84966552475 03/05/2016       19 Citations
  • Response. (Jardim DL, Schwaederle M, Lee JJ, Wei C, Mendelsohn J, Schilsky RL, Kurzrock R) J Natl Cancer Inst 2016 Mar;108(3):djw001 PMID: 26912651 SCOPUS ID: 2-s2.0-84962539198 02/26/2016    
  • Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. (Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, Lippman SM, Kurzrock R) Mol Cancer Ther 2016 04;15(4):743-52 PMID: 26873727 SCOPUS ID: 2-s2.0-84964329295 02/14/2016       106 Citations
  • Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. (Sicklick JK, Fanta PT, Shimabukuro K, Kurzrock R) Cancer Metastasis Rev 2016 06;35(2):263-75 PMID: 26857926 PMCID: PMC4912391 SCOPUS ID: 2-s2.0-84975801836 02/10/2016       39 Citations
  • Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. (Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Banks KC, Lanman RB, Talasaz A, Parker BA, Kurzrock R) Oncotarget 2016 Mar 01;7(9):9707-17 PMID: 26848768 PMCID: PMC4891078 SCOPUS ID: 2-s2.0-84961636991 02/06/2016       97 Citations
  • Erratum: Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-Analysis of Clinical Trials Leading to FDA Approval (Journal of the National Cancer Institute (2015) 107:11 (djv253) DOI:10.1093/jnci/djv253) (Fontes Jardim DL, Schwaederle M, Wei M, Lee JJ, Hong DS, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R) Journal of the National Cancer Institute 1 February 2016;108(2) SCOPUS ID: 2-s2.0-84962491924 02/01/2016    
  • Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers. (Liu S, Nikanjam M, Kurzrock R) Oncotarget 2016 Mar 08;7(10):11310-20 PMID: 26824502 PMCID: PMC4905475 SCOPUS ID: 2-s2.0-84962019809 01/30/2016       33 Citations
  • Click chemistry, 3D-printing, and omics: the future of drug development. (Kurzrock R, Stewart DJ) Oncotarget 2016 Jan 19;7(3):2155-8 PMID: 26734837 PMCID: PMC4823025 SCOPUS ID: 2-s2.0-84962296906 01/07/2016       17 Citations
  • Molecular dynamics use in personalized cancer medicine example of MET Y501C mutation (Tsigelny IF, Kurzrock R, Skjevik AA, Kouznetsova VL, Ikeda S) SIMULTECH 2016 - Proceedings of the 6th International Conference on Simulation and Modeling Methodologies, Technologies and Applications 2016:71-74 SCOPUS ID: 2-s2.0-84991214058 01/01/2016       2 Citations
  • Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. (Siqing F, Culotta KS, Falchook GS, Hong DS, Myers AL, Zhang YP, Naing A, Janku F, Hou MM, Kurzrock R) Cancer Chemother Pharmacol 2016 Feb;77(2):357-64 PMID: 26698868 SCOPUS ID: 2-s2.0-84958046283 12/25/2015       3 Citations
  • Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors. (Falchook GS, Zhou X, Venkatakrishnan K, Kurzrock R, Mahalingam D, Goldman JW, Jung J, Ullmann CD, Milch C, Rosen LS, Sarantopoulos J) Drugs R D 2016 Mar;16(1):45-52 PMID: 26689566 PMCID: PMC4767718 SCOPUS ID: 2-s2.0-84959233070 12/23/2015       7 Citations
  • Actionability and precision oncology. (Schwaederle M, Kurzrock R) Oncoscience 2015;2(10):779-80 PMID: 26682241 PMCID: PMC4671916 SCOPUS ID: 2-s2.0-84958740092 12/19/2015       7 Citations
  • Precision medicine: lessons learned from the SHIVA trial. (Tsimberidou AM, Kurzrock R) Lancet Oncol 2015 Dec;16(16):e579-80 PMID: 26678197 SCOPUS ID: 2-s2.0-84961662117 12/19/2015       42 Citations
  • Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease. (Fajgenbaum DC, Kurzrock R) Immunotherapy 2016;8(1):17-26 PMID: 26634298 SCOPUS ID: 2-s2.0-84950265207 12/05/2015       15 Citations
  • Understanding Toxicities of Targeted Agents: Implications for Anti-tumor Activity and Management. (Liu S, Kurzrock R) Semin Oncol 2015 Dec;42(6):863-75 PMID: 26615131 SCOPUS ID: 2-s2.0-84962205976 11/29/2015       22 Citations
  • Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress. (Falchook GS, Bastida CC, Kurzrock R) Semin Oncol 2015 Dec;42(6):832-48 PMID: 26615129 SCOPUS ID: 2-s2.0-84962210668 11/29/2015       66 Citations
  • Targeted Inhibitors: Novel Strategies for Response Optimization. (Kurzrock R) Semin Oncol 2015 Dec;42(6):773-4 PMID: 26615124 SCOPUS ID: 2-s2.0-84962298275 11/29/2015    
  • First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. (Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R) Clin Cancer Res 2016 Apr 15;22(8):1932-9 PMID: 26603258 SCOPUS ID: 2-s2.0-84966292102 11/26/2015       54 Citations
  • AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. (Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MV, Mohseni M, Lawson D, Reimer C, Blakey DC, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR) Sci Transl Med 2015 Nov 18;7(314):314ra185 PMID: 26582900 PMCID: PMC5279222 SCOPUS ID: 2-s2.0-84947724597 11/20/2015       256 Citations
  • NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. (Kurzrock R, Colevas AD, Olszanski A, Akerley W, Arteaga CL, Carson WE 3rd, Clark JW, DiPersio JF, Ettinger DS, Morgan RJ Jr, Schwartzberg LS, Venook AP, Gocke CD, Tait J, Stewart FM) J Natl Compr Canc Netw 2015 Nov;13(11):1337-46 PMID: 26553764 SCOPUS ID: 2-s2.0-84947285897 11/11/2015       17 Citations
  • Combining Targeted Therapies (Rodon J, Azaro A, Torrejon D, Kurzrock R) Targeted Therapy in Translational Cancer Research 30 October 2015:14-26 SCOPUS ID: 2-s2.0-85015936361 10/30/2015    
  • Targeted Therapy in Translational Cancer Research (Tsimberidou AM, Kurzrock R, Anderson KC) Targeted Therapy in Translational Cancer Research 30 October 2015:1-378 SCOPUS ID: 2-s2.0-84983529361 10/30/2015       2 Citations
  • Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma. (Hong DS, Kurzrock R, Falchook GS, Andresen C, Kwak J, Ren M, Xu L, George GC, Kim KB, Nguyen LM, O'Brien JP, Nemunaitis J) Oncotarget 2015 Dec 15;6(40):43127-34 PMID: 26503473 PMCID: PMC4767496 SCOPUS ID: 2-s2.0-84952360368 10/28/2015       16 Citations
  • Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. (Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett C, Karp D, Kurzrock R, Zinner R, Raghav K, Subbiah V, Hess K, Meric-Bernstam F, Hong DS, Overman MJ) BMC Cancer 2015 Oct 16;15:713 PMID: 26474549 PMCID: PMC4609167 SCOPUS ID: 2-s2.0-84944472805 10/18/2015       31 Citations
  • The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases. (Stewart DJ, Batist G, Kantarjian HM, Bradford JP, Schiller JH, Kurzrock R) Clin Cancer Res 2015 Oct 15;21(20):4561-8 PMID: 26473192 SCOPUS ID: 2-s2.0-84945544300 10/17/2015       22 Citations
  • Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies. (Jain RK, Hong DS, Naing A, Wheler J, Helgason T, Shi NY, Gad Y, Kurzrock R) Cell Cycle 2015;14(21):3434-40 PMID: 26467427 PMCID: PMC4825574 SCOPUS ID: 2-s2.0-84959465321 10/16/2015       2 Citations
  • The National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare Cancers. (Schott AF, Welch JJ, Verschraegen CF, Kurzrock R) Semin Oncol 2015 Oct;42(5):731-9 PMID: 26433554 PMCID: PMC4673983 SCOPUS ID: 2-s2.0-84952655056 10/05/2015       13 Citations
  • Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. (Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R) Oncotarget 2015 Oct 20;6(32):32602-9 PMID: 26418953 PMCID: PMC4741715 SCOPUS ID: 2-s2.0-84946026939 09/30/2015       14 Citations
  • Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. (Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R) Oncotarget 2015 Sep 15;6(27):24581 PMID: 26405159 PMCID: PMC4695208 SCOPUS ID: 2-s2.0-84943417391 09/26/2015       2 Citations
  • Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. (Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S) J Clin Oncol 2015 Dec 01;33(34):4023-31 PMID: 26392102 PMCID: PMC4669588 SCOPUS ID: 2-s2.0-84951745408 09/24/2015       316 Citations
  • Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. (Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R) J Natl Cancer Inst 2015 Nov;107(11) PMID: 26378224 PMCID: PMC4857149 SCOPUS ID: 2-s2.0-84946208882 09/18/2015       125 Citations
  • The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. (Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R) Clin Cancer Res 2016 Jan 01;22(1):259-67 PMID: 26373574 SCOPUS ID: 2-s2.0-84954469968 09/17/2015       342 Citations
  • BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. (Janku F, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, Bempt IV, Reijans M, Naing A, Fu S, Piha-Paul SA, Hong DS, Holley VR, Tsimberidou AM, Stepanek VM, Patel SP, Kopetz ES, Subbiah V, Wheler JJ, Zinner RG, Karp DD, Luthra R, Roy-Chowdhuri S, Sablon E, Meric-Bernstam F, Maertens G, Kurzrock R) Oncotarget 2015 Sep 29;6(29):26886-94 PMID: 26330075 PMCID: PMC4694960 SCOPUS ID: 2-s2.0-84944463600 09/04/2015       41 Citations
  • A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. (van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, Qin X, Qi M, Tromp B, Kurzrock R) Oncotarget 2015 Oct 06;6(30):30408-19 PMID: 26327301 PMCID: PMC4745809 SCOPUS ID: 2-s2.0-84945143881 09/04/2015       40 Citations
  • Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. (Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R) J Clin Oncol 2015 Nov 10;33(32):3817-25 PMID: 26304871 PMCID: PMC4737863 SCOPUS ID: 2-s2.0-84946053976 08/26/2015       269 Citations
  • Genomic landscape of salivary gland tumors. (Kato S, Elkin SK, Schwaederle M, Tomson BN, Helsten T, Carter JL, Kurzrock R) Oncotarget 2015 Sep 22;6(28):25631-45 PMID: 26247885 PMCID: PMC4694855 SCOPUS ID: 2-s2.0-84944474508 08/08/2015       31 Citations
  • Challenges and perspective of drug repurposing strategies in early phase clinical trials. (Kato S, Moulder SL, Ueno NT, Wheler JJ, Meric-Bernstam F, Kurzrock R, Janku F) Oncoscience 2015;2(6):576-80 PMID: 26244164 PMCID: PMC4506360 SCOPUS ID: 2-s2.0-84954512298 08/06/2015       28 Citations
  • Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center. (Parker BA, Schwaederlé M, Scur MD, Boles SG, Helsten T, Subramanian R, Schwab RB, Kurzrock R) J Oncol Pract 2015 Nov;11(6):442-9 PMID: 26243651 SCOPUS ID: 2-s2.0-84947216680 08/06/2015       43 Citations
  • Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. (Helsten T, Schwaederle M, Kurzrock R) Cancer Metastasis Rev 2015 Sep;34(3):479-96 PMID: 26224133 PMCID: PMC4573649 SCOPUS ID: 2-s2.0-84942194341 08/01/2015       77 Citations
  • A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors. (Henary H, George GC, Wheler J, Naing A, Piha-Paul S, Fu S, Mistry R, Zinner R, Kurzrock R, Hong DS) Cancer Chemother Pharmacol 2015 Sep;76(3):597-603 PMID: 26210681 SCOPUS ID: 2-s2.0-84939571666 07/27/2015    
  • Molecular landscape of prostate cancer: implications for current clinical trials. (Khemlina G, Ikeda S, Kurzrock R) Cancer Treat Rev 2015 Nov;41(9):761-6 PMID: 26210103 SCOPUS ID: 2-s2.0-84945470634 07/27/2015       48 Citations
  • Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps. (Cobain EF, Chinnaiyan AM, Kurzrock R, Baker LH) JAMA Oncol 2015 Jul;1(4):542 PMID: 26181268 SCOPUS ID: 2-s2.0-84982871887 07/17/2015       1 Citation
  • Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. (Hong DS, Kurzrock R, Wheler JJ, Naing A, Falchook GS, Fu S, Kim KB, Davies MA, Nguyen LM, George GC, Xu L, Shumaker R, Ren M, Mink J, Bedell C, Andresen C, Sachdev P, O'Brien JP, Nemunaitis J) Clin Cancer Res 2015 Nov 01;21(21):4801-10 PMID: 26169970 PMCID: PMC4840931 SCOPUS ID: 2-s2.0-84947233902 07/15/2015       50 Citations
  • Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. (Subbiah IM, Falchook GS, Kaseb AO, Hess KR, Tsimberidou AM, Fu S, Subbiah V, Hong DS, Naing A, Piha-Paul SA, Akmal O, Janku F, Kurzrock R) Oncotarget 2015 Sep 29;6(29):28453-62 PMID: 26164085 PMCID: PMC4695071 SCOPUS ID: 2-s2.0-84944449976 07/15/2015       8 Citations
  • A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. (Hong DS, Rosen P, Lockhart AC, Fu S, Janku F, Kurzrock R, Khan R, Amore B, Caudillo I, Deng H, Hwang YC, Loberg R, Ngarmchamnanrith G, Beaupre DM, Lee P) Oncotarget 2015 Jul 30;6(21):18693-706 PMID: 26155941 PMCID: PMC4621921 SCOPUS ID: 2-s2.0-84938800976 07/15/2015       17 Citations
  • Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma. (Ikeda S, Hansel DE, Kurzrock R) Cancer Treat Rev 2015 Sep;41(8):699-706 PMID: 26138514 SCOPUS ID: 2-s2.0-84941023230 07/04/2015       11 Citations
  • Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors. (Falchook GS, Venkatakrishnan K, Sarantopoulos J, Kurzrock R, Mita AC, Fu S, Mita MM, Zhou X, Jung JA, Ullmann CD, Milch C, Rosen LS) Int J Clin Pharmacol Ther 2015 Jul;53(7):563-72 PMID: 26073352 SCOPUS ID: 2-s2.0-84936748326 06/16/2015       6 Citations
  • The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab. (Busaidy NL, LoRusso P, Lawhorn K, Hess KR, Habra MA, Fu S, Hong DS, Chen HX, Doyle LA, Kurzrock R, Naing A) Oncologist 2015 Jul;20(7):737-41 PMID: 26054632 PMCID: PMC4492245 SCOPUS ID: 2-s2.0-84936871168 06/10/2015       11 Citations
  • The checklist: BEST medical center employment requirements 2015. (Cohen PR, Kurzrock R) Clin Dermatol 2015 Jul-Aug;33(4):493-7 PMID: 26051067 SCOPUS ID: 2-s2.0-84955306918 06/09/2015       4 Citations
  • Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types. (Schwaederle M, Elkin SK, Tomson BN, Carter JL, Kurzrock R) Cell Cycle 2015;14(14):2355-61 PMID: 26030731 PMCID: PMC4613537 SCOPUS ID: 2-s2.0-84943793501 06/02/2015       41 Citations
  • Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes. (Kurzrock R, Giles FJ) Cell Cycle 2015;14(14):2219-21 PMID: 26030337 PMCID: PMC4615125 SCOPUS ID: 2-s2.0-84940181679 06/02/2015       48 Citations
  • Multiple gene aberrations and breast cancer: lessons from super-responders. (Wheler JJ, Atkins JT, Janku F, Moulder SL, Yelensky R, Stephens PJ, Kurzrock R) BMC Cancer 2015 May 29;15:442 PMID: 26021831 PMCID: PMC4446801 SCOPUS ID: 2-s2.0-84930203293 05/30/2015       14 Citations
  • Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. (Said R, Kurzrock R, Naing A, Hong DS, Fu S, Piha-Paul SA, Wheler JJ, Janku F, Kee BK, Bidyasar S, Lim J, Wallace M, Tsimberidou AM) Invest New Drugs 2015 Aug;33(4):911-20 PMID: 25990659 PMCID: PMC4492845 SCOPUS ID: 2-s2.0-84944441702 05/21/2015       7 Citations
  • Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. (Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R) Oncotarget 2015 May 20;6(14):12809-21 PMID: 25980577 PMCID: PMC4494976 SCOPUS ID: 2-s2.0-84930025659 05/20/2015       74 Citations
  • Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics. (Parish A, Schwaederle M, Daniels G, Piccioni D, Fanta P, Schwab R, Shimabukuro K, Parker BA, Helsten T, Kurzrock R) Cell Cycle 2015;14(13):2121-8 PMID: 25950492 PMCID: PMC4614941 SCOPUS ID: 2-s2.0-84943737092 05/08/2015       30 Citations
  • A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. (Lazar V, Rubin E, Depil S, Pawitan Y, Martini JF, Gomez-Navarro J, Yver A, Kan Z, Dry JR, Kehren J, Validire P, Rodon J, Vielh P, Ducreux M, Galbraith S, Lehnert M, Onn A, Berger R, Pierotti MA, Porgador A, Pramesh CS, Ye DW, Carvalho AL, Batist G, Le Chevalier T, Morice P, Besse B, Vassal G, Mortlock A, Hansson J, Berindan-Neagoe I, Dann R, Haspel J, Irimie A, Laderman S, Nechushtan H, Al Omari AS, Haywood T, Bresson C, Soo KC, Osman I, Mata H, Lee JJ, Jhaveri K, Meurice G, Palmer G, Lacroix L, Koscielny S, Eterovic KA, Blay JY, Buller R, Eggermont A, Schilsky RL, Mendelsohn J, Soria JC, Rothenberg M, Scoazec JY, Hong WK, Kurzrock R) Oncotarget 2015 Jun 10;6(16):14139-52 PMID: 25944621 PMCID: PMC4546456 SCOPUS ID: 2-s2.0-84931037125 05/07/2015       20 Citations
  • Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer. (Schwaederle M, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R) Cell Cycle 2015;14(11):1730-7 PMID: 25928476 PMCID: PMC4614790 SCOPUS ID: 2-s2.0-84943780413 05/01/2015       8 Citations
  • Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. (Rodon J, Soria JC, Berger R, Batist G, Tsimberidou A, Bresson C, Lee JJ, Rubin E, Onn A, Schilsky RL, Miller WH, Eggermont AM, Mendelsohn J, Lazar V, Kurzrock R) Ann Oncol 2015 Aug;26(8):1791-8 PMID: 25908602 PMCID: PMC5006164 SCOPUS ID: 2-s2.0-84931841428 04/25/2015       57 Citations
  • Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. (Rodrigues HV, Ke D, Lim J, Stephen B, Bellido J, Janku F, Zinner R, Tsimberidou A, Hong D, Piha-Paul S, Fu S, Naing A, Subbiah V, Karp D, Falchook G, Kurzrock R, Wheler J) Invest New Drugs 2015 Jun;33(3):700-9 PMID: 25902899 SCOPUS ID: 2-s2.0-84937758561 04/24/2015       12 Citations
  • Castleman's disease and sarcoidosis, a rare association resulting in a "mixed" response: a case report. (Mohammed A, Janku F, Qi M, Kurzrock R) J Med Case Rep 2015 Feb 28;9:45 PMID: 25884809 PMCID: PMC4365524 SCOPUS ID: 2-s2.0-84928230342 04/18/2015       4 Citations
  • Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. (Wheler J, Yelensky R, Falchook G, Kim KB, Hwu P, Tsimberidou AM, Stephens PJ, Hong D, Cronin MT, Kurzrock R) BMC Cancer 2015 Feb 18;15:61 PMID: 25886620 PMCID: PMC4340232 SCOPUS ID: 2-s2.0-84924056275 04/18/2015       20 Citations
  • Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. (Moulder S, Helgason T, Janku F, Wheler J, Moroney J, Booser D, Albarracin C, Morrow PK, Atkins J, Koenig K, Gilcrease M, Kurzrock R) Ann Oncol 2015 Jul;26(7):1346-52 PMID: 25878190 PMCID: PMC6267938 SCOPUS ID: 2-s2.0-84942096399 04/17/2015       44 Citations
  • Merkel Cell Carcinoma with a Suppressor of Fused (SUFU) Mutation: Case Report and Potential Therapeutic Implications. (Cohen PR, Kurzrock R) Dermatol Ther (Heidelb) 2015 Jun;5(2):129-43 PMID: 25876211 PMCID: PMC4470960 SCOPUS ID: 2-s2.0-84935856294 04/16/2015       8 Citations
  • On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients. (Schwaederle M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R) Mol Cancer Ther 2015 Jun;14(6):1488-94 PMID: 25852059 SCOPUS ID: 2-s2.0-84937990975 04/09/2015       66 Citations
  • VEGF and dual-EGFR inhibition in colorectal cancer. (Falchook GS, Kurzrock R) Cell Cycle 2015;14(8):1129-30 PMID: 25845022 PMCID: PMC4614794 SCOPUS ID: 2-s2.0-84928024823 04/07/2015       11 Citations
  • Meir Wetzler, MD. (Kurzrock R, Estrov Z, Talpaz M, Kantarjian HM) Cancer 2015 Jul 01;121(13):2106-7 PMID: 25832851 SCOPUS ID: 2-s2.0-84925955326 04/03/2015    
  • Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. (Hong DS, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R) Invest New Drugs 2015 Jun;33(3):621-31 PMID: 25822109 PMCID: PMC4482235 SCOPUS ID: 2-s2.0-84937760589 03/31/2015       39 Citations
  • Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. (Tsimberidou AM, Said R, Culotta K, Wistuba I, Jelinek J, Fu S, Falchook G, Naing A, Piha-Paul S, Zinner R, Siddik ZH, He G, Hess K, Stewart DJ, Kurzrock R, Issa JP) Clin Epigenetics 2015;7:29 PMID: 25806091 PMCID: PMC4371799 SCOPUS ID: 2-s2.0-84927563696 03/26/2015       11 Citations
  • Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. (Tsigelny IF, Wheler JJ, Greenberg JP, Kouznetsova VL, Stewart DJ, Bazhenova L, Kurzrock R) Oncotarget 2015 Mar 20;6(8):6029-39 PMID: 25760241 PMCID: PMC4467419 SCOPUS ID: 2-s2.0-84925587482 03/12/2015       26 Citations
  • Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome. (Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V, Pan-Cancer Working Group) Discov Med 2015 Feb;19(103):109-16 PMID: 25725225 SCOPUS ID: 2-s2.0-84940528105 03/01/2015       13 Citations
  • Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies. (Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V, Pan-Cancer Working Group) Discov Med 2015 Feb;19(103):101-8 PMID: 25725224 SCOPUS ID: 2-s2.0-84940477944 03/01/2015       2 Citations
  • Molecular landscape of pancreatic cancer: implications for current clinical trials. (Heestand GM, Kurzrock R) Oncotarget 2015 Mar 10;6(7):4553-61 PMID: 25714017 PMCID: PMC4467098 SCOPUS ID: 2-s2.0-84925004122 02/26/2015       69 Citations
  • HER2 expression status in diverse cancers: review of results from 37,992 patients. (Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R) Cancer Metastasis Rev 2015 Mar;34(1):157-64 PMID: 25712293 PMCID: PMC4368842 SCOPUS ID: 2-s2.0-84925382907 02/26/2015       207 Citations
  • PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. (Patel SP, Kurzrock R) Mol Cancer Ther 2015 Apr;14(4):847-56 PMID: 25695955 SCOPUS ID: 2-s2.0-84935474357 02/20/2015       1243 Citations
  • Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics. (Kato S, Schwaederle M, Daniels GA, Piccioni D, Kesari S, Bazhenova L, Shimabukuro K, Parker BA, Fanta P, Kurzrock R) Cell Cycle 2015;14(8):1252-9 PMID: 25695927 PMCID: PMC4614867 SCOPUS ID: 2-s2.0-84928014990 02/20/2015       36 Citations
  • SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. (Gonzalez-Angulo AM, Krop I, Akcakanat A, Chen H, Liu S, Li Y, Culotta KS, Tarco E, Piha-Paul S, Moulder-Thompson S, Velez-Bravo V, Sahin AA, Doyle LA, Do KA, Winer EP, Mills GB, Kurzrock R, Meric-Bernstam F) J Natl Cancer Inst 2015 Mar;107(3) PMID: 25688104 PMCID: PMC4342675 SCOPUS ID: 2-s2.0-84930402659 02/18/2015       25 Citations
  • Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines. (Naing A, Dalal S, Abdelrahim M, Wheler J, Hess K, Fu S, Hong DS, Janku F, Falchook GS, Ilustre A, Ouyang F, Kurzrock R) Support Care Cancer 2015 Sep;23(9):2649-54 PMID: 25680763 SCOPUS ID: 2-s2.0-84938423819 02/15/2015       20 Citations
  • VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy. (Schwaederlé M, Lazar V, Validire P, Hansson J, Lacroix L, Soria JC, Pawitan Y, Kurzrock R) Cancer Res 2015 Apr 01;75(7):1187-90 PMID: 25672981 SCOPUS ID: 2-s2.0-84929334169 02/13/2015       74 Citations
  • Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. (Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, Wolff R, Kurzrock R, Meric-Bernstam F) Ann Oncol 2015 May;26(5):1012-1018 PMID: 25669829 PMCID: PMC6279067 SCOPUS ID: 2-s2.0-84929089379 02/12/2015       41 Citations
  • Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. (Bilen MA, Fu S, Falchook GS, Ng CS, Wheler JJ, Abdelrahim M, Erguvan-Dogan B, Hong DS, Tsimberidou AM, Kurzrock R, Naing A) Cancer Chemother Pharmacol 2015 Apr;75(4):869-74 PMID: 25666183 SCOPUS ID: 2-s2.0-84925515381 02/11/2015       20 Citations
  • Cyclin alterations in diverse cancers: Outcome and co-amplification network. (Schwaederlé M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R) Oncotarget 2015 Feb 20;6(5):3033-42 PMID: 25596748 PMCID: PMC4413635 SCOPUS ID: 2-s2.0-84923294701 01/19/2015       23 Citations
  • Androgen receptors beyond prostate cancer: an old marker as a new target. (Munoz J, Wheler JJ, Kurzrock R) Oncotarget 2015 Jan 20;6(2):592-603 PMID: 25595907 PMCID: PMC4359241 SCOPUS ID: 2-s2.0-84921778182 01/18/2015       24 Citations
  • Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. (Falchook GS, Naing A, Wheler JJ, Tsimberidou AM, Zinner R, Hong DS, Fu S, Piha-Paul SA, Janku F, Hess KR, Bastida C, Kurzrock R) Oncoscience 2014;1(8):540-9 PMID: 25594061 PMCID: PMC4278330 SCOPUS ID: 2-s2.0-84928004963 01/17/2015       14 Citations
  • A framework for genomic biomarker actionability and its use in clinical decision making. (Vidwans SJ, Turski ML, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R) Oncoscience 2014;1(10):614-623 PMID: 25593991 PMCID: PMC4278279 SCOPUS ID: 2-s2.0-84942117421 01/17/2015       24 Citations
  • MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. (Tang C, Jardim DL, Falchook GS, Hess K, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, De Melo Galgiato D, Westin SN, Meric-Bernstam F, Kurzrock R, Hong DS) Oncoscience 2014;1(1):5-13 PMID: 25593979 PMCID: PMC4295762 SCOPUS ID: 2-s2.0-84898629248 01/17/2015       24 Citations
  • Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience. (Corrales-Medina FF, Herzog C, Hess K, Egas-Bejar D, Hong DS, Falchook G, Anderson P, Nunez C, Huh WW, Naing A, Tsimberidou AM, Wheler J, Paul SP, Janku F, Kleinerman ES, Kurzrock R, Subbiah V) Oncoscience 2014 Jul 27;1(7):522-530 PMID: 25587555 PMCID: PMC4278323 SCOPUS ID: 2-s2.0-84928004935 01/15/2015       6 Citations
  • Promoting Precision Cancer Medicine through a Community-Driven Knowledgebase. (Geifman N, Haviv I, Kurzrock R, Rubin E) J Pers Med 2014 Dec 15;4(4):475-88 PMID: 25563458 PMCID: PMC4282884 01/08/2015    
  • Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. (Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V, Pan-Cancer Working Group) Discov Med 2014 Dec;18(101):331-9 PMID: 25549704 SCOPUS ID: 2-s2.0-84937816121 01/01/2015       12 Citations
  • Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome. (Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V, Pan-Cancer Working Group) Discov Med 2014 Dec;18(101):323-30 PMID: 25549703 SCOPUS ID: 2-s2.0-84938291101 01/01/2015       8 Citations
  • Hematopoietic Growth Factors and Cytokines (Ekmekcioglu S, Kurzrock R, Grimm EA) The Molecular Basis of Cancer: Fourth Edition March 2014 SCOPUS ID: 2-s2.0-84903030738 01/01/2015       1 Citation
  • Expression of estrogen and progesterone receptors across human malignancies: new therapeutic opportunities. (Munoz J, Wheler J, Kurzrock R) Cancer Metastasis Rev 2015 Dec;34(4):547-61 PMID: 25543191 SCOPUS ID: 2-s2.0-84958762586 12/30/2014       11 Citations
  • A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours. (Hong DS, Kurzrock R, Mulay M, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Rosen LS) Oncotarget 2014 Nov 30;5(22):11154-67 PMID: 25525888 PMCID: PMC4294348 SCOPUS ID: 2-s2.0-84917690919 12/20/2014       11 Citations
  • Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. (Hou MM, Liu X, Wheler J, Naing A, Hong D, Coleman RL, Tsimberidou A, Janku F, Zinner R, Lu K, Kurzrock R, Fu S) Oncotarget 2014 Nov 30;5(22):11168-79 PMID: 25426553 PMCID: PMC4294378 SCOPUS ID: 2-s2.0-84917710610 11/27/2014       46 Citations
  • Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. (Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, Angelo LS, Vishwamitra D, Hess K, Howard AN, Parkhurst KL, Amin HM, Kurzrock R) Oncotarget 2014 Nov 15;5(21):10280-92 PMID: 25373733 PMCID: PMC4279372 SCOPUS ID: 2-s2.0-84916912453 11/07/2014       40 Citations
  • Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art. (Randall JM, Millard F, Kurzrock R) Cancer Metastasis Rev 2014 Dec;33(4):1109-24 PMID: 25365943 SCOPUS ID: 2-s2.0-84914122349 11/05/2014       65 Citations
  • Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. (Falchook GS, Wheler JJ, Naing A, Piha-Paul SA, Fu S, Tsimberidou AM, Hong DS, Janku F, Zinner R, Jiang Y, Huang M, Lin Q, Parkhurst K, Kurzrock R) Invest New Drugs 2015 Feb;33(1):215-24 PMID: 25363205 PMCID: PMC4477529 SCOPUS ID: 2-s2.0-84922005567 11/05/2014       9 Citations
  • NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. (Venook AP, Arcila ME, Benson AB 3rd, Berry DA, Camidge DR, Carlson RW, Choueiri TK, Guild V, Kalemkerian GP, Kurzrock R, Lovly CM, McKee AE, Morgan RJ, Olszanski AJ, Redman MW, Stearns V, McClure J, Birkeland ML) J Natl Compr Canc Netw 2014 Nov;12(11):1629-49 PMID: 25361808 PMCID: PMC5241088 SCOPUS ID: 2-s2.0-84908530231 11/02/2014       15 Citations
  • Unique molecular landscapes in cancer: implications for individualized, curated drug combinations. (Wheler J, Lee JJ, Kurzrock R) Cancer Res 2014 Dec 15;74(24):7181-4 PMID: 25326492 PMCID: PMC4292868 SCOPUS ID: 2-s2.0-84918529556 10/19/2014       49 Citations
  • Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. (Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, Salgia R, Kurzrock R, Meric-Bernstam F, Hong DS) Clin Cancer Res 2014 Dec 15;20(24):6336-45 PMID: 25326232 SCOPUS ID: 2-s2.0-84919703143 10/19/2014       62 Citations
  • Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. (Hyman DM, Diamond EL, Vibat CR, Hassaine L, Poole JC, Patel M, Holley VR, Cabrilo G, Lu TT, Arcila ME, Chung YR, Rampal R, Lacouture ME, Rosen N, Meric-Bernstam F, Baselga J, Kurzrock R, Erlander MG, Janku F, Abdel-Wahab O) Cancer Discov 2015 Jan;5(1):64-71 PMID: 25324352 PMCID: PMC5705028 SCOPUS ID: 2-s2.0-84922372527 10/18/2014       99 Citations
  • A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. (Falchook GS, Moulder S, Naing A, Wheler JJ, Hong DS, Piha-Paul SA, Tsimberidou AM, Fu S, Zinner R, Janku F, Jiang Y, Huang M, Parkhurst KL, Kurzrock R) Invest New Drugs 2015 Feb;33(1):177-86 PMID: 25323060 PMCID: PMC4297242 SCOPUS ID: 2-s2.0-84921384013 10/18/2014       18 Citations
  • Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic. (Tang C, Hess K, Jardim DL, Gagliato Dde M, Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul S, Subbiah V, Wheler J, Zinner RG, Kurzrock R, Ellis LM, Meric-Berstam F, Hong DS) Clin Cancer Res 2014 Dec 01;20(23):5956-63 PMID: 25316815 SCOPUS ID: 2-s2.0-84918548091 10/16/2014       9 Citations
  • Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. (Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR Jr, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, Tsimberidou AM) Oncotarget 2014 Oct 15;5(19):8937-46 PMID: 25313136 PMCID: PMC4253408 SCOPUS ID: 2-s2.0-84910088551 10/15/2014       6 Citations
  • BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. (Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack SG, Cabanillas ME, Sherman SI, Ma B, Curtis M, Goodman V, Kurzrock R) Thyroid 2015 Jan;25(1):71-7 PMID: 25285888 PMCID: PMC4291160 SCOPUS ID: 2-s2.0-84920841992 10/07/2014       118 Citations
  • Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. (Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ) Mol Cancer Ther 2014 Dec;13(12):3175-84 PMID: 25253784 PMCID: PMC4258414 SCOPUS ID: 2-s2.0-84918500160 09/26/2014       24 Citations
  • Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors. (Jiang Y, Subbiah V, Janku F, Ludwig JA, Naing A, Benjamin RS, Brown RE, Anderson P, Kurzrock R) PLoS One 2014;9(8):e93676 PMID: 25119929 PMCID: PMC4131855 SCOPUS ID: 2-s2.0-84905915756 08/15/2014       34 Citations
  • MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. (Jardim DL, de Melo Gagliato D, Falchook G, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir N, Corn P, Tang C, Hess K, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS) Clin Genitourin Cancer 2015 Feb;13(1):e19-26 PMID: 25087088 PMCID: PMC5144738 SCOPUS ID: 2-s2.0-84920623892 08/05/2014       14 Citations
  • Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples. (Stewart DJ, Nunez MI, Jelinek J, Hong D, Gupta S, Aldaz M, Issa JP, Kurzrock R, Wistuba II) Clin Epigenetics 2014;6(1):13 PMID: 25024751 PMCID: PMC4094901 SCOPUS ID: 2-s2.0-84923367056 07/16/2014       6 Citations
  • BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. (Janku F, Vibat CR, Kosco K, Holley VR, Cabrilo G, Meric-Bernstam F, Stepanek VM, Lin PP, Leppin L, Hassaine L, Poole JC, Kurzrock R, Erlander MG) Oncotarget 2014 Jun 15;5(11):3607-10 PMID: 25003820 PMCID: PMC4116506 SCOPUS ID: 2-s2.0-84903512238 07/09/2014       57 Citations
  • Characteristics and survival of patients with advanced cancer and p53 mutations. (Said R, Ye Y, Hong DS, Janku F, Fu S, Naing A, Wheler JJ, Kurzrock R, Thomas C, Palmer GA, Hess KR, Aldape K, Tsimberidou AM) Oncotarget 2014 Jun 15;5(11):3871-9 PMID: 25003695 PMCID: PMC4116527 SCOPUS ID: 2-s2.0-84903545565 07/09/2014       10 Citations
  • Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. (Tsimberidou AM, Wen S, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Aldape K, Ye Y, Kurzrock R, Berry D) Clin Cancer Res 2014 Sep 15;20(18):4827-36 PMID: 24987059 PMCID: PMC4518867 SCOPUS ID: 2-s2.0-84907912530 07/06/2014       148 Citations
  • Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436). (Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau HT, Brown MP, Hamid O, Infante JR, Millward M, Pavlick A, Chin MT, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF) Clin Cancer Res 2014 Sep 01;20(17):4449-58 PMID: 24958809 SCOPUS ID: 2-s2.0-84917728415 06/25/2014       47 Citations
  • Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. (Janku F, Kaseb AO, Tsimberidou AM, Wolff RA, Kurzrock R) Oncotarget 2014 May 30;5(10):3012-22 PMID: 24931142 PMCID: PMC4102787 SCOPUS ID: 2-s2.0-84902118103 06/17/2014       71 Citations
  • First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors. (Hong DS, Henary H, Falchook GS, Naing A, Fu S, Moulder S, Wheler JJ, Tsimberidou A, Durand JB, Khan R, Yang P, Johansen M, Newman RA, Kurzrock R) Invest New Drugs 2014 Dec;32(6):1204-12 PMID: 24919855 SCOPUS ID: 2-s2.0-84938690353 06/13/2014       44 Citations
  • Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. (Wheler JJ, Moulder SL, Naing A, Janku F, Piha-Paul SA, Falchook GS, Zinner R, Tsimberidou AM, Fu S, Hong DS, Atkins JT, Yelensky R, Stephens PJ, Kurzrock R) Oncotarget 2014 May 30;5(10):3029-38 PMID: 24912489 PMCID: PMC4102789 SCOPUS ID: 2-s2.0-84902110097 06/11/2014       33 Citations
  • Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study. (Falchook G, Kurzrock R, Gouw L, Hong D, McGregor KA, Zhou X, Shi H, Fingert H, Sharma S) Invest New Drugs 2014 Dec;32(6):1181-7 PMID: 24879333 PMCID: PMC4229392 SCOPUS ID: 2-s2.0-84939882181 06/01/2014       31 Citations
  • Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms. (Liu S, Kurzrock R) Cancer Treat Rev 2014 Aug;40(7):883-91 PMID: 24867380 SCOPUS ID: 2-s2.0-84901979851 05/29/2014       98 Citations
  • Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. (Bendell JC, Hong DS, Burris HA 3rd, Naing A, Jones SF, Falchook G, Bricmont P, Elekes A, Rock EP, Kurzrock R) Cancer Chemother Pharmacol 2014 Jul;74(1):125-30 PMID: 24819685 SCOPUS ID: 2-s2.0-84903816370 05/14/2014       74 Citations
  • Erdheim-Chester disease: characteristics and management. (Munoz J, Janku F, Cohen PR, Kurzrock R) Mayo Clin Proc 2014 Jul;89(7):985-96 PMID: 24814521 SCOPUS ID: 2-s2.0-84904766986 05/13/2014       47 Citations
  • Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. (Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, Stephens MP, Meric-Bernstam F, Kurzrock R) Oncotarget 2014 May 15;5(9):2349-54 PMID: 24811890 PMCID: PMC4058010 SCOPUS ID: 2-s2.0-84901217741 05/09/2014       49 Citations
  • Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. (Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, Bazhenova LA, Subramanian R, Coutinho AC, Ojeda-Fournier H, Datnow B, Webster NJ, Lippman SM, Kurzrock R) Oncologist 2014 Jun;19(6):631-6 PMID: 24797821 PMCID: PMC4041669 SCOPUS ID: 2-s2.0-84901918076 05/07/2014       125 Citations
  • Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. (Hou MM, Liu X, Wheler J, Naing A, Hong D, Bodurka D, Schmeler K, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Hu CY, Lu K, Kurzrock R, Fu S) Anticancer Res 2014 May;34(5):2349-55 PMID: 24778042 SCOPUS ID: 2-s2.0-84902960575 04/30/2014       6 Citations
  • Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. (Bilen MA, Durand JB, McQuinn L, Hess KR, Fu S, Falchook GS, Hong DS, Wheler JJ, Said R, Ewer MS, Kurzrock R, Naing A) Invest New Drugs 2014 Aug;32(4):717-22 PMID: 24764123 SCOPUS ID: 2-s2.0-84904461273 04/26/2014       3 Citations
  • Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. (Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R) Cancer 2014 Jul 15;120(14):2164-73 PMID: 24752867 SCOPUS ID: 2-s2.0-84903768222 04/23/2014       26 Citations
  • MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. (Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R) Lancet Oncol 2014 May;15(6):656-66 PMID: 24746841 SCOPUS ID: 2-s2.0-84899989426 04/22/2014       141 Citations
  • Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. (Piha-Paul SA, Wheler JJ, Fu S, Levenback C, Lu K, Falchook GS, Naing A, Hong DS, Tsimberidou AM, Kurzrock R) Oncotarget 2014 Apr 15;5(7):1846-55 PMID: 24742900 PMCID: PMC4039109 SCOPUS ID: 2-s2.0-84899011208 04/20/2014       26 Citations
  • MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. (Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS) Oncotarget 2014 Apr 15;5(7):1837-45 PMID: 24742823 PMCID: PMC4039117 SCOPUS ID: 2-s2.0-84899030304 04/20/2014       25 Citations
  • U.S. Food and Drug Administration inspections of clinical investigators: overview of results from 1977 to 2009. (Morgan-Linnell SK, Stewart DJ, Kurzrock R) Clin Cancer Res 2014 Jul 01;20(13):3364-70 PMID: 24737548 SCOPUS ID: 2-s2.0-84903827051 04/17/2014       11 Citations
  • Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus. (Piha-Paul SA, Shin SJ, Vats T, Guha-Thakurta N, Aaron J, Rytting M, Kleinerman E, Kurzrock R) Anticancer Res 2014 Apr;34(4):1939-45 PMID: 24692729 PMCID: PMC5685166 SCOPUS ID: 2-s2.0-84902246311 04/03/2014       20 Citations
  • Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. (Liu X, Lorusso P, Mita M, Piha-Paul S, Hong DS, Fu S, McQuinn L, Asatiani E, Doyle LA, Chen HX, Hess KR, Kurzrock R, Naing A) Oncologist 2014 Apr;19(4):426-8 PMID: 24668327 PMCID: PMC3983812 SCOPUS ID: 2-s2.0-84898429501 03/29/2014       10 Citations
  • HER2 aberrations in cancer: implications for therapy. (Yan M, Parker BA, Schwab R, Kurzrock R) Cancer Treat Rev 2014 Jul;40(6):770-80 PMID: 24656976 SCOPUS ID: 2-s2.0-84899948353 03/25/2014       156 Citations
  • Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience. (Tsimberidou AM, Vaklavas C, Fu S, Wen S, Lim JA, Hong D, Wheler J, Naing A, Uehara C, Wallace M, Kurzrock R) Hepatogastroenterology 2013 Oct;60(127):1611-23 PMID: 24634931 SCOPUS ID: 2-s2.0-84893971275 03/19/2014       10 Citations
  • Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. (Tsimberidou AM, Adamopoulos AM, Ye Y, Piha-Paul S, Janku F, Fu S, Hong D, Falchook GS, Naing A, Wheler J, Fortier A, Kurzrock R, Hess KR) J Natl Compr Canc Netw 2014 Feb;12(2):194-203 PMID: 24586081 SCOPUS ID: 2-s2.0-84895809305 03/04/2014       2 Citations
  • A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. (Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, van Laethem JL, Ottensmeier C, Lopez-Martin JA, Clive S, Joly F, Ray-Coquard I, Dirix L, Machiels JP, Steven N, Reddy M, Hall B, Puchalski TA, Bandekar R, van de Velde H, Tromp B, Vermeulen J, Kurzrock R) Clin Cancer Res 2014 Apr 15;20(8):2192-204 PMID: 24563479 SCOPUS ID: 2-s2.0-84898967209 02/25/2014       116 Citations
  • Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia. (Anzalone CL, Cohen PR, Kurzrock R, Cortes JE) Dermatol Online J 2014 Jan 15;20(1):21242 PMID: 24456946 SCOPUS ID: 2-s2.0-84892704051 01/25/2014       4 Citations
  • Anakinra-responsive lichen planus in a woman with Erdheim-Chester disease: a therapeutic enigma. (Cohen PR, Kurzrock R) Dermatol Online J 2014 Jan 15;20(1):21241 PMID: 24456945 SCOPUS ID: 2-s2.0-84892706184 01/25/2014       6 Citations
  • Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. (Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ, Kurzrock R) Cell Rep 2014 Jan 30;6(2):377-87 PMID: 24440717 PMCID: PMC4409143 SCOPUS ID: 2-s2.0-84895906492 01/21/2014       182 Citations
  • Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. (Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA, Atkins JT, Garcia-Manero G, Kurzrock R) Cancer Chemother Pharmacol 2014 Mar;73(3):495-501 PMID: 24435060 PMCID: PMC4148903 SCOPUS ID: 2-s2.0-84896031643 01/18/2014       42 Citations
  • A cancer trial scandal and its regulatory backlash. (Kurzrock R, Kantarjian H, Stewart DJ) Nat Biotechnol 2014 Jan;32(1):27-31 PMID: 24406925 SCOPUS ID: 2-s2.0-84892181395 01/11/2014       12 Citations
  • Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors. (Stewart DJ, Nunez MI, Jelinek J, Hong D, Gupta S, Issa JP, Wistuba II, Kurzrock R) Clin Epigenetics 2014 Jan 09;6(1):2 PMID: 24401732 PMCID: PMC3895853 SCOPUS ID: 2-s2.0-84901308117 01/10/2014       9 Citations
  • NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations. (Schroeder RD, Angelo LS, Kurzrock R) Oncotarget 2014 Jan 15;5(1):67-77 PMID: 24393766 PMCID: PMC3960189 SCOPUS ID: 2-s2.0-84893870298 01/08/2014       37 Citations
  • Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. (Mahadevan D, Sutton GR, Arteta-Bulos R, Bowden CJ, Miller PJ, Swart RE, Walker MS, Haluska P, Munster PN, Marshall J, Hamid O, Kurzrock R) Cancer Chemother Pharmacol 2014 Mar;73(3):467-73 PMID: 24390424 SCOPUS ID: 2-s2.0-84896040011 01/07/2014       29 Citations
  • A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma. (Hong DS, Gordon MS, Samlowski WE, Kurzrock R, Tannir N, Friedland D, Mendelson DS, Vogelzang NJ, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Appleman LJ) Clin Genitourin Cancer 2014 Jun;12(3):167-177.e2 PMID: 24365125 PMCID: PMC4754667 SCOPUS ID: 2-s2.0-84900319173 12/25/2013       20 Citations
  • Retreatment after secondary resistance or mixed response: a pilot study. (Naing A, Agarwal R, Falchook G, Hong DS, Janku F, Wheler J, Fu S, Kurzrock R) Oncology 2013;85(6):350-5 PMID: 24335388 SCOPUS ID: 2-s2.0-84892143563 12/18/2013       3 Citations
  • Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. (Fu S, Hou MM, Wheler J, Hong D, Naing A, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Falchook G, Kuo MT, Kurzrock R) Invest New Drugs 2014 Jun;32(3):465-72 PMID: 24306314 SCOPUS ID: 2-s2.0-84904646532 12/07/2013       23 Citations
  • A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. (Hong DS, Kurzrock R, Naing A, Wheler JJ, Falchook GS, Schiffman JS, Faulkner N, Pilat MJ, O'Brien J, LoRusso P) Invest New Drugs 2014 Jun;32(3):436-44 PMID: 24258465 SCOPUS ID: 2-s2.0-84904635074 11/22/2013       124 Citations
  • Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs. (Jardim DL, Hess KR, Lorusso P, Kurzrock R, Hong DS) Clin Cancer Res 2014 Jan 15;20(2):281-8 PMID: 24190980 SCOPUS ID: 2-s2.0-84892690026 11/06/2013       37 Citations
  • Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer. (Falchook GS, Moulder SL, Wheler JJ, Jiang Y, Bastida CC, Kurzrock R) Ann Oncol 2013 Dec;24(12):3004-11 PMID: 24158411 PMCID: PMC3841018 SCOPUS ID: 2-s2.0-84888816383 10/26/2013       22 Citations
  • Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit. (Fu S, McQuinn L, Naing A, Wheler JJ, Janku F, Falchook GS, Piha-Paul SA, Tu D, Howard A, Tsimberidou A, Zinner R, Hong DS, Kurzrock R) Oncologist 2013;18(12):1315-20 PMID: 24153239 PMCID: PMC3868426 SCOPUS ID: 2-s2.0-84890044052 10/25/2013       17 Citations
  • Genetics on a WHIM. (Al Ustwani O, Kurzrock R, Wetzler M) Br J Haematol 2014 Jan;164(1):15-23 PMID: 24111611 PMCID: PMC3961560 SCOPUS ID: 2-s2.0-84889599822 10/12/2013       35 Citations
  • Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases. (Garcia SS, Atkins JT, Falchook GS, Tsimberidou AM, Hong DS, Trivedi MV, Kurzrock R) Cancer Chemother Pharmacol 2013 Dec;72(6):1265-71 PMID: 24101145 SCOPUS ID: 2-s2.0-84890332473 10/09/2013       2 Citations
  • Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. (Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, Kurzrock R) Mol Cancer Ther 2013 Dec;12(12):2857-63 PMID: 24092809 PMCID: PMC4158732 SCOPUS ID: 2-s2.0-84890520181 10/05/2013       36 Citations
  • Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. (Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, Falchook G, Hong D, Akcakanat A, Chen H, Naing A, Fu S, Wheler J, Moulder S, Helgason T, Li S, Elias I, Desai N, Kurzrock R) Clin Cancer Res 2013 Oct 01;19(19):5474-84 PMID: 24089446 PMCID: PMC3935482 SCOPUS ID: 2-s2.0-84886413865 10/04/2013       54 Citations
  • Equipoise abandoned? Randomization and clinical trials. (Kurzrock R, Stewart DJ) Ann Oncol 2013 Oct;24(10):2471-2474 PMID: 24072520 SCOPUS ID: 2-s2.0-84884708410 09/28/2013       21 Citations
  • Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. (Gadgeel SM, Lew DL, Synold TW, LoRusso P, Chung V, Christensen SD, Smith DC, Kingsbury L, Hoering A, Kurzrock R) Cancer Chemother Pharmacol 2013 Nov;72(5):1089-96 PMID: 24057042 PMCID: PMC4072025 SCOPUS ID: 2-s2.0-84887187698 09/24/2013       21 Citations
  • Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. (Wheler JJ, Tsimberidou AM, Falchook GS, Zinner RG, Hong DS, Fok JY, Fu S, Piha-Paul SA, Naing A, Kurzrock R) Mol Cancer Ther 2013 Oct;12(10):2167-75 PMID: 23963360 PMCID: PMC4138057 SCOPUS ID: 2-s2.0-84885621292 08/22/2013       30 Citations
  • Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1). (Subbiah V, Brown RE, Jiang Y, Buryanek J, Hayes-Jordan A, Kurzrock R, Anderson PM) PLoS One 2013;8(7):e68985 PMID: 23922674 PMCID: PMC3726753 SCOPUS ID: 2-s2.0-84880774563 08/08/2013       33 Citations
  • Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. (Falchook GS, Fu S, Naing A, Hong DS, Hu W, Moulder S, Wheler JJ, Sood AK, Bustinza-Linares E, Parkhurst KL, Kurzrock R) Invest New Drugs 2013 Oct;31(5):1192-200 PMID: 23907406 PMCID: PMC3809091 SCOPUS ID: 2-s2.0-84884812613 08/03/2013       38 Citations
  • A pilot study of temsirolimus and body composition. (Veasey-Rodrigues H, Parsons HA, Janku F, Naing A, Wheler JJ, Tsimberidou AM, Kurzrock R) J Cachexia Sarcopenia Muscle 2013 Dec;4(4):259-65 PMID: 23893509 PMCID: PMC3830004 SCOPUS ID: 2-s2.0-84888038950 07/31/2013       18 Citations
  • Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. (Hong D, Said R, Falchook G, Naing A, Moulder S, Tsimberidou AM, Galluppi G, Dakappagari N, Storgard C, Kurzrock R, Rosen LS) Clin Cancer Res 2013 Sep 01;19(17):4824-31 PMID: 23873691 PMCID: PMC3935614 SCOPUS ID: 2-s2.0-84883474830 07/23/2013       14 Citations
  • Body composition and survival in the early clinical trials setting. (Veasey Rodrigues H, Baracos VE, Wheler JJ, Parsons HA, Hong DS, Naing A, Fu S, Falchoock G, Tsimberidou AM, Piha-Paul S, Chisholm G, Kurzrock R) Eur J Cancer 2013 Oct;49(15):3068-75 PMID: 23867127 SCOPUS ID: 2-s2.0-84884905418 07/23/2013       28 Citations
  • Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment. (Falchook GS, Lippman SM, Bastida CC, Kurzrock R) Head Neck 2014 Mar;36(3):E25-7 PMID: 23852769 PMCID: PMC3893310 SCOPUS ID: 2-s2.0-84894228106 07/16/2013       38 Citations
  • Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. (Wheler J, Falchook G, Tsimberidou AM, Hong D, Naing A, Piha-Paul S, Chen SS, Heymach J, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R) Oncotarget 2013 May;4(5):772-84 PMID: 23800712 PMCID: PMC3742837 SCOPUS ID: 2-s2.0-84880303931 06/27/2013       17 Citations
  • Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications. (Jiang Y, Janku F, Subbiah V, Angelo LS, Naing A, Anderson PM, Herzog CE, Fu S, Benjamin RS, Kurzrock R) Oncotarget 2013 Jun;4(6):884-9 PMID: 23800680 PMCID: PMC3757245 SCOPUS ID: 2-s2.0-84880823765 06/27/2013       25 Citations
  • Effect of duration of scan acquisition on CT perfusion parameter values in primary and metastatic tumors in the lung. (Ng CS, Chandler AG, Wei W, Anderson EF, Herron DH, Kurzrock R, Charnsangavej C) Eur J Radiol 2013 Oct;82(10):1811-8 PMID: 23769187 SCOPUS ID: 2-s2.0-84893693780 06/19/2013       5 Citations
  • Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses. (Wheler J, Hong D, Swisher SG, Falchook G, Tsimberidou AM, Helgason T, Naing A, Stephen B, Janku F, Stephens PJ, Yelensky R, Kurzrock R) Oncotarget 2013 Jun;4(6):890-8 PMID: 23765114 PMCID: PMC3757246 SCOPUS ID: 2-s2.0-84880780127 06/15/2013       31 Citations
  • Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. (Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Fu S, Hong DS, Kurzrock R, Janku F, Laday S, Bedikian AY, Kies M, Wolff RA, Tsimberidou AM) Invest New Drugs 2014 Apr;32(2):279-86 PMID: 23756764 PMCID: PMC5730367 SCOPUS ID: 2-s2.0-84896395358 06/13/2013       10 Citations
  • Posterior reversible encephalopathy syndrome: more than meets the eye. (Munoz J, Kumar VA, Hamilton J, Pasche LJ, Langford LA, Taggart MW, Kamiya-Matsuoka C, Tummala S, Moulder S, Kurzrock R) J Clin Oncol 2013 Jul 10;31(20):e360-3 PMID: 23733774 SCOPUS ID: 2-s2.0-84883871485 06/05/2013       9 Citations
  • Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. (Munoz J, Schlette E, Kurzrock R) J Clin Oncol 2013 Jul 10;31(20):e351-2 PMID: 23733763 SCOPUS ID: 2-s2.0-84883875497 06/05/2013       52 Citations
  • Molecular profiling and the reclassification of cancer: divide and conquer. (Munoz J, Swanton C, Kurzrock R) Am Soc Clin Oncol Educ Book 2013:127-34 PMID: 23714478 SCOPUS ID: 2-s2.0-84901199614 05/30/2013       22 Citations
  • Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. (Kurzrock R, Atkins J, Wheler J, Fu S, Naing A, Busaidy N, Hong D, Sherman S) Ann Oncol 2013 Sep;24(9):2256-61 PMID: 23676418 SCOPUS ID: 2-s2.0-84883414362 05/17/2013       24 Citations
  • P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. (Said R, Hong DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, Naing A, Falchook GS, Fu S, Piha-Paul S, Tsimberidou AM, Kurzrock R) Oncotarget 2013 May;4(5):705-14 PMID: 23670029 PMCID: PMC3742831 SCOPUS ID: 2-s2.0-84880321253 05/15/2013       89 Citations
  • A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. (Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, van Rhee F) Clin Cancer Res 2013 Jul 01;19(13):3659-70 PMID: 23659971 SCOPUS ID: 2-s2.0-84879849025 05/11/2013       156 Citations
  • RE: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. (Jain RK, Lee JJ, Hong D, Kurzrock R) J Natl Cancer Inst 2013 Jun 05;105(11):833 PMID: 23628598 SCOPUS ID: 2-s2.0-84878858832 05/01/2013    
  • Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors. (Naing A, Fu S, Zinner RG, Wheler JJ, Hong DS, Arakawa K, Falchook GS, Kurzrock R) Invest New Drugs 2014 Feb;32(1):154-9 PMID: 23609829 PMCID: PMC3913855 SCOPUS ID: 2-s2.0-84899058447 04/24/2013       7 Citations
  • The Karabus affair speaks to larger issues for American academic and medical centers. (Zwelling LA, Kurzrock R, Cohen PR, Levin B, Parish LC) Clin Dermatol 2013 May-Jun;31(3):325-6 PMID: 23608452 SCOPUS ID: 2-s2.0-84876704897 04/24/2013       1 Citation
  • Fool's gold, lost treasures, and the randomized clinical trial. (Stewart DJ, Kurzrock R) BMC Cancer 2013 Apr 16;13:193 PMID: 23587187 PMCID: PMC3639810 SCOPUS ID: 2-s2.0-84876096711 04/17/2013       39 Citations
  • Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. (Henary H, Hong DS, Falchook GS, Tsimberidou A, George GC, Wen S, Wheler J, Fu S, Naing A, Piha-Paul S, Janku F, Kim KB, Hwu P, Kurzrock R) Ann Oncol 2013 Aug;24(8):2158-65 PMID: 23576709 PMCID: PMC4081655 SCOPUS ID: 2-s2.0-84881221698 04/12/2013       14 Citations
  • Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib. (Falchook GS, Rady P, Hymes S, Nguyen HP, Tyring SK, Prieto VG, Hong DS, Kurzrock R) JAMA Dermatol 2013 Mar;149(3):322-6 PMID: 23552670 PMCID: PMC4085990 SCOPUS ID: 2-s2.0-84875399925 04/05/2013       27 Citations
  • A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal. (Janku F, Huang HJ, Angelo LS, Kurzrock R) Oncotarget 2013 Mar;4(3):463-73 PMID: 23531874 PMCID: PMC3717308 SCOPUS ID: 2-s2.0-84879020294 03/28/2013       25 Citations
  • BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. (Falchook GS, Trent JC, Heinrich MC, Beadling C, Patterson J, Bastida CC, Blackman SC, Kurzrock R) Oncotarget 2013 Feb;4(2):310-5 PMID: 23470635 PMCID: PMC3712576 SCOPUS ID: 2-s2.0-84875761522 03/09/2013       110 Citations
  • Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy. (Hong DS, George GC, Iwuanyanwu EC, Tavana B, Falchook GS, Piha-Paul SA, Wheler JJ, Mistry RH, Lei X, Kurzrock R) J Cancer Res Clin Oncol 2013 Jun;139(6):963-70 PMID: 23455881 SCOPUS ID: 2-s2.0-84878313006 03/05/2013       8 Citations
  • Compliance in early-phase cancer clinical trials research. (Kurzrock R, Stewart DJ) Oncologist 2013;18(3):308-13 PMID: 23457001 PMCID: PMC3607528 SCOPUS ID: 2-s2.0-84875467845 03/05/2013       9 Citations
  • Reply to A. Levy et al. (Jain RK, Lee JJ, Hong D, Kurzrock R) J Clin Oncol 2013 Jan 20;31(3):396 PMID: 23451354 SCOPUS ID: 2-s2.0-84873383586 03/02/2013       1 Citation
  • Dodging a dogma: is treating beyond progression beneficial? (Naing A, Kurzrock R) Cancer Chemother Pharmacol 2013 May;71(5):1385-6 PMID: 23443308 SCOPUS ID: 2-s2.0-84877926446 02/28/2013       4 Citations
  • Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. (Falchook GS, Naing A, Hong DS, Zinner R, Fu S, Piha-Paul SA, Tsimberidou AM, Morgan-Linnell SK, Jiang Y, Bastida C, Wheler JJ, Kurzrock R) Oncotarget 2013 Jan;4(1):118-27 PMID: 23435217 PMCID: PMC3702212 SCOPUS ID: 2-s2.0-84875789255 02/26/2013       30 Citations
  • A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. (Cohen RB, Aamdal S, Nyakas M, Cavallin M, Green D, Learoyd M, Smith I, Kurzrock R) Eur J Cancer 2013 May;49(7):1521-9 PMID: 23433846 SCOPUS ID: 2-s2.0-84876160240 02/26/2013       31 Citations
  • Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. (Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, Phan AT, Habra MA, Kurzrock R) Br J Cancer 2013 Mar 05;108(4):826-30 PMID: 23412108 PMCID: PMC3590681 SCOPUS ID: 2-s2.0-84875230967 02/16/2013       84 Citations
  • Unilateral proptosis. (Munoz J, Kurzrock R) JAMA 2013 Feb 13;309(6):605-6 PMID: 23403685 SCOPUS ID: 2-s2.0-84873650635 02/14/2013       2 Citations
  • Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. (Janku F, Wheler JJ, Hong DS, Kurzrock R) Target Oncol 2013 Sep;8(3):183-188 PMID: 23400451 PMCID: PMC3766504 SCOPUS ID: 2-s2.0-84884287113 02/13/2013       5 Citations
  • Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. (Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R) Oncotarget 2013 Jan;4(1):156-65 PMID: 23391555 PMCID: PMC3702215 SCOPUS ID: 2-s2.0-84893391899 02/09/2013       27 Citations
  • A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies. (Naing A, Cohen R, Dy GK, Hong DS, Dyster L, Hangauer DG, Kwan R, Fetterly G, Kurzrock R, Adjei AA) Invest New Drugs 2013 Aug;31(4):967-73 PMID: 23361621 SCOPUS ID: 2-s2.0-84880919122 01/31/2013       23 Citations
  • Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway. (Holsinger FC, Piha-Paul SA, Janku F, Hong DS, Atkins JT, Tsimberidou AM, Kurzrock R) J Clin Oncol 2013 Mar 20;31(9):e137-40 PMID: 23358976 PMCID: PMC5950501 SCOPUS ID: 2-s2.0-84875978234 01/30/2013       27 Citations
  • Effect of sampling frequency on perfusion values in perfusion CT of lung tumors. (Ng CS, Chandler AG, Wei W, Anderson EF, Herron DH, Kurzrock R, Charnsangavej C) AJR Am J Roentgenol 2013 Feb;200(2):W155-62 PMID: 23345379 PMCID: PMC3880201 SCOPUS ID: 2-s2.0-84873584621 01/25/2013       11 Citations
  • Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment. (Falchook GS, Janku F, Tsao AS, Bastida CC, Stewart DJ, Kurzrock R) J Thorac Oncol 2013 Feb;8(2):e19-20 PMID: 23328556 PMCID: PMC3551245 SCOPUS ID: 2-s2.0-84873830350 01/19/2013       22 Citations
  • A tale of two histiocytic disorders. (Janku F, Munoz J, Subbiah V, Kurzrock R) Oncologist 2013;18(1):2-4 PMID: 23299771 PMCID: PMC3556250 SCOPUS ID: 2-s2.0-84873045978 01/10/2013       7 Citations
  • Binding partners for curcumin in human schwannoma cells: biologic implications. (Angelo LS, Maxwell DS, Wu JY, Sun D, Hawke DH, McCutcheon IE, Slopis JM, Peng Z, Bornmann WG, Kurzrock R) Bioorg Med Chem 2013 Feb 15;21(4):932-9 PMID: 23294827 SCOPUS ID: 2-s2.0-84873306516 01/09/2013       17 Citations
  • PIK3CA mutations in advanced cancers: characteristics and outcomes. (Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R) Oncotarget 2012 Dec;3(12):1566-75 PMID: 23248156 PMCID: PMC3681495 SCOPUS ID: 2-s2.0-84874736849 12/19/2012       73 Citations
  • Warning signal: unaware of an in absentia conviction, South African cancer specialist jailed on return to the United Arab Emirates. (Cohen PR, Kurzrock R, Parish LC) Clin Dermatol 2013 Jan-Feb;31(1):128-30 PMID: 23245984 SCOPUS ID: 2-s2.0-84871047471 12/19/2012       2 Citations
  • Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. (Hong DS, Banerji U, Tavana B, George GC, Aaron J, Kurzrock R) Cancer Treat Rev 2013 Jun;39(4):375-87 PMID: 23199899 SCOPUS ID: 2-s2.0-84875519144 12/04/2012       177 Citations
  • It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy. (Westin JR, Kurzrock R) Mol Cancer Ther 2012 Dec;11(12):2549-55 PMID: 23204432 PMCID: PMC4107422 SCOPUS ID: 2-s2.0-84871396050 12/04/2012       38 Citations
  • A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. (Hong DS, Choe JH, Naing A, Wheler JJ, Falchook GS, Piha-Paul S, Moulder SL, George GC, Choe JM, Strauss LC, Gallick GE, Kurzrock R) Invest New Drugs 2013 Aug;31(4):918-26 PMID: 23179336 PMCID: PMC4482128 SCOPUS ID: 2-s2.0-84880921289 11/28/2012       28 Citations
  • Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. (Tsimberidou AM, Leick MB, Lim J, Fu S, Wheler J, Piha-Paul SA, Hong D, Falchook GS, Naing A, Subbiah IM, Fortier A, Avritscher R, Kurzrock R) Cancer Chemother Pharmacol 2013 Feb;71(2):389-97 PMID: 23143207 SCOPUS ID: 2-s2.0-84874104755 11/13/2012       11 Citations
  • Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy. (Wheler JJ, Falchook GS, Tsimberidou AM, Hong DS, Naing A, Piha-Paul SA, Chen SS, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R) Ann Oncol 2013 Mar;24(3):838-42 PMID: 23139256 PMCID: PMC4110484 SCOPUS ID: 2-s2.0-84874564640 11/10/2012       18 Citations
  • PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. (Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R) Cancer Res 2013 Jan 01;73(1):276-84 PMID: 23066039 PMCID: PMC3537862 SCOPUS ID: 2-s2.0-84871968444 10/16/2012       222 Citations
  • The "shield sign" in two men with metastatic salivary duct carcinoma to the skin: cutaneous metastases presenting as carcinoma hemorrhagiectoides. (Cohen PR, Prieto VG, Piha-Paul SA, Kurzrock R) J Clin Aesthet Dermatol 2012 Sep;5(9):27-36 PMID: 23050032 PMCID: PMC3460659 10/11/2012    
  • Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009. (Janku F, Berry DA, Gong J, Parsons HA, Stewart DJ, Kurzrock R) Clin Cancer Res 2012 Nov 15;18(22):6356-63 PMID: 23014530 SCOPUS ID: 2-s2.0-84869209150 09/28/2012       18 Citations
  • Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. (Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R) Clin Cancer Res 2012 Nov 15;18(22):6373-83 PMID: 22966018 PMCID: PMC4454458 SCOPUS ID: 2-s2.0-84869223443 09/12/2012       391 Citations
  • Targeted therapy in rare cancers--adopting the orphans. (Munoz J, Kurzrock R) Nat Rev Clin Oncol 2012 Nov;9(11):631-42 PMID: 22965154 SCOPUS ID: 2-s2.0-84868204526 09/12/2012       26 Citations
  • Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. (Naing A, Aghajanian C, Raymond E, Olmos D, Schwartz G, Oelmann E, Grinsted L, Burke W, Taylor R, Kaye S, Kurzrock R, Banerji U) Br J Cancer 2012 Sep 25;107(7):1093-9 PMID: 22935583 PMCID: PMC3461162 SCOPUS ID: 2-s2.0-84866928171 09/01/2012       96 Citations
  • The "shield sign" in two men with metastatic salivary duct carcinoma to the skin: Cutaneous metastases presenting as carcinoma hemorrhagiectoides (Cohen PR, Prieto VG, Piha-Paul SA, Kurzrock R) Journal of Clinical and Aesthetic Dermatology September 2012;5(9):27-36 SCOPUS ID: 2-s2.0-84866847928 09/01/2012       8 Citations
  • Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. (Moroney J, Fu S, Moulder S, Falchook G, Helgason T, Levenback C, Hong D, Naing A, Wheler J, Kurzrock R) Clin Cancer Res 2012 Oct 15;18(20):5796-805 PMID: 22927482 SCOPUS ID: 2-s2.0-84867551535 08/29/2012       69 Citations
  • Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist. (Subbiah V, Brown RE, Buryanek J, Trent J, Ashkenazi A, Herbst R, Kurzrock R) Mol Cancer Ther 2012 Nov;11(11):2541-6 PMID: 22914439 PMCID: PMC3496030 SCOPUS ID: 2-s2.0-84869206991 08/24/2012       47 Citations
  • Mechanistic basis for overcoming platinum resistance using copper chelating agents. (Liang ZD, Long Y, Tsai WB, Fu S, Kurzrock R, Gagea-Iurascu M, Zhang F, Chen HH, Hennessy BT, Mills GB, Savaraj N, Kuo MT) Mol Cancer Ther 2012 Nov;11(11):2483-94 PMID: 22914438 PMCID: PMC3496003 SCOPUS ID: 2-s2.0-84866360659 08/24/2012       61 Citations
  • Effect of dual vascular input functions on CT perfusion parameter values and reproducibility in liver tumors and normal liver. (Ng CS, Chandler AG, Wei W, Anderson EF, Herron DH, Kurzrock R, Charnsangavej C) J Comput Assist Tomogr 2012 Jul-Aug;36(4):388-93 PMID: 22805665 PMCID: PMC3891838 SCOPUS ID: 2-s2.0-84863892216 07/19/2012       12 Citations
  • Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. (Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, Burris HA 3rd, Messersmith WA, O'Dwyer PJ, Kim KB, Flaherty K, Bendell JC, Gonzalez R, Kurzrock R, Fecher LA) Lancet Oncol 2012 Aug;13(8):782-9 PMID: 22805292 PMCID: PMC4109286 SCOPUS ID: 2-s2.0-84864371119 07/19/2012       395 Citations
  • Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. (Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris HA 3rd, Messersmith WA) Lancet Oncol 2012 Aug;13(8):773-81 PMID: 22805291 SCOPUS ID: 2-s2.0-84864340896 07/19/2012       370 Citations
  • Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience. (Fu S, Barber FD, Naing A, Wheler J, Hong D, Falchook G, Piha-Paul S, Tsimberidou A, Howard A, Kurzrock R) J Clin Oncol 2012 Aug 10;30(23):2891-6 PMID: 22778314 SCOPUS ID: 2-s2.0-84865062413 07/11/2012       23 Citations
  • Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. (Naing A, Veasey-Rodrigues H, Hong DS, Fu S, Falchook GS, Wheler JJ, Tsimberidou AM, Wen S, Fessahaye SN, Golden EC, Aaron J, Ewer MS, Kurzrock R) Ann Oncol 2012 Nov;23(11):2960-2963 PMID: 22745218 PMCID: PMC4092255 SCOPUS ID: 2-s2.0-84868113707 06/30/2012       33 Citations
  • Ewing's sarcoma: overcoming the therapeutic plateau. (Subbiah V, Kurzrock R) Discov Med 2012 Jun;13(73):405-15 PMID: 22742646 PMCID: PMC3893930 SCOPUS ID: 2-s2.0-84867649825 06/30/2012       16 Citations
  • A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. (Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, Vo AC, Klucher K, Herbst RS, Eckhardt SG, Peterson S, Hausman DF, Kurzrock R, Jimeno A) Clin Cancer Res 2012 Aug 01;18(15):4173-82 PMID: 22693357 SCOPUS ID: 2-s2.0-84864493357 06/14/2012       136 Citations
  • Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. (Jain RK, Lee JJ, Ng C, Hong D, Gong J, Naing A, Wheler J, Kurzrock R) J Clin Oncol 2012 Jul 20;30(21):2684-90 PMID: 22689801 PMCID: PMC3413279 SCOPUS ID: 2-s2.0-84864047388 06/13/2012       68 Citations
  • KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. (Garrido-Laguna I, Hong DS, Janku F, Nguyen LM, Falchook GS, Fu S, Wheler JJ, Luthra R, Naing A, Wang X, Kurzrock R) PLoS One 2012;7(5):e38033 PMID: 22675430 PMCID: PMC3364990 SCOPUS ID: 2-s2.0-84861704697 06/08/2012       43 Citations
  • Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. (Kurzrock R, Goel S, Wheler J, Hong D, Fu S, Rezai K, Morgan-Linnell SK, Urien S, Mani S, Chaudhary I, Ghalib MH, Buchbinder A, Lokiec F, Mulcahy M) Cancer 2012 Dec 15;118(24):6144-51 PMID: 22674635 SCOPUS ID: 2-s2.0-84870715169 06/08/2012       38 Citations
  • A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. (Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, Lawrence D, Eder JP, Meyer CJ, Ferguson DA, Mier J, Konopleva M, Konoplev S, Andreeff M, Kufe D, Lazarus H, Shapiro GI, Dezube BJ) Clin Cancer Res 2012 Jun 15;18(12):3396-406 PMID: 22634319 PMCID: PMC4494099 SCOPUS ID: 2-s2.0-84862557429 05/29/2012       162 Citations
  • Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. (Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF) Lancet 2012 May 19;379(9829):1893-901 PMID: 22608338 PMCID: PMC4109288 SCOPUS ID: 2-s2.0-84861083983 05/23/2012       732 Citations
  • Eyelash trichomegaly: review of congenital, acquired, and drug-associated etiologies for elongation of the eyelashes. (Paul LJ, Cohen PR, Kurzrock R) Int J Dermatol 2012 Jun;51(6):631-46; quiz 643-4, 646 PMID: 22607279 SCOPUS ID: 2-s2.0-84861312163 05/23/2012       15 Citations
  • Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. (Tsimberidou AM, Fu S, Subbiah IM, Naing A, Hong DS, Wen S, Fortier AH, Lim J, Kurzrock R) Hepatogastroenterology 2012 Jun;59(116):960-4 PMID: 22580643 SCOPUS ID: 2-s2.0-84861389490 05/15/2012       2 Citations
  • Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. (Hong DS, Patel JC, Wheler J, Naing A, Garrido-Laguna I, Falchook G, Fu S, Tsimberidou AM, Kopetz S, Win S, Kurzrock R) Clin Colorectal Cancer 2012 Dec;11(4):297-303 PMID: 22537607 SCOPUS ID: 2-s2.0-84868361922 04/28/2012       6 Citations
  • Cutaneous Castleman disease. (Munoz J, Naing A, Qi M, Kurzrock R) Br J Haematol 2012 Jun;157(6):652 PMID: 22533925 SCOPUS ID: 2-s2.0-84861528318 04/27/2012       5 Citations
  • Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. (Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R, Wheler JJ) J Clin Oncol 2012 Jul 01;30(19):2348-53 PMID: 22529266 PMCID: PMC5950496 SCOPUS ID: 2-s2.0-84864018642 04/25/2012       185 Citations
  • Overcoming platinum resistance through the use of a copper-lowering agent. (Fu S, Naing A, Fu C, Kuo MT, Kurzrock R) Mol Cancer Ther 2012 Jun;11(6):1221-5 PMID: 22491798 PMCID: PMC3667596 SCOPUS ID: 2-s2.0-84862570268 04/12/2012       52 Citations
  • Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. (Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC Jr, Mills GB) Gynecol Oncol 2012 Jul;126(1):47-53 PMID: 22487539 PMCID: PMC3738300 SCOPUS ID: 2-s2.0-84862773728 04/11/2012       60 Citations
  • Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. (Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA, Kurzrock R) Clin Cancer Res 2012 May 01;18(9):2625-31 PMID: 22465830 PMCID: PMC3875297 SCOPUS ID: 2-s2.0-84860506226 04/03/2012       159 Citations
  • Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, (997-1005)) (Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R) Journal of Clinical Endocrinology and Metabolism April 2012;97(4):1399 SCOPUS ID: 2-s2.0-84859525661 04/01/2012    
  • Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. (Wheler J, Tsimberidou AM, Hong D, Naing A, Falchook G, Piha-Paul S, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R) Clin Cancer Res 2012 May 15;18(10):2922-9 PMID: 22452943 PMCID: PMC4176886 SCOPUS ID: 2-s2.0-84861133847 03/29/2012       65 Citations
  • Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. (Wheler JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R) Ann Oncol 2012 Aug;23(8):1963-1967 PMID: 22377564 PMCID: PMC4092254 SCOPUS ID: 2-s2.0-84864939835 03/02/2012       13 Citations
  • BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. (Hong DS, Vence L, Falchook G, Radvanyi LG, Liu C, Goodman V, Legos JJ, Blackman S, Scarmadio A, Kurzrock R, Lizee G, Hwu P) Clin Cancer Res 2012 Apr 15;18(8):2326-35 PMID: 22355009 SCOPUS ID: 2-s2.0-84859807701 02/23/2012       90 Citations
  • Reply to L.D. Locati et al (Piha-Paul SA, Kurzrock R) Journal of Clinical Oncology 20 February 2012;30(6):672-673 SCOPUS ID: 2-s2.0-84857555439 02/20/2012    
  • In reply (El-Osta HE, Kurzrock R) Oncologist 2012;17(1):147-148 SCOPUS ID: 2-s2.0-84856289548 02/01/2012    
  • PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. (Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R) J Clin Oncol 2012 Mar 10;30(8):777-82 PMID: 22271473 PMCID: PMC3295566 SCOPUS ID: 2-s2.0-84863338519 01/25/2012       369 Citations
  • Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. (Parsons HA, Baracos VE, Dhillon N, Hong DS, Kurzrock R) PLoS One 2012;7(1):e29330 PMID: 22235285 PMCID: PMC3250428 SCOPUS ID: 2-s2.0-84855318187 01/12/2012       74 Citations
  • Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy. (Parsons HA, Tsimberidou AM, Pontikos M, Fu S, Hong D, Wen S, Baracos VE, Kurzrock R) Nutr Cancer 2012;64(2):206-17 PMID: 22229660 PMCID: PMC3886552 SCOPUS ID: 2-s2.0-84862262378 01/11/2012       28 Citations
  • Treatment of chronic myelogenous leukemia as a paradigm for solid tumors: how targeted agents in newly diagnosed disease transformed outcomes. (Westin JR, Kantarjian H, Kurzrock R) Am Soc Clin Oncol Educ Book 2012:179-85 PMID: 24451731 01/01/2012    
  • Biotargets in sarcomas: The past, present, and a look into the future (Subbiah V, Kurzrock R) Biotargets of Cancer in Current Clinical Practice 1 January 2012:419-438 SCOPUS ID: 2-s2.0-85026205392 01/01/2012    
  • Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies. (Falchook GS, Duvic M, Hong DS, Wheler J, Naing A, Lim J, Kurzrock R) Cancer Chemother Pharmacol 2012 May;69(5):1117-26 PMID: 22205203 PMCID: PMC4091047 SCOPUS ID: 2-s2.0-84862281935 12/30/2011       11 Citations
  • Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. (Subbiah V, Slopis J, Hong DS, Ketonen LM, Hamilton J, McCutcheon IE, Kurzrock R) J Clin Oncol 2012 Feb 10;30(5):e64-8 PMID: 22203760 PMCID: PMC3295556 SCOPUS ID: 2-s2.0-84856873458 12/29/2011       35 Citations
  • Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. (Kurzrock R, Gabrail N, Chandhasin C, Moulder S, Smith C, Brenner A, Sankhala K, Mita A, Elian K, Bouchard D, Sarantopoulos J) Mol Cancer Ther 2012 Feb;11(2):308-16 PMID: 22203732 SCOPUS ID: 2-s2.0-84863131334 12/29/2011       120 Citations
  • Anticoagulation-induced severe bleeding in a patient receiving bevacizumab therapy. (Munoz J, Hong D, Kurzrock R) Int J Hematol 2012 Jan;95(1):1-2 PMID: 22170230 SCOPUS ID: 2-s2.0-84857634010 12/16/2011       2 Citations
  • BRAF mutations in advanced cancers: clinical characteristics and outcomes. (El-Osta H, Falchook G, Tsimberidou A, Hong D, Naing A, Kim K, Wen S, Janku F, Kurzrock R) PLoS One 2011;6(10):e25806 PMID: 22039425 PMCID: PMC3198456 SCOPUS ID: 2-s2.0-80054790555 11/01/2011       73 Citations
  • R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis. (Huang HJ, Angelo LS, Rodon J, Sun M, Kuenkele KP, Parsons HA, Trent JC, Kurzrock R) PLoS One 2011;6(10):e26060 PMID: 22022506 PMCID: PMC3191161 SCOPUS ID: 2-s2.0-80053994190 10/25/2011       33 Citations
  • Erdheim-Chester disease of the central nervous system: new manifestations of a rare disease. (Sedrak P, Ketonen L, Hou P, Guha-Thakurta N, Williams MD, Kurzrock R, Debnam JM) AJNR Am J Neuroradiol 2011 Dec;32(11):2126-31 PMID: 21960492 PMCID: PMC7964409 SCOPUS ID: 2-s2.0-84455188350 10/01/2011       40 Citations
  • Advancing the scope of nursing practice: hepatic arterial catheter removal. (Barosh BA, Holmes C, Keerikattu LM, Manappurathu MS, Segovia JH, Hasen PC, Pai SV, Lobiondo-Wood G, Kurzrock R) Clin J Oncol Nurs 2011 Oct;15(5):465-8 PMID: 21951733 SCOPUS ID: 2-s2.0-80053239283 09/29/2011       1 Citation
  • Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver - Will it hit the moving target? (Subbiah V, Angelo LS, Kurzrock R) Expert Opin Investig Drugs 2011 Nov;20(11):1471-7 PMID: 21936711 SCOPUS ID: 2-s2.0-80053959825 09/23/2011       2 Citations
  • Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways. (Angelo LS, Wu JY, Meng F, Sun M, Kopetz S, McCutcheon IE, Slopis JM, Kurzrock R) Mol Cancer Ther 2011 Nov;10(11):2094-103 PMID: 21903608 SCOPUS ID: 2-s2.0-81055124264 09/10/2011       28 Citations
  • A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. (Moroney JW, Schlumbrecht MP, Helgason T, Coleman RL, Moulder S, Naing A, Bodurka DC, Janku F, Hong DS, Kurzrock R) Clin Cancer Res 2011 Nov 01;17(21):6840-6 PMID: 21890452 PMCID: PMC3207033 SCOPUS ID: 2-s2.0-80455173410 09/06/2011       40 Citations
  • Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience. (El-Osta H, Hong D, Wheler J, Fu S, Naing A, Falchook G, Hicks M, Wen S, Tsimberidou AM, Kurzrock R) Oncologist 2011;16(9):1292-8 PMID: 21859821 PMCID: PMC3228176 SCOPUS ID: 2-s2.0-80053196189 08/24/2011       53 Citations
  • Novel therapeutic targets in non-small cell lung cancer. (Janku F, Garrido-Laguna I, Petruzelka LB, Stewart DJ, Kurzrock R) J Thorac Oncol 2011 Sep;6(9):1601-12 PMID: 21849857 SCOPUS ID: 2-s2.0-80052252181 08/19/2011       113 Citations
  • Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus. (Piha-Paul SA, Cohen PR, Kurzrock R) J Clin Oncol 2011 Sep 10;29(26):e727-30 PMID: 21844496 SCOPUS ID: 2-s2.0-80053047138 08/17/2011       37 Citations
  • Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program. (Fu S, Hong DS, Naing A, Wheler J, Falchook G, Wen S, Howard A, Barber D, Nates J, Price K, Kurzrock R) J Clin Oncol 2011 Sep 10;29(26):3547-52 PMID: 21844494 SCOPUS ID: 2-s2.0-80052979047 08/17/2011       24 Citations
  • A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. (Hong DS, Kurzrock R, Oh Y, Wheler J, Naing A, Brail L, Callies S, André V, Kadam SK, Nasir A, Holzer TR, Meric-Bernstam F, Fishman M, Simon G) Clin Cancer Res 2011 Oct 15;17(20):6582-91 PMID: 21831956 PMCID: PMC5036398 SCOPUS ID: 2-s2.0-80054114844 08/13/2011       94 Citations
  • PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. (Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R) PLoS One 2011;6(7):e22769 PMID: 21829508 PMCID: PMC3146490 SCOPUS ID: 2-s2.0-79960927451 08/11/2011       149 Citations
  • Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. (Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R) Cancer 2012 Mar 01;118(5):1422-8 PMID: 21823111 SCOPUS ID: 2-s2.0-84857339127 08/09/2011       59 Citations
  • The inverted pyramid of biomarker-driven trials. (Garrido-Laguna I, Hidalgo M, Kurzrock R) Nat Rev Clin Oncol 2011 08 02;8(9):562-6 PMID: 21808269 SCOPUS ID: 2-s2.0-80052228891 08/03/2011       14 Citations
  • Reproducibility of CT perfusion parameters in liver tumors and normal liver. (Ng CS, Chandler AG, Wei W, Herron DH, Anderson EF, Kurzrock R, Charnsangavej C) Radiology 2011 Sep;260(3):762-70 PMID: 21788525 PMCID: PMC3156998 SCOPUS ID: 2-s2.0-84860389713 07/27/2011       55 Citations
  • Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. (Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, Hong D, Chen HX, Doyle LA, Heilbrun LK, Rohren E, Ng C, Chandhasin C, LoRusso P) Clin Cancer Res 2011 Sep 15;17(18):6052-60 PMID: 21750201 PMCID: PMC3176947 SCOPUS ID: 2-s2.0-80052831572 07/14/2011       99 Citations
  • Transformation of human mesenchymal cells and skin fibroblasts into hematopoietic cells. (Harris DM, Hazan-Haley I, Coombes K, Bueso-Ramos C, Liu J, Liu Z, Li P, Ravoori M, Abruzzo L, Han L, Singh S, Sun M, Kundra V, Kurzrock R, Estrov Z) PLoS One 2011;6(6):e21250 PMID: 21731684 PMCID: PMC3120836 SCOPUS ID: 2-s2.0-79959469517 07/07/2011       28 Citations
  • Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, 997-1005) (Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Waguespack SG, Hernandez M, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R, Busaidy NL) Journal of Clinical Endocrinology and Metabolism 1 July 2011;96(7):2286 SCOPUS ID: 2-s2.0-79960102479 07/01/2011    
  • Reproducibility of perfusion parameters obtained from perfusion CT in lung tumors. (Ng CS, Chandler AG, Wei W, Anderson EF, Herron DH, Charnsangavej C, Kurzrock R) AJR Am J Roentgenol 2011 Jul;197(1):113-21 PMID: 21701018 SCOPUS ID: 2-s2.0-79960530519 06/28/2011       44 Citations
  • A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors. (Infante JR, Kurzrock R, Spratlin J, Burris HA, Eckhardt SG, Li J, Wu K, Skolnik JM, Hylander-Gans L, Osmukhina A, Huszar D, Herbst RS) Cancer Chemother Pharmacol 2012 Jan;69(1):165-72 PMID: 21638123 SCOPUS ID: 2-s2.0-84856745726 06/04/2011       29 Citations
  • Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. (Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R) J Clin Oncol 2011 Jul 01;29(19):2660-6 PMID: 21606412 PMCID: PMC3646303 SCOPUS ID: 2-s2.0-79959936054 05/25/2011       449 Citations
  • Autophagy as a target for anticancer therapy. (Janku F, McConkey DJ, Hong DS, Kurzrock R) Nat Rev Clin Oncol 2011 May 17;8(9):528-39 PMID: 21587219 SCOPUS ID: 2-s2.0-80052227050 05/19/2011       605 Citations
  • Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity. (Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R) Mol Cancer Ther 2011 Jul;10(7):1300-7 PMID: 21571911 SCOPUS ID: 2-s2.0-79960119359 05/17/2011       15 Citations
  • Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience. (Naing A, Stephen SK, Frenkel M, Chandhasin C, Hong DS, Lei X, Falchook G, Wheler JJ, Fu S, Kurzrock R) Cancer 2011 Nov 15;117(22):5142-50 PMID: 21538342 SCOPUS ID: 2-s2.0-80555150818 05/04/2011       46 Citations
  • Phase 1 clinical trials for sarcomas: the cutting edge. (Subbiah V, Kurzrock R) Curr Opin Oncol 2011 Jul;23(4):352-60 PMID: 21519259 SCOPUS ID: 2-s2.0-79958820840 04/27/2011       30 Citations
  • Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer. (Tsimberidou AM, Lewis N, Reid T, Burris H, Urban P, Tan EY, Anand S, Uehara C, Kurzrock R) Cancer Chemother Pharmacol 2011 Dec;68(6):1507-16 PMID: 21499896 SCOPUS ID: 2-s2.0-85027921054 04/19/2011       5 Citations
  • Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. (Subbiah V, Naing A, Brown RE, Chen H, Doyle L, LoRusso P, Benjamin R, Anderson P, Kurzrock R) PLoS One 2011 Apr 06;6(4):e18424 PMID: 21494688 PMCID: PMC3071831 SCOPUS ID: 2-s2.0-79953742425 04/16/2011       63 Citations
  • Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. (Moulder S, Moroney J, Helgason T, Wheler J, Booser D, Albarracin C, Morrow PK, Koenig K, Kurzrock R) J Clin Oncol 2011 Jul 01;29(19):e572-5 PMID: 21482991 SCOPUS ID: 2-s2.0-79960127513 04/13/2011       55 Citations
  • Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. (Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC Jr) Cancer 2011 Apr 15;117(8):1661-9 PMID: 21472713 PMCID: PMC3062960 SCOPUS ID: 2-s2.0-79952266135 04/08/2011       132 Citations
  • Castleman's disease: from basic mechanisms to molecular therapeutics. (El-Osta HE, Kurzrock R) Oncologist 2011;16(4):497-511 PMID: 21441298 PMCID: PMC3228122 SCOPUS ID: 2-s2.0-79955556128 03/29/2011       103 Citations
  • Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience. (Tsimberidou AM, Letourneau K, Wen S, Wheler J, Hong D, Naing A, Iskander NG, Uehara C, Kurzrock R) Clin Cancer Res 2011 Jun 15;17(12):4110-8 PMID: 21415223 PMCID: PMC3410654 SCOPUS ID: 2-s2.0-79959268009 03/19/2011       21 Citations
  • Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic. (Janku F, Tsimberidou AM, Wang X, Hong DS, Naing A, Gong J, Garrido-Laguna I, Parsons HA, Zinner RG, Kurzrock R) Oncologist 2011;16(3):327-35 PMID: 21339262 PMCID: PMC3228100 SCOPUS ID: 2-s2.0-79953004809 02/23/2011       7 Citations
  • Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors. (Naing A, Reuben JM, Camacho LH, Gao H, Lee BN, Cohen EN, Verschraegen C, Stephen S, Aaron J, Hong D, Wheler J, Kurzrock R) J Cancer 2011 Feb 10;2:81-9 PMID: 21326629 PMCID: PMC3039225 SCOPUS ID: 2-s2.0-80052015381 02/18/2011       34 Citations
  • Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. (Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R) J Clin Endocrinol Metab 2011 Apr;96(4):997-1005 PMID: 21289252 PMCID: PMC3070247 SCOPUS ID: 2-s2.0-79953904634 02/04/2011       87 Citations
  • Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment. (Piha-Paul SA, Hong DS, Kurzrock R) J Clin Oncol 2011 Apr 20;29(12):e333-5 PMID: 21263090 SCOPUS ID: 2-s2.0-79955045309 01/26/2011       12 Citations
  • Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial. (Tsimberidou AM, Takimoto CH, Moulder S, Uehara C, Mita M, Mita A, Urban P, Tan E, Wang Y, Vining D, Kurzrock R) Mol Cancer Ther 2011 Jan;10(1):209-17 PMID: 21220503 SCOPUS ID: 2-s2.0-78751521502 01/12/2011       5 Citations
  • PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. (Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R) Mol Cancer Ther 2011 Mar;10(3):558-65 PMID: 21216929 PMCID: PMC3072168 SCOPUS ID: 2-s2.0-79952690921 01/11/2011       281 Citations
  • Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases. (Camacho LH, Garcia S, Panchal AM, Lim J, Hong DS, Ng C, Madoff DC, Fu S, Gayed I, Kurzrock R) Clin Colorectal Cancer 2010 Dec;9(5):311-4 PMID: 21208846 PMCID: PMC3088086 01/07/2011    
  • Optimizing the development of targeted therapies in the phase i clinical trial setting (Jain RK, Kurzrock R) Targeted Therapy for Solid Tumors and Hematologic Malignancies 1 January 2011:23-40 SCOPUS ID: 2-s2.0-85029928709 01/01/2011    
  • Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. (Tsimberidou AM, Akerley W, Schabel MC, Hong DS, Uehara C, Chhabra A, Warren T, Mather GG, Evans BA, Woodland DP, Swabb EA, Kurzrock R) Mol Cancer Ther 2010 Dec;9(12):3410-9 PMID: 21159616 SCOPUS ID: 2-s2.0-78650450212 12/17/2010       40 Citations
  • Farnesyltransferase inhibitors: where are we now? (Tsimberidou AM, Chandhasin C, Kurzrock R) Expert Opin Investig Drugs 2010 Dec;19(12):1569-80 PMID: 21083522 SCOPUS ID: 2-s2.0-78649524587 11/19/2010       35 Citations
  • MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. (Srivastava RK, Kurzrock R, Shankar S) Mol Cancer Ther 2010 Dec;9(12):3254-66 PMID: 21041383 SCOPUS ID: 2-s2.0-78650443648 11/03/2010       104 Citations
  • A first-in-human study of conatumumab in adult patients with advanced solid tumors. (Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L, Juan G, Hwang YC, Wong S, Hill JS, Friberg G, LoRusso PM) Clin Cancer Res 2010 Dec 01;16(23):5883-91 PMID: 20947515 SCOPUS ID: 2-s2.0-78650340456 10/16/2010       101 Citations
  • Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement. (Tsimberidou AM, Letourneau K, Fu S, Hong D, Naing A, Wheler J, Uehara C, McRae SE, Wen S, Kurzrock R) Cancer Chemother Pharmacol 2011 Jul;68(1):247-53 PMID: 20941597 PMCID: PMC3410641 SCOPUS ID: 2-s2.0-79959574175 10/14/2010       18 Citations
  • A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors. (Naing A, Kurzrock R, Adams LM, Kleha JF, Laubscher KH, Bonate PL, Weller S, Fitzgerald C, Xu Y, LoRusso PM) Invest New Drugs 2012 Feb;30(1):327-34 PMID: 20842406 SCOPUS ID: 2-s2.0-84856540747 09/16/2010       15 Citations
  • Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience. (Vaklavas C, Tsimberidou AM, Wen S, Hong D, Wheler J, Ng CS, Naing A, Uehara C, Wolff RA, Kurzrock R) Cancer 2011 Jan 01;117(1):77-85 PMID: 20737567 PMCID: PMC3410640 SCOPUS ID: 2-s2.0-78650711793 08/26/2010       7 Citations
  • Response of histiocytoses to imatinib mesylate: fire to ashes. (Janku F, Amin HM, Yang D, Garrido-Laguna I, Trent JC, Kurzrock R) J Clin Oncol 2010 Nov 01;28(31):e633-6 PMID: 20733125 SCOPUS ID: 2-s2.0-78149267163 08/25/2010       71 Citations
  • Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors. (Cohen PR, Escudier SM, Kurzrock R) Am J Clin Dermatol 2011 Feb 01;12(1):63-7 PMID: 20726623 SCOPUS ID: 2-s2.0-78649684719 08/24/2010       28 Citations
  • Reply to A. Ocana et al (Stewart DJ, Kurzrock R) Journal of Clinical Oncology 20 August 2010;28(24) SCOPUS ID: 2-s2.0-79951828290 08/20/2010    
  • Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. (van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M, Qin X, Herring J, Casper C, Kurzrock R) J Clin Oncol 2010 Aug 10;28(23):3701-8 PMID: 20625121 SCOPUS ID: 2-s2.0-77957283115 07/14/2010       171 Citations
  • Development of curcumin as an epigenetic agent. (Fu S, Kurzrock R) Cancer 2010 Oct 15;116(20):4670-6 PMID: 20597137 SCOPUS ID: 2-s2.0-78349269863 07/03/2010       136 Citations
  • Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors. (Subbiah V, Trent JC, Kurzrock R) J Clin Oncol 2010 Aug 20;28(24):e415 PMID: 20567010 SCOPUS ID: 2-s2.0-77956240797 06/23/2010       44 Citations
  • Timing of palliative care referral and symptom burden in phase 1 cancer patients: a retrospective cohort study. (Hui D, Parsons H, Nguyen L, Palla SL, Yennurajalingam S, Kurzrock R, Bruera E) Cancer 2010 Sep 15;116(18):4402-9 PMID: 20564164 PMCID: PMC2936661 SCOPUS ID: 2-s2.0-77957367729 06/22/2010       46 Citations
  • A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. (Tsimberidou AM, Fu S, Ng C, Lim JA, Wen S, Hong D, Wheler J, Bedikian AY, Eng C, Wallace M, Camacho LH, Kurzrock R) Cancer 2010 Sep 01;116(17):4086-94 PMID: 20564148 PMCID: PMC2930110 SCOPUS ID: 2-s2.0-77956791334 06/22/2010       27 Citations
  • Targeted therapy in non-small-cell lung cancer--is it becoming a reality? (Janku F, Stewart DJ, Kurzrock R) Nat Rev Clin Oncol 2010 Jul;7(7):401-14 PMID: 20551945 SCOPUS ID: 2-s2.0-79960042770 06/17/2010       225 Citations
  • Salirasib in the treatment of pancreatic cancer. (Bustinza-Linares E, Kurzrock R, Tsimberidou AM) Future Oncol 2010 Jun;6(6):885-91 PMID: 20528225 SCOPUS ID: 2-s2.0-77957261391 06/10/2010       40 Citations
  • Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment. (Garrido-Laguna I, Janku F, Falchook GS, Fu S, Hong DS, Naing A, Aaron J, Wang X, Kies M, Kurzrock R) Clin Cancer Res 2010 Aug 01;16(15):4031-7 PMID: 20525754 SCOPUS ID: 2-s2.0-77955115663 06/08/2010       15 Citations
  • Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra). (El-Osta H, Janku F, Kurzrock R) Mol Cancer Ther 2010 Jun;9(6):1485-8 PMID: 20501803 PMCID: PMC3108331 SCOPUS ID: 2-s2.0-77953441380 05/27/2010       56 Citations
  • Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. (Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS) J Clin Oncol 2010 Jun 10;28(17):2839-46 PMID: 20458040 SCOPUS ID: 2-s2.0-77956414973 05/12/2010       336 Citations
  • Equipoise lost: ethics, costs, and the regulation of cancer clinical research. (Stewart DJ, Whitney SN, Kurzrock R) J Clin Oncol 2010 Jun 10;28(17):2925-35 PMID: 20406924 SCOPUS ID: 2-s2.0-77956401725 04/22/2010       83 Citations
  • Evaluation of liposomal curcumin cytochrome p450 metabolism. (Mach CM, Chen JH, Mosley SA, Kurzrock R, Smith JA) Anticancer Res 2010 Mar;30(3):811-4 PMID: 20393001 SCOPUS ID: 2-s2.0-77951042580 04/16/2010       27 Citations
  • Chemotherapy resistance and retreatment: a dogma revisited. (Naing A, Kurzrock R) Clin Colorectal Cancer 2010 Apr;9(2):E1-4 PMID: 20378496 04/10/2010    
  • A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. (Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, Benjamin R, Eckhardt SG, Eid JE, Greig G, Habben K, McCarthy CD, Gore L) Clin Cancer Res 2010 Apr 15;16(8):2458-65 PMID: 20371689 SCOPUS ID: 2-s2.0-77950974697 04/08/2010       152 Citations
  • Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience. (Moroney J, Wheler J, Hong D, Naing A, Falchook G, Bodurka D, Coleman R, Lu K, Xiao L, Kurzrock R) Gynecol Oncol 2010 Jun;117(3):467-72 PMID: 20347123 PMCID: PMC2882061 SCOPUS ID: 2-s2.0-77951939639 03/30/2010       14 Citations
  • Epidermal growth factor receptor mutation and diverse tumors: case report and concise literature review. (Chintala L, Kurzrock R) Mol Oncol 2010 Aug;4(4):306-8 PMID: 20346742 PMCID: PMC5527912 SCOPUS ID: 2-s2.0-77955276849 03/30/2010       15 Citations
  • Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. (Tsimberidou AM, Moulder S, Fu S, Wen S, Naing A, Bedikian AY, Daring S, Uehara C, Ng C, Wallace M, Camacho L, Kurzrock R) Cancer Chemother Pharmacol 2010 Nov;66(6):1087-93 PMID: 20204368 PMCID: PMC3410638 SCOPUS ID: 2-s2.0-78149415403 03/06/2010       15 Citations
  • Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. (Jain RK, Lee JJ, Hong D, Markman M, Gong J, Naing A, Wheler J, Kurzrock R) Clin Cancer Res 2010 Feb 15;16(4):1289-97 PMID: 20145187 PMCID: PMC2822881 SCOPUS ID: 2-s2.0-76749161498 02/11/2010       96 Citations
  • A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. (Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, Ing J, Tohnya TM, Sager J, Ashkenazi A, Bray G, Mendelson D) Clin Cancer Res 2010 Feb 15;16(4):1256-63 PMID: 20145186 SCOPUS ID: 2-s2.0-76749110412 02/11/2010       129 Citations
  • Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? (Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM) Oncologist 2010;15(2):130-41 PMID: 20139170 PMCID: PMC3227935 SCOPUS ID: 2-s2.0-77649168107 02/09/2010       91 Citations
  • Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience. (Wheler J, Tsimberidou AM, Moulder S, Cristofanilli M, Hong D, Naing A, Pathak R, Liu S, Feng L, Kurzrock R) Clin Breast Cancer 2010 Feb;10(1):46-51 PMID: 20133258 02/06/2010    
  • Juice plus or toxicity plus. (Naing A, Aaron J, Kurzrock R) Am J Med 2010 Jan;123(1):e1-2 PMID: 20102976 SCOPUS ID: 2-s2.0-72649103824 01/28/2010       3 Citations
  • Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses. (Ng CS, Raunig DL, Jackson EF, Ashton EA, Kelcz F, Kim KB, Kurzrock R, McShane TM) AJR Am J Roentgenol 2010 Feb;194(2):W134-40 PMID: 20093564 SCOPUS ID: 2-s2.0-76149095916 01/23/2010       55 Citations
  • Combining targeted therapies: practical issues to consider at the bench and bedside. (Rodon J, Perez J, Kurzrock R) Oncologist 2010;15(1):37-50 PMID: 20080862 PMCID: PMC3227881 SCOPUS ID: 2-s2.0-75649145389 01/19/2010       42 Citations
  • Target validation using Phase 0 clinical trials: Promises and pitfalls. (Angelo LS, Kurzrock R) Cancer Biol Ther 2009 Nov;8(21):2010-2 PMID: 20037466 SCOPUS ID: 2-s2.0-73549108941 12/29/2009       1 Citation
  • Adjuvant interferon in high-risk melanoma: end of the era? (Janku F, Kurzrock R) J Clin Oncol 2010 Jan 10;28(2):e15-6; author reply e17-8 PMID: 19949007 SCOPUS ID: 2-s2.0-74949129652 12/02/2009       12 Citations
  • Could antitumor activity of curcumin in patients be due to its metabolites? A response (Dhillon N, Sung B, Kurzrock R, Aggarwal BB) Clinical Cancer Research 15 November 2009;15(22):7108-7109 SCOPUS ID: 2-s2.0-72549102585 11/15/2009       5 Citations
  • Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. (Hong DS, Sebti SM, Newman RA, Blaskovich MA, Ye L, Gagel RF, Moulder S, Wheler JJ, Naing A, Tannir NM, Ng CS, Sherman SI, El Naggar AK, Khan R, Trent J, Wright JJ, Kurzrock R) Clin Cancer Res 2009 Nov 15;15(22):7061-8 PMID: 19903778 PMCID: PMC2784003 SCOPUS ID: 2-s2.0-72549092909 11/12/2009       75 Citations
  • Sulforaphane inhibits angiogenesis through activation of FOXO transcription factors. (Davis R, Singh KP, Kurzrock R, Shankar S) Oncol Rep 2009 Dec;22(6):1473-8 PMID: 19885601 SCOPUS ID: 2-s2.0-70449479882 11/04/2009       60 Citations
  • Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial. (Tsimberidou AM, Braiteh F, Stewart DJ, Kurzrock R) J Clin Oncol 2009 Dec 20;27(36):6243-50 PMID: 19826112 SCOPUS ID: 2-s2.0-74949139051 10/15/2009       70 Citations
  • Molecular imaging of gefitinib activity in an epidermal growth factor receptor (EGFR)-bearing xenograft model. (Gong J, Yang DJ, Kohanim S, Angelo LS, Kurzrock R) Cancer Biol Ther 2009 Dec;8(23):2239-47 PMID: 19823028 SCOPUS ID: 2-s2.0-73949101989 10/14/2009       1 Citation
  • Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. (Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M, Sherman SI, Kurzrock R) J Clin Endocrinol Metab 2009 Nov;94(11):4423-32 PMID: 19820016 PMCID: PMC2775645 SCOPUS ID: 2-s2.0-70449090354 10/13/2009       29 Citations
  • Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. (Meng Z, Yang P, Shen Y, Bei W, Zhang Y, Ge Y, Newman RA, Cohen L, Liu L, Thornton B, Chang DZ, Liao Z, Kurzrock R) Cancer 2009 Nov 15;115(22):5309-18 PMID: 19701908 PMCID: PMC2856335 SCOPUS ID: 2-s2.0-70449376872 08/25/2009       210 Citations
  • Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes. (Reyes-Gibby CC, Shete S, Yennurajalingam S, Frazier M, Bruera E, Kurzrock R, Crane CH, Abbruzzese J, Evans D, Spitz MR) J Pain Symptom Manage 2009 Dec;38(6):894-902 PMID: 19692203 PMCID: PMC2795073 SCOPUS ID: 2-s2.0-71249086891 08/21/2009       38 Citations
  • Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. (Evans DG, Kalamarides M, Hunter-Schaedle K, Blakeley J, Allen J, Babovic-Vuskanovic D, Belzberg A, Bollag G, Chen R, DiTomaso E, Golfinos J, Harris G, Jacob A, Kalpana G, Karajannis M, Korf B, Kurzrock R, Law M, McClatchey A, Packer R, Roehm P, Rubenstein A, Slattery W 3rd, Tonsgard JH, Welling DB, Widemann B, Yohay K, Giovannini M) Clin Cancer Res 2009 Aug 15;15(16):5032-5039 PMID: 19671848 PMCID: PMC4513640 SCOPUS ID: 2-s2.0-68149180536 08/13/2009       61 Citations
  • Project Zero Delay: a process for accelerating the activation of cancer clinical trials. (Kurzrock R, Pilat S, Bartolazzi M, Sanders D, Van Wart Hood J, Tucker SD, Webster K, Mallamaci MA, Strand S, Babcock E, Bast RC Jr) J Clin Oncol 2009 Sep 10;27(26):4433-40 PMID: 19652061 SCOPUS ID: 2-s2.0-70349348941 08/05/2009       14 Citations
  • A phase I clinical trial of darinaparsin in patients with refractory solid tumors. (Tsimberidou AM, Camacho LH, Verstovsek S, Ng C, Hong DS, Uehara CK, Gutierrez C, Daring S, Stevens J, Komarnitsky PB, Schwartz B, Kurzrock R) Clin Cancer Res 2009 Jul 15;15(14):4769-76 PMID: 19584162 SCOPUS ID: 2-s2.0-68049109550 07/09/2009       31 Citations
  • Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. (Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, Le N, Rosen LS) J Clin Oncol 2009 Jul 20;27(21):3557-65 PMID: 19546406 SCOPUS ID: 2-s2.0-70249114453 06/24/2009       212 Citations
  • Reply to J.J.L. Jacobs et al (Stewart DJ, Kurzrock R) Journal of Clinical Oncology 20 June 2009;27(18):3063-3064 SCOPUS ID: 2-s2.0-74549210098 06/20/2009    
  • Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model. (Mach CM, Mathew L, Mosley SA, Kurzrock R, Smith JA) Anticancer Res 2009 Jun;29(6):1895-9 PMID: 19528445 SCOPUS ID: 2-s2.0-67650882757 06/17/2009       43 Citations
  • Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. (Shankar S, Davis R, Singh KP, Kurzrock R, Ross DD, Srivastava RK) Mol Cancer Ther 2009 Jun;8(6):1596-605 PMID: 19509267 SCOPUS ID: 2-s2.0-67649354926 06/11/2009       46 Citations
  • A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. (Moulder S, Dhillon N, Ng C, Hong D, Wheler J, Naing A, Tse S, La Paglia A, Dorr R, Hersh E, Boytim M, Kurzrock R) Invest New Drugs 2010 Oct;28(5):634-40 PMID: 19499186 SCOPUS ID: 2-s2.0-77956056306 06/06/2009       26 Citations
  • Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. (Tsimberidou AM, Rudek MA, Hong D, Ng CS, Blair J, Goldsweig H, Kurzrock R) Cancer Chemother Pharmacol 2010 Jan;65(2):235-41 PMID: 19484470 SCOPUS ID: 2-s2.0-71349085359 06/02/2009       35 Citations
  • Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. (Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, Hong D, Oki Y, Guo Z, Gupta S, Wistuba II) Clin Cancer Res 2009 Jun 01;15(11):3881-8 PMID: 19470736 SCOPUS ID: 2-s2.0-66649105473 05/28/2009       103 Citations
  • Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience. (Vemulapalli S, Chintala L, Tsimberidou AM, Dhillon N, Lei X, Hong D, Kurzrock R) Am J Hematol 2009 Jul;84(7):408-13 PMID: 19437507 SCOPUS ID: 2-s2.0-67649739493 05/14/2009       12 Citations
  • Electronic clinical challenges and images in GI. Image 2. Extensive bilateral extracranial subcutaneous fluid collection. (Braiteh F, Kurzrock R) Gastroenterology 2009 Jun;136(7):e3-6 PMID: 19427926 SCOPUS ID: 2-s2.0-66449127702 05/12/2009    
  • Molecular imaging of Bcr-Abl phosphokinase in a xenograft model. (Wu JY, Yang DJ, Angelo LS, Kohanim S, Kurzrock R) Mol Cancer Ther 2009 Mar;8(3):703-10 PMID: 19258427 PMCID: PMC2679515 SCOPUS ID: 2-s2.0-66449130945 03/05/2009       4 Citations
  • Turmeric and green tea: a recipe for the treatment of B-chronic lymphocytic leukemia. (Angelo LS, Kurzrock R) Clin Cancer Res 2009 Feb 15;15(4):1123-5 PMID: 19228716 PMCID: PMC2646173 SCOPUS ID: 2-s2.0-63149100975 02/21/2009       30 Citations
  • Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience. (Wheler J, Tsimberidou AM, Hong D, Naing A, Jackson T, Liu S, Feng L, Kurzrock R) Cancer 2009 Mar 01;115(5):1091-9 PMID: 19165805 SCOPUS ID: 2-s2.0-61449180271 01/24/2009       62 Citations
  • The changing face of phase 1 cancer clinical trials: new challenges in study requirements. (Craft BS, Kurzrock R, Lei X, Herbst R, Lippman S, Fu S, Karp DD) Cancer 2009 Apr 15;115(8):1592-7 PMID: 19165808 PMCID: PMC2668727 SCOPUS ID: 2-s2.0-65249146114 01/24/2009       16 Citations
  • In Response (Kurzrock R, Dhillon N) Clinical Cancer Research 15 January 2009;15(2):747 SCOPUS ID: 2-s2.0-59449088610 01/15/2009    
  • Cancer: the road to Amiens. (Stewart DJ, Kurzrock R) J Clin Oncol 2009 Jan 20;27(3):328-33 PMID: 19064964 SCOPUS ID: 2-s2.0-58549094955 12/10/2008       88 Citations
  • The role of investigational therapy in management of patients with advanced metastatic malignancy. (Freireich EJ, Kurzrock R) J Clin Oncol 2009 Jan 10;27(2):304-6 PMID: 19064962 SCOPUS ID: 2-s2.0-58249084144 12/10/2008       27 Citations
  • Hematopoietic Growth Factors and Cytokines (Ekmekcioglu S, Kurzrock R, Grimm EA) The Molecular Basis of Cancer 2008:605-619 SCOPUS ID: 2-s2.0-84882844396 12/01/2008    
  • Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. (Sun G, Berthelot C, Li Y, Glass DA 2nd, George D, Pandya A, Kurzrock R, Duvic M) J Am Acad Dermatol 2009 Feb;60(2):231-5 PMID: 19026464 SCOPUS ID: 2-s2.0-58149490970 11/26/2008       53 Citations
  • The influence of tumor necrosis factor-alpha -308 G/A and IL-6 -174 G/C on pain and analgesia response in lung cancer patients receiving supportive care. (Reyes-Gibby CC, El Osta B, Spitz MR, Parsons H, Kurzrock R, Wu X, Shete S, Bruera E) Cancer Epidemiol Biomarkers Prev 2008 Nov;17(11):3262-7 PMID: 18990769 PMCID: PMC3398799 SCOPUS ID: 2-s2.0-55849095849 11/08/2008       50 Citations
  • Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. (Braiteh F, Soriano AO, Garcia-Manero G, Hong D, Johnson MM, Silva Lde P, Yang H, Alexander S, Wolff J, Kurzrock R) Clin Cancer Res 2008 Oct 01;14(19):6296-301 PMID: 18829512 PMCID: PMC2582814 SCOPUS ID: 2-s2.0-58149174109 10/03/2008       140 Citations
  • Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. (Rodon J, DeSantos V, Ferry RJ Jr, Kurzrock R) Mol Cancer Ther 2008 Sep;7(9):2575-88 PMID: 18790742 PMCID: PMC3101870 SCOPUS ID: 2-s2.0-54049108939 09/16/2008       144 Citations
  • The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. (Tsimberidou AM, Estey E, Wen S, Pierce S, Kantarjian H, Albitar M, Kurzrock R) Cancer 2008 Oct 01;113(7):1605-13 PMID: 18683214 SCOPUS ID: 2-s2.0-84866113642 08/07/2008       97 Citations
  • Molecular epidemiology, cancer-related symptoms, and cytokines pathway. (Reyes-Gibby CC, Wu X, Spitz M, Kurzrock R, Fisch M, Bruera E, Shete S) Lancet Oncol 2008 Aug;9(8):777-85 PMID: 18672213 PMCID: PMC3390774 SCOPUS ID: 2-s2.0-47849090505 08/02/2008       82 Citations
  • Phase II trial of curcumin in patients with advanced pancreatic cancer. (Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R) Clin Cancer Res 2008 Jul 15;14(14):4491-9 PMID: 18628464 SCOPUS ID: 2-s2.0-51649118928 07/17/2008       1030 Citations
  • Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. (Braiteh F, Kurzrock R, Johnson FM) J Clin Oncol 2008 Jul 10;26(20):3460-2 PMID: 18612164 SCOPUS ID: 2-s2.0-49149087664 07/10/2008       37 Citations
  • Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. (Hong DS, Reddy SB, Prieto VG, Wright JJ, Tannir NM, Cohen PR, Diwan AH, Evans HL, Kurzrock R) Arch Dermatol 2008 Jun;144(6):779-82 PMID: 18559769 SCOPUS ID: 2-s2.0-45349101568 06/19/2008       45 Citations
  • Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. (Hong D, Ye L, Gagel R, Chintala L, El Naggar AK, Wright J, Kurzrock R) Mol Cancer Ther 2008 May;7(5):1001-6 PMID: 18445656 SCOPUS ID: 2-s2.0-49849083911 05/01/2008       46 Citations
  • Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. (Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R) Mol Cancer Ther 2008 Mar;7(3):464-73 PMID: 18347134 SCOPUS ID: 2-s2.0-41649090153 03/19/2008       362 Citations
  • Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides. (Cen P, Duvic M, Cohen PR, Kurzrock R) J Am Acad Dermatol 2008 Mar;58(3):382-6 PMID: 18280334 SCOPUS ID: 2-s2.0-38949191987 02/19/2008       5 Citations
  • Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome. (Kurzrock R, Kantarjian HM, Blascovich MA, Bucher C, Verstovsek S, Wright JJ, Pilat SR, Cortes JE, Estey EH, Giles FJ, Beran M, Sebti SM) Clin Cancer Res 2008 Jan 15;14(2):509-14 PMID: 18223226 SCOPUS ID: 2-s2.0-38949159210 01/29/2008       19 Citations
  • Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. (Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ) J Clin Oncol 2008 Jan 10;26(2):196-203 PMID: 18182662 SCOPUS ID: 2-s2.0-38349163290 01/10/2008       126 Citations
  • Cytokine genes and pain severity in lung cancer: exploring the influence of TNF-alpha-308 G/A IL6-174G/C and IL8-251T/A. (Reyes-Gibby CC, Spitz M, Wu X, Merriman K, Etzel C, Bruera E, Kurzrock R, Shete S) Cancer Epidemiol Biomarkers Prev 2007 Dec;16(12):2745-51 PMID: 18086782 SCOPUS ID: 2-s2.0-38849168754 12/19/2007       58 Citations
  • The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines. (Lyu MA, Kurzrock R, Rosenblum MG) Biochem Pharmacol 2008 Feb 15;75(4):836-46 PMID: 18082672 SCOPUS ID: 2-s2.0-38649132890 12/18/2007       12 Citations
  • Interleukin-6 and its receptor in cancer: implications for translational therapeutics. (Hong DS, Angelo LS, Kurzrock R) Cancer 2007 Nov 01;110(9):1911-28 PMID: 17849470 SCOPUS ID: 2-s2.0-35648995976 09/13/2007       316 Citations
  • Studies in target-based treatment. (Kurzrock R) Mol Cancer Ther 2007 Sep;6(9):2385 PMID: 17846118 SCOPUS ID: 2-s2.0-34748864802 09/12/2007       3 Citations
  • Cutaneous castleman's disease responds to anti interleukin-6 treatment. (Ahmed B, Tschen JA, Cohen PR, Zaki MH, Rady PL, Tyring SK, Corringham RE, Kurzrock R) Mol Cancer Ther 2007 Sep;6(9):2386-90 PMID: 17766835 SCOPUS ID: 2-s2.0-34748822990 09/04/2007       43 Citations
  • I have good news! You have leukemia. (Kurzrock R) Clin Dermatol 2007 May-Jun;25(3):350-2 PMID: 17560314 SCOPUS ID: 2-s2.0-34249798682 06/15/2007       1 Citation
  • Sarcoidosis and malignancy. (Cohen PR, Kurzrock R) Clin Dermatol 2007 May-Jun;25(3):326-33 PMID: 17560310 SCOPUS ID: 2-s2.0-34249867194 06/15/2007       164 Citations
  • Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. (Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, Silverman J, Koutsoukos A, Sun YN, Bass MB, Xu RY, Polverino A, Wiezorek JS, Chang DD, Benjamin R, Herbst RS) J Clin Oncol 2007 Jun 10;25(17):2369-76 PMID: 17557949 SCOPUS ID: 2-s2.0-34347235531 06/15/2007       175 Citations
  • Vascular endothelial growth factor and its relationship to inflammatory mediators. (Angelo LS, Kurzrock R) Clin Cancer Res 2007 May 15;13(10):2825-30 PMID: 17504979 SCOPUS ID: 2-s2.0-34249825478 05/17/2007       193 Citations
  • Studies in target-based treatment. (Kurzrock R) Mol Cancer Ther 2007 May;6(5):1477 PMID: 17483434 SCOPUS ID: 2-s2.0-34250791337 05/08/2007       2 Citations
  • Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver. (Camacho LH, Kurzrock R, Cheung A, Barber DF, Gupta S, Madoff DC, Wallace MJ, Kim EE, Curley SA, Hortobagyi GN, Mavligit G) Cancer 2007 Jun 01;109(11):2190-6 PMID: 17464952 SCOPUS ID: 2-s2.0-34249111498 04/28/2007       27 Citations
  • Improving the institutional submission and approval process for clinical research protocols in oncology. (Camacho LH, Marubio L, Purdom MA, Leonard D, Hong DS, Moulder S, Pilat SR, Kurzrock R) J Clin Oncol 2007 Apr 20;25(12):1632-3 PMID: 17443009 SCOPUS ID: 2-s2.0-34248153686 04/20/2007       3 Citations
  • Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. (Li L, Ahmed B, Mehta K, Kurzrock R) Mol Cancer Ther 2007 Apr;6(4):1276-82 PMID: 17431105 SCOPUS ID: 2-s2.0-34248193849 04/14/2007       283 Citations
  • Uncommon tumors and exceptional therapies: paradox or paradigm? (Braiteh F, Kurzrock R) Mol Cancer Ther 2007 Apr;6(4):1175-9 PMID: 17431100 SCOPUS ID: 2-s2.0-34248204234 04/14/2007       46 Citations
  • A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. (Fenaux P, Raza A, Mufti GJ, Aul C, Germing U, Kantarjian H, Cripe L, Kerstens R, De Porre P, Kurzrock R) Blood 2007 May 15;109(10):4158-63 PMID: 17264294 SCOPUS ID: 2-s2.0-34248363673 02/01/2007       102 Citations
  • CAT scan reveals BAT sign. (Braiteh F, Cohen PR, Kurzrock R) Lancet 2007 Jan 20;369(9557):217 PMID: 17240288 SCOPUS ID: 2-s2.0-33846216742 01/24/2007    
  • Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies. (Gong J, Yang D, Kohanim S, Humphreys R, Broemeling L, Kurzrock R) Mol Cancer Ther 2006 Dec;5(12):2991-3000 PMID: 17148761 SCOPUS ID: 2-s2.0-33846185483 12/07/2006       33 Citations
  • Polycystic ovary syndrome in men: Stein-Leventhal syndrome revisited. (Kurzrock R, Cohen PR) Med Hypotheses 2007;68(3):480-3 PMID: 17134841 SCOPUS ID: 2-s2.0-33845981087 12/01/2006       20 Citations
  • Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome. (Montero AJ, Estrov Z, Freireich EJ, Khouri IF, Koller CA, Kurzrock R) Leuk Lymphoma 2006 Oct;47(10):2049-54 PMID: 17071475 SCOPUS ID: 2-s2.0-33750453783 10/31/2006       20 Citations
  • Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. (Khanbolooki S, Nawrocki ST, Arumugam T, Andtbacka R, Pino MS, Kurzrock R, Logsdon CD, Abbruzzese JL, McConkey DJ) Mol Cancer Ther 2006 Sep;5(9):2251-60 PMID: 16985059 SCOPUS ID: 2-s2.0-33749578608 09/21/2006       123 Citations
  • Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance. (Kurzrock R, Talpaz M, Li L, Estrov Z) Leuk Lymphoma 2006 Aug;47(8):1651-64 PMID: 16966279 SCOPUS ID: 2-s2.0-33748541956 09/13/2006       2 Citations
  • Computed axial tomography scanning (CT scan). (Braiteh F, Lim JT, Kurzrock R) Clin Anat 2006 Oct;19(7):682-3 PMID: 16964604 SCOPUS ID: 2-s2.0-33748618943 09/12/2006    
  • Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. (Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N) Clin Lymphoma Myeloma 2006 Jul;7(1):51-8 PMID: 16879770 SCOPUS ID: 2-s2.0-33748320723 08/02/2006       137 Citations
  • Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot study. (Tsimberidou AM, Keating MJ, Bueso-Ramos CE, Kurzrock R) Leuk Lymphoma 2006 May;47(5):827-36 PMID: 16753866 SCOPUS ID: 2-s2.0-33744928408 06/07/2006       34 Citations
  • Purine analogues in advanced T-cell lymphoid malignancies. (Kurzrock R, Ravandi F) Semin Hematol 2006 Apr;43(2 Suppl 2):S27-34 PMID: 16549112 SCOPUS ID: 2-s2.0-33645007850 03/22/2006       7 Citations
  • CASE 1. Langerhans cell histiocytosis of the thyroid. (Braiteh F, Kurzrock R) J Clin Oncol 2006 Jan 20;24(3):522-3 PMID: 16421429 SCOPUS ID: 2-s2.0-33644841427 01/20/2006       16 Citations
  • Refractory Hodgkin lymphoma responds to pentostatin (2'-deoxycoformycin). (Braiteh F, Ng C, Kurzrock R) Leuk Lymphoma 2006 Feb;47(2):373-5 PMID: 16321875 SCOPUS ID: 2-s2.0-30644461685 12/03/2005       5 Citations
  • Farnesyltransferase inhibitors. (Kurzrock R) Clin Adv Hematol Oncol 2005 Mar;3(3):161-2 PMID: 16166986 SCOPUS ID: 2-s2.0-25844461711 09/17/2005       7 Citations
  • Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. (Li L, Braiteh FS, Kurzrock R) Cancer 2005 Sep 15;104(6):1322-31 PMID: 16092118 SCOPUS ID: 2-s2.0-24644508916 08/11/2005       554 Citations
  • Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. (Braiteh F, Boxrud C, Esmaeli B, Kurzrock R) Blood 2005 Nov 01;106(9):2992-4 PMID: 16020507 SCOPUS ID: 2-s2.0-27644519727 07/16/2005       161 Citations
  • Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. (Siwak DR, Shishodia S, Aggarwal BB, Kurzrock R) Cancer 2005 Aug 15;104(4):879-90 PMID: 16007726 SCOPUS ID: 2-s2.0-23444449848 07/12/2005       204 Citations
  • Phase 1 clinical trials in oncology. (Miller MJ) N Engl J Med 2005 Jun 09;352(23):2451-3; author reply 2451-3 PMID: 15948270 SCOPUS ID: 2-s2.0-20344391432 06/11/2005       13 Citations
  • Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. (Tibes R, Trent J, Kurzrock R) Annu Rev Pharmacol Toxicol 2005;45:357-84 PMID: 15822181 SCOPUS ID: 2-s2.0-13844316734 04/12/2005       99 Citations
  • Thrombopoietic factors in chronic bone marrow failure states: the platelet problem revisited. (Kurzrock R) Clin Cancer Res 2005 Feb 15;11(4):1361-7 PMID: 15746033 SCOPUS ID: 2-s2.0-14644393642 03/05/2005       25 Citations
  • Risks and benefits of phase 1 oncology trials, revisited. (Kurzrock R, Benjamin RS) N Engl J Med 2005 Mar 03;352(9):930-2 PMID: 15745986 SCOPUS ID: 2-s2.0-14544286345 03/05/2005       75 Citations
  • Metastasis--an alternative hypothesis. (Freireich EJ, Kurzrock R, Estrov Z) Cancer 2005 Apr 15;103(8):1537-9 PMID: 15739196 SCOPUS ID: 2-s2.0-16844376798 03/02/2005       8 Citations
  • Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. (Cortes J, Faderl S, Estey E, Kurzrock R, Thomas D, Beran M, Garcia-Manero G, Ferrajoli A, Giles F, Koller C, O'Brien S, Wright J, Bai SA, Kantarjian H) J Clin Oncol 2005 Apr 20;23(12):2805-12 PMID: 15728224 SCOPUS ID: 2-s2.0-21044459973 02/25/2005       47 Citations
  • Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. (Tsimberidou AM, Giles FJ, Khouri I, Bueso-Ramos C, Pilat S, Thomas DA, Cortes J, Kurzrock R) Ann Oncol 2005 Jan;16(1):139-45 PMID: 15598951 SCOPUS ID: 2-s2.0-12344288374 12/16/2004       47 Citations
  • Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. (Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R) Cancer 2004 Dec 15;101(12):2727-36 PMID: 15526319 SCOPUS ID: 2-s2.0-10044261013 11/05/2004       247 Citations
  • Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. (Li L, Aggarwal BB, Shishodia S, Abbruzzese J, Kurzrock R) Cancer 2004 Nov 15;101(10):2351-62 PMID: 15476283 SCOPUS ID: 2-s2.0-7644223910 10/12/2004       270 Citations
  • Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas. (Tsimberidou AM, Giles FJ, Duvic M, Kurzrock R) J Am Acad Dermatol 2004 Aug;51(2):200-4 PMID: 15280837 SCOPUS ID: 2-s2.0-4644281717 07/29/2004       27 Citations
  • Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview. (Barber FD, Mavligit G, Kurzrock R) Cancer Treat Rev 2004 Aug;30(5):425-36 PMID: 15245775 SCOPUS ID: 2-s2.0-3242797445 07/13/2004       37 Citations
  • Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. (Lenihan DJ, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M) Blood 2004 Aug 01;104(3):655-8 PMID: 15073032 SCOPUS ID: 2-s2.0-3242816208 04/10/2004       114 Citations
  • Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. (Kurzrock R, Albitar M, Cortes JE, Estey EH, Faderl SH, Garcia-Manero G, Thomas DA, Giles FJ, Ryback ME, Thibault A, De Porre P, Kantarjian HM) J Clin Oncol 2004 Apr 01;22(7):1287-92 PMID: 15051776 SCOPUS ID: 2-s2.0-2142712474 03/31/2004       144 Citations
  • Epstein-Barr virus and cancer. (Thompson MP, Kurzrock R) Clin Cancer Res 2004 Feb 01;10(3):803-21 PMID: 14871955 SCOPUS ID: 2-s2.0-1042301963 02/12/2004       568 Citations
  • Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies. (Tsimberidou AM, Giles F, Romaguera J, Duvic M, Kurzrock R) Cancer 2004 Feb 01;100(3):574-80 PMID: 14745875 SCOPUS ID: 2-s2.0-1642494642 01/28/2004       21 Citations
  • Community-acquired methicillin-resistant Staphylococcus aureus skin infection: an emerging clinical problem. (Cohen PR, Kurzrock R) J Am Acad Dermatol 2004 Feb;50(2):277-80 PMID: 14726887 SCOPUS ID: 2-s2.0-0842310882 01/17/2004       87 Citations
  • Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. (Tsimberidou AM, Giles F, Duvic M, Fayad L, Kurzrock R) Cancer 2004 Jan 15;100(2):342-9 PMID: 14716770 SCOPUS ID: 2-s2.0-0346724524 01/13/2004       67 Citations
  • Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses. (Wu HH, Talpaz M, Champlin RE, Pilat SR, Kurzrock R) Cancer 2003 Dec 01;98(11):2410-9 PMID: 14635076 SCOPUS ID: 2-s2.0-0345275884 11/25/2003       19 Citations
  • Autocrine lymphotoxin production in Epstein-Barr virus-immortalized B cells: induction via NF-kappaB activation mediated by EBV-derived latent membrane protein 1. (Thompson MP, Aggarwal BB, Shishodia S, Estrov Z, Kurzrock R) Leukemia 2003 Nov;17(11):2196-201 PMID: 14523478 SCOPUS ID: 2-s2.0-0242643609 10/03/2003       14 Citations
  • Sweet's syndrome revisited: a review of disease concepts. (Cohen PR, Kurzrock R) Int J Dermatol 2003 Oct;42(10):761-78 PMID: 14521689 SCOPUS ID: 2-s2.0-0142248933 10/03/2003       314 Citations
  • Impact of p210(Bcr-Abl) on ultraviolet C wavelength-induced DNA damage and repair. (Laurent E, Mitchell DL, Estrov Z, Lowery M, Tucker SL, Talpaz M, Kurzrock R) Clin Cancer Res 2003 Sep 01;9(10 Pt 1):3722-30 PMID: 14506164 SCOPUS ID: 2-s2.0-0141791308 09/25/2003       12 Citations
  • Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. (Kurzrock R, Kantarjian HM, Cortes JE, Singhania N, Thomas DA, Wilson EF, Wright JJ, Freireich EJ, Talpaz M, Sebti SM) Blood 2003 Dec 15;102(13):4527-34 PMID: 12947010 SCOPUS ID: 2-s2.0-10744227474 08/30/2003       126 Citations
  • Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. (Yazji S, Giles FJ, Tsimberidou AM, Estey EH, Kantarjian HM, O'Brien SA, Kurzrock R) Leukemia 2003 Nov;17(11):2101-6 PMID: 12931212 SCOPUS ID: 2-s2.0-0242643661 08/22/2003       77 Citations
  • Phase II study of alemtuzumab in chronic lymphoproliferative disorders. (Ferrajoli A, O'Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S, Kurzrock R, Lerner S, Kontoyiannis DP, Keating MJ) Cancer 2003 Aug 15;98(4):773-8 PMID: 12910522 SCOPUS ID: 2-s2.0-0042071567 08/12/2003       122 Citations
  • Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. (Duvic M, Apisarnthanarax N, Cohen DS, Smith TL, Ha CS, Kurzrock R) J Am Acad Dermatol 2003 Jul;49(1):35-49 PMID: 12833006 SCOPUS ID: 2-s2.0-0037710200 07/02/2003       60 Citations
  • Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. (Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M) Ann Intern Med 2003 May 20;138(10):819-30 PMID: 12755554 SCOPUS ID: 2-s2.0-0037672877 05/21/2003       267 Citations
  • Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome. (Kurzrock R, Cortes J, Kantarjian H) Semin Hematol 2002 Oct;39(4 Suppl 3):20-4 PMID: 12447848 SCOPUS ID: 2-s2.0-0036814927 11/26/2002       33 Citations
  • Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. (Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A, Rackoff W, Koller C, O'Brien S, Garcia-Manero G, Talpaz M, Kantarjian H) Blood 2003 Mar 01;101(5):1692-7 PMID: 12411300 SCOPUS ID: 2-s2.0-0037372488 11/02/2002       212 Citations
  • Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies. (Kantarjian HM, Cortes JE, Rowe JM, Kurzrock R) Semin Hematol 2002 Jul;39(3 Suppl 2):36-8 PMID: 12214292 SCOPUS ID: 2-s2.0-0036655776 09/06/2002       5 Citations
  • Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies. (Cortes JE, Kurzrock R, Kantarjian HM) Semin Hematol 2002 Jul;39(3 Suppl 2):26-30 PMID: 12214290 SCOPUS ID: 2-s2.0-0036655361 09/06/2002       20 Citations
  • Myelodysplastic syndrome overview. (Kurzrock R) Semin Hematol 2002 Jul;39(3 Suppl 2):18-25 PMID: 12214289 SCOPUS ID: 2-s2.0-0036655766 09/06/2002       25 Citations
  • Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies. (Tsimberidou AM, Thomas D, O'Brien S, Andreeff M, Kurzrock R, Keating M, Albitar M, Kantarjian H, Giles F) Cancer Chemother Pharmacol 2002 Sep;50(3):237-42 PMID: 12203106 SCOPUS ID: 2-s2.0-0036047814 08/31/2002       23 Citations
  • The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. (Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, Estrov Z, Koller CA, Kurzrock R, Thomas DA, Faderl S, Lerner S, O'Brien S, Albitar M) Blood 2002 Aug 15;100(4):1215-9 PMID: 12149200 SCOPUS ID: 2-s2.0-0037103258 08/01/2002       148 Citations
  • Reduced focal adhesion kinase and paxillin phosphorylation in BCR-ABL-transfected cells. (Cheng K, Kurzrock R, Qiu X, Estrov Z, Ku S, Dulski KM, Wang JY, Talpaz M) Cancer 2002 Jul 15;95(2):440-50 PMID: 12124845 SCOPUS ID: 2-s2.0-0037099643 07/19/2002       23 Citations
  • Chronic myelogenous leukemia in chronic phase. (Kurzrock R, Kantarjian H, Talpaz M) Curr Treat Options Oncol 2001 Jun;2(3):245-52 PMID: 12057124 SCOPUS ID: 2-s2.0-0035383005 06/12/2002       7 Citations
  • Sweet's syndrome: a review of current treatment options. (Cohen PR, Kurzrock R) Am J Clin Dermatol 2002;3(2):117-31 PMID: 11893223 SCOPUS ID: 2-s2.0-0036197290 03/15/2002       120 Citations
  • How to detect skin signs of malignancy (Cohen PR, Kurzrock R) Patient Care March 2002;36(5):21-35 SCOPUS ID: 2-s2.0-0038891805 03/01/2002    
  • Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53. (Angelo LS, Talpaz M, Kurzrock R) Cancer Res 2002 Feb 01;62(3):932-40 PMID: 11830554 SCOPUS ID: 2-s2.0-0036469114 02/07/2002       80 Citations
  • Cytokine deregulation in cancer. (Kurzrock R) Biomed Pharmacother 2001 Nov;55(9-10):543-7 PMID: 11769963 SCOPUS ID: 2-s2.0-0035652203 01/05/2002       80 Citations
  • Interferon therapy for orbital infiltration secondary to Erdheim-Chester disease. (Esmaeli B, Ahmadi A, Tang R, Schiffman J, Kurzrock R) Am J Ophthalmol 2001 Dec;132(6):945-7 PMID: 11730673 SCOPUS ID: 2-s2.0-0035205734 12/04/2001       47 Citations
  • Pilot study of low-dose interleukin-11 in patients with bone marrow failure. (Kurzrock R, Cortes J, Thomas DA, Jeha S, Pilat S, Talpaz M) J Clin Oncol 2001 Nov 01;19(21):4165-72 PMID: 11689585 SCOPUS ID: 2-s2.0-0035503148 11/02/2001       58 Citations
  • The role of cytokines in cancer-related fatigue. (Kurzrock R) Cancer 2001 Sep 15;92(6 Suppl):1684-8 PMID: 11598887 SCOPUS ID: 2-s2.0-0035883484 10/13/2001       213 Citations
  • Therapy of T cell lymphomas with pentostatin. (Kurzrock R) Ann N Y Acad Sci 2001 Sep;941:200-5 PMID: 11594574 SCOPUS ID: 2-s2.0-0034809004 10/12/2001       16 Citations
  • BCR rearrangement-negative chronic myelogenous leukemia revisited. (Kurzrock R, Bueso-Ramos CE, Kantarjian H, Freireich E, Tucker SL, Siciliano M, Pilat S, Talpaz M) J Clin Oncol 2001 Jun 01;19(11):2915-26 PMID: 11387365 SCOPUS ID: 2-s2.0-0035367160 06/02/2001       79 Citations
  • Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by interferon alpha: involvement of tumor necrosis factor as ligand for the CD95 receptor. (Gisslinger H, Kurzrock R, Gisslinger B, Jiang S, Li S, Virgolini I, Woloszczuk W, Andreeff M, Talpaz M) Blood 2001 May 01;97(9):2791-7 PMID: 11313273 SCOPUS ID: 2-s2.0-0035353199 04/21/2001       15 Citations
  • The BCR gene and philadelphia chromosome-positive leukemogenesis. (Laurent E, Talpaz M, Kantarjian H, Kurzrock R) Cancer Res 2001 Mar 15;61(6):2343-55 PMID: 11289094 SCOPUS ID: 2-s2.0-0035866754 04/06/2001       109 Citations
  • Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. (Fayad L, Keating MJ, Reuben JM, O'Brien S, Lee BN, Lerner S, Kurzrock R) Blood 2001 Jan 01;97(1):256-63 PMID: 11133769 SCOPUS ID: 2-s2.0-0035160749 01/03/2001       230 Citations
  • Cytoplasmic and nuclear localization of the 130 and 160 kDa Bcr proteins. (Laurent E, Talpaz M, Wetzler M, Kurzrock R) Leukemia 2000 Nov;14(11):1892-7 PMID: 11069024 SCOPUS ID: 2-s2.0-0033758839 11/09/2000       10 Citations
  • rhIL-11 for the prevention of dose-limiting chemotherapy-induced thrombocytopenia. (Kurzrock R) Oncology (Williston Park) 2000 Sep;14(9 Suppl 8):9-11 PMID: 11033833 SCOPUS ID: 2-s2.0-0034278344 10/18/2000       9 Citations
  • Autoantibodies to Abl and Bcr proteins. (Talpaz M, Qiu X, Cheng K, Cortes JE, Kantarjian H, Kurzrock R) Leukemia 2000 Sep;14(9):1661-6 PMID: 10995014 SCOPUS ID: 2-s2.0-0033835428 09/20/2000       3 Citations
  • Pentostatin (Nipent) in T-cell lymphomas. (Kurzrock R) Semin Oncol 2000 Apr;27(2 Suppl 5):64-6 PMID: 10877055 SCOPUS ID: 2-s2.0-0033918832 07/06/2000       8 Citations
  • Sweet's syndrome: a neutrophilic dermatosis classically associated with acute onset and fever. (Cohen PR, Kurzrock R) Clin Dermatol 2000 May-Jun;18(3):265-82 PMID: 10856659 SCOPUS ID: 2-s2.0-0034611977 06/17/2000       142 Citations
  • A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. (Nash RA, Kurzrock R, DiPersio J, Vose J, Linker C, Maharaj D, Nademanee AP, Negrin R, Nimer S, Shulman H, Ashby M, Jones D, Appelbaum FR, Champlin R) Biol Blood Marrow Transplant 2000;6(1):25-34 PMID: 10707996 SCOPUS ID: 2-s2.0-0033631018 03/09/2000       66 Citations
  • RAS inhibitors in hematologic cancers: biologic considerations and clinical applications. (Beaupre DM, Kurzrock R) Invest New Drugs 1999;17(2):137-43 PMID: 10638484 SCOPUS ID: 2-s2.0-0032793889 01/19/2000       7 Citations
  • A phase I study of recombinant interferon-beta in patients with advanced malignant disease. (Ravandi F, Estrov Z, Kurzrock R, Breitmeyer JB, Maschek BJ, Talpaz M) Clin Cancer Res 1999 Dec;5(12):3990-8 PMID: 10632330 SCOPUS ID: 2-s2.0-0033382012 01/13/2000       14 Citations
  • A pilot study of recombinant human interleukin-4 therapy of myelofibrosis. (Giles FJ, Keating AR, Kurzrock R, Talpaz M) J Interferon Cytokine Res 1999 Nov;19(11):1253-5 PMID: 10574617 SCOPUS ID: 2-s2.0-0032705273 11/26/1999       4 Citations
  • Minimal residual disease in hematologic disorders. (Faderl S, Kurzrock R, Estrov Z) Arch Pathol Lab Med 1999 Nov;123(11):1030-4 PMID: 10539902 SCOPUS ID: 2-s2.0-0032697407 10/28/1999       14 Citations
  • Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. (Kurzrock R, Pilat S, Duvic M) J Clin Oncol 1999 Oct;17(10):3117-21 PMID: 10506607 SCOPUS ID: 2-s2.0-0032888693 10/03/1999       90 Citations
  • The biology of chronic myeloid leukemia. (Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM) N Engl J Med 1999 Jul 15;341(3):164-72 PMID: 10403855 SCOPUS ID: 2-s2.0-0033565561 07/15/1999       1044 Citations
  • Autocrine interleukin-1beta production in leukemia: evidence for the involvement of mutated RAS. (Beaupre DM, Talpaz M, Marini FC 3rd, Cristiano RJ, Roth JA, Estrov Z, Albitar M, Freedman MH, Kurzrock R) Cancer Res 1999 Jun 15;59(12):2971-80 PMID: 10383163 SCOPUS ID: 2-s2.0-0033563322 06/26/1999       45 Citations
  • Prognostic factor analysis in mycosis fungoides/Sézary syndrome. (Diamandidou E, Colome M, Fayad L, Duvic M, Kurzrock R) J Am Acad Dermatol 1999 Jun;40(6 Pt 1):914-24 PMID: 10365922 SCOPUS ID: 2-s2.0-0033001982 06/12/1999       141 Citations
  • RAS and leukemia: from basic mechanisms to gene-directed therapy. (Beaupre DM, Kurzrock R) J Clin Oncol 1999 Mar;17(3):1071-9 PMID: 10071302 SCOPUS ID: 2-s2.0-0033014304 03/10/1999       164 Citations
  • Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture. (Kantarjian HM, Talpaz M, O'Brien S, Kurzrock R, Gutterman J, Keating MJ, McCredie KB, Freireich EJ) Clin Cancer Res 1997 Dec;3(12 Pt 2):2723-33 PMID: 10068280 SCOPUS ID: 2-s2.0-0031426987 03/06/1999       15 Citations
  • 2-chlorodeoxyadenosine-associated transient acantholytic dermatosis in hairy cell leukemia patients. (Cohen PR, Kurzrock R) Am J Dermatopathol 1999 Feb;21(1):106-8 PMID: 10027536 SCOPUS ID: 2-s2.0-0032926562 02/23/1999       10 Citations
  • Cytokine deregulation in hematological malignancies: clinical and biological implications. (Kurzrock R) Clin Cancer Res 1997 Dec;3(12 Pt 2):2581-4 PMID: 9815659 SCOPUS ID: 2-s2.0-0031409091 11/17/1998       44 Citations
  • Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation. (Ferrajoli A, Talpaz M, Kurzrock R, Harris D, Van Q, Estey EH, Estrov Z) Leuk Lymphoma 1998 Jul;30(3-4):279-92 PMID: 9713960 SCOPUS ID: 2-s2.0-0031844968 08/26/1998       8 Citations
  • High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. (Fayad L, Cabanillas F, Talpaz M, McLaughlin P, Kurzrock R) Leuk Lymphoma 1998 Aug;30(5-6):563-71 PMID: 9711918 SCOPUS ID: 2-s2.0-0031822779 08/26/1998       43 Citations
  • Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. (Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R) Blood 1998 Aug 15;92(4):1150-9 PMID: 9694702 SCOPUS ID: 2-s2.0-0032529675 08/08/1998       269 Citations
  • Z-138: a new mature B-cell acute lymphoblastic leukemia cell line from a patient with transformed chronic lymphocytic leukemia. (Estrov Z, Talpaz M, Ku S, Harris D, Van Q, Beran M, Hirsch-Ginsberg C, Huh Y, Yee G, Kurzrock R) Leuk Res 1998 Apr;22(4):341-53 PMID: 9669839 SCOPUS ID: 2-s2.0-17144453582 07/21/1998       29 Citations
  • GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia. (Cortes J, Kantarjian H, O'Brien S, Kurzrock R, Keating M, Talpaz M) Leukemia 1998 Jun;12(6):860-4 PMID: 9639411 SCOPUS ID: 2-s2.0-0031833734 06/25/1998       51 Citations
  • Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. (Kurzrock R, Estrov Z, Kantarjian H, Talpaz M) J Clin Oncol 1998 Apr;16(4):1526-31 PMID: 9552062 SCOPUS ID: 2-s2.0-0031950324 04/29/1998       52 Citations
  • Interleukin-1 increases expression of the LYT-10 (NFkappaB2) proto-oncogene/transcription factor in renal cell carcinoma lines. (Kurzrock R, Estrov Z, Ku S, Leonard M, Talpaz M) J Lab Clin Med 1998 Mar;131(3):261-8 PMID: 9523851 SCOPUS ID: 2-s2.0-0032033413 04/02/1998       4 Citations
  • DNA in situ hybridization of individual colonies to determine lineage derivation in leukemia. (Kurzrock R, Talpaz M, Beran M, Harris D, Estrov Z) Leukemia 1998 Feb;12(2):242-6 PMID: 9519789 SCOPUS ID: 2-s2.0-0031885718 03/31/1998       3 Citations
  • Ki-lymphoma and interleukin-6. (Kubonishi I, Machida H, Miyoshi I) Ann Intern Med 1998 Mar 15;128(6):506-7 PMID: 9499341 SCOPUS ID: 2-s2.0-0032521043 03/14/1998    
  • Transient acantholytic dermatosis after treatment with 2-chlorodeoxyadenosine. (Cohen PR, Kurzrock R) Acta Derm Venereol 1997 Sep;77(5):412-3 PMID: 9298152 SCOPUS ID: 2-s2.0-0030885011 09/23/1997       7 Citations
  • Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. (Preti HA, Cabanillas F, Talpaz M, Tucker SL, Seymour JF, Kurzrock R) Ann Intern Med 1997 Aug 01;127(3):186-94 PMID: 9245223 SCOPUS ID: 2-s2.0-0030861218 08/01/1997       97 Citations
  • Interleukin-10 in non-Hodgkin's lymphoma. (Cortes J, Kurzrock R) Leuk Lymphoma 1997 Jul;26(3-4):251-9 PMID: 9322887 SCOPUS ID: 2-s2.0-0030866267 07/01/1997       71 Citations
  • The M.D. Anderson Cancer Center experience with interferon-alpha therapy in chronic myelogenous leukaemia. (Talpaz M, Kantarjian HM, O'Brien S, Kurzrock R) Baillieres Clin Haematol 1997 Jun;10(2):291-305 PMID: 9376665 SCOPUS ID: 2-s2.0-0030773978 06/01/1997       13 Citations
  • Suppressed formation of bone marrow adherent layers derived from acute myeloid leukemia patients after in vitro exposure to interleukin-4. (Wetzler M, Kurzrock R, Estrov Z, Barone S, Estey E, Talpaz M) Leuk Res 1997 Jun;21(6):519-27 PMID: 9279363 SCOPUS ID: 2-s2.0-0030929390 06/01/1997       2 Citations
  • Mucocutaneous paraneoplastic syndromes. (Cohen PR, Kurzrock R) Semin Oncol 1997 Jun;24(3):334-59 PMID: 9208889 SCOPUS ID: 2-s2.0-0030988771 06/01/1997       64 Citations
  • Second cancer risk in hairy cell leukemia: analysis of 350 patients. (Kurzrock R, Strom SS, Estey E, O'Brien S, Keating MJ, Jiang H, Adams T, Talpaz M) J Clin Oncol 1997 May;15(5):1803-10 PMID: 9164188 SCOPUS ID: 2-s2.0-0031004465 05/01/1997       106 Citations
  • Mycosis fungoides and total skin electron beam radiation. (Jones GW, Wilson LD) Blood 1997 Apr 15;89(8):3062-4 PMID: 9108429 SCOPUS ID: 2-s2.0-0030894799 04/15/1997       6 Citations
  • Apoptosis in chronic myelogenous leukemia: studies of stage-specific differences. (Gisslinger H, Kurzrock R, Wetzler M, Tucker S, Kantarjian H, Robertson B, Talpaz M) Leuk Lymphoma 1997 Mar;25(1-2):121-33 PMID: 9130620 SCOPUS ID: 2-s2.0-0030945972 03/01/1997       18 Citations
  • Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. (Younes A, Ayoub JP, Sarris A, Hagemeister F, North L, Pate O, McLaughlin P, Rodriguez MA, Romaguera J, Kurzrock R, Preti A, Bachier C, Smith T, Cabanillas F) Br J Haematol 1997 Feb;96(2):328-32 PMID: 9029021 SCOPUS ID: 2-s2.0-8044242947 02/01/1997       36 Citations
  • Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease. (Seymour JF, Talpaz M, Hagemeister FB, Cabanillas F, Kurzrock R) Am J Med 1997 Jan;102(1):21-8 PMID: 9209197 SCOPUS ID: 2-s2.0-0031046182 01/01/1997       75 Citations
  • Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up. (Seymour JF, Talpaz M, Kurzrock R) Leukemia 1997 Jan;11(1):42-7 PMID: 9001417 SCOPUS ID: 2-s2.0-0031052623 01/01/1997       61 Citations
  • Mycosis fungoides and Sezary syndrome. (Diamandidou E, Cohen PR, Kurzrock R) Blood 1996 Oct 01;88(7):2385-409 PMID: 8839829 SCOPUS ID: 2-s2.0-0029822176 10/01/1996       251 Citations
  • Molecular and biologic characterization of a newly established Philadelphia-positive acute lymphoblastic leukemia cell line (Z-33) with an autocrine response to GM-CSF. (Estrov Z, Talpaz M, Ku S, Harris D, LaPushin R, Koller CA, Hirsh-Ginsberg C, Huh Y, Yee G, Kurzrock R) Leukemia 1996 Sep;10(9):1534-43 PMID: 8751477 SCOPUS ID: 2-s2.0-9544248645 09/01/1996       17 Citations
  • Mucocutaneous paraneoplastic manifestations of hematologic malignancies. (Naschitz JE, Yeshurun D) Am J Med 1996 Aug;101(2):231-3 PMID: 8757366 SCOPUS ID: 2-s2.0-0029796259 08/01/1996       5 Citations
  • Combined modality therapy for cutaneous T-cell lymphoma. (Duvic M, Lemak NA, Redman JR, Eifel PJ, Tucker SL, Cabanillas FF, Kurzrock R) J Am Acad Dermatol 1996 Jun;34(6):1022-9 PMID: 8647968 SCOPUS ID: 2-s2.0-0029982190 06/01/1996       79 Citations
  • Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways. (Kellokumpu-Lehtinen P, Talpaz M, Harris D, Van Q, Kurzrock R, Estrov Z) Int J Cancer 1996 May 16;66(4):515-9 PMID: 8635867 SCOPUS ID: 2-s2.0-0029888789 05/16/1996       78 Citations
  • Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid. (Estey E, Thall PF, Mehta K, Rosenblum M, Brewer T Jr, Simmons V, Cabanillas F, Kurzrock R, Lopez-Berestein G) Blood 1996 May 01;87(9):3650-4 PMID: 8611689 SCOPUS ID: 2-s2.0-0029933428 05/01/1996       66 Citations
  • Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181). (Estrov Z, Talpaz M, Zipf TF, Kantarjian HM, Ku S, Ouspenskaia MV, Hirsch-Ginsberg C, Huh Y, Yee G, Kurzrock R) J Cell Physiol 1996 Mar;166(3):618-30 PMID: 8600166 SCOPUS ID: 2-s2.0-0030008056 03/01/1996       26 Citations
  • Interleukin-6: biologic properties and role in lymphoproliferative disorders. (Seymour JF, Kurzrock R) Cancer Treat Res 1996;84:167-206 PMID: 8724631 SCOPUS ID: 2-s2.0-0029704041 01/01/1996       9 Citations
  • Erratum: Combined modality therapy for cutaneous T-cell lymphoma (Journal of the American Academy of Dermatology (1996) 34 (1022-1029)) (Duvic M, Lemak NA, Redman JR, Eifel PJ, Tucker SL, Cabanillas FF, Kurzrock R) Journal of the American Academy of Dermatology 1996;35(4):587 SCOPUS ID: 2-s2.0-0030469567 01/01/1996       1 Citation
  • Presence of Epstein-Barr virus viral interleukin-10 in the serum of patients with non-human-immunodeficiency-virus-related diffuse large-cell non-Hodgkin's lymphomas. (Blay JY, Voorzanger N, Favrot M, Burdin N, Rousset F, Banchereau J) Blood 1995 Dec 15;86(12):4702-4 PMID: 8541566 SCOPUS ID: 2-s2.0-0028829021 12/15/1995       12 Citations
  • KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts. (Andersson BS, Collins VP, Kurzrock R, Larkin DW, Childs C, Ost A, Cork A, Trujillo JM, Freireich EJ, Siciliano MJ) Leukemia 1995 Dec;9(12):2100-8 PMID: 8609723 12/01/1995    
  • Cutaneous paraneoplastic syndromes in solid tumors. (Kurzrock R, Cohen PR) Am J Med 1995 Dec;99(6):662-71 PMID: 7503090 SCOPUS ID: 2-s2.0-0029590005 12/01/1995       147 Citations
  • Leukemia inhibitory factor binds to human breast cancer cells and stimulates their proliferation. (Estrov Z, Samal B, Lapushin R, Kellokumpu-Lehtinen P, Sahin AA, Kurzrock R, Talpaz M, Aggarwal BB) J Interferon Cytokine Res 1995 Oct;15(10):905-13 PMID: 8564713 SCOPUS ID: 2-s2.0-0028841064 10/01/1995       45 Citations
  • Interferon-alpha therapy for chronic myelogenous leukemia. (Wetzler M, Kantarjian H, Kurzrock R, Talpaz M) Am J Med 1995 Oct;99(4):402-11 PMID: 7573097 SCOPUS ID: 2-s2.0-0029087556 10/01/1995       52 Citations
  • Interleukin-1 and its inhibitors: a biologic and therapeutic model for the role of growth regulatory factors in leukemias. (Kurzrock R, Wetzler M, Estrov Z, Talpaz M) Cytokines Mol Ther 1995 Sep;1(3):177-84 PMID: 9384674 SCOPUS ID: 2-s2.0-0029360717 09/01/1995       10 Citations
  • Transformation of chronic lymphocytic leukemia to lymphoma of true histiocytic type. (Wetzler M, Kurzrock R, Goodacre AM, McLaughlin P, Ku S, Talpaz M) Cancer 1995 Aug 15;76(4):609-17 PMID: 8625154 SCOPUS ID: 2-s2.0-0029087226 08/15/1995       26 Citations
  • Mucocutaneous paraneoplastic manifestations of hematologic malignancies. (Kurzrock R, Cohen PR) Am J Med 1995 Aug;99(2):207-16 PMID: 7625426 SCOPUS ID: 2-s2.0-0029088354 08/01/1995       67 Citations
  • Cytokines and their antagonists in myeloid disorders. (Estrov Z, Kurzrock R, Talpaz M) Semin Hematol 1995 Jul;32(3):220-31 PMID: 7570065 SCOPUS ID: 2-s2.0-0029119048 07/01/1995       14 Citations
  • Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. (Estrov Z, Talpaz M, Mavligit G, Pazdur R, Harris D, Greenberg SM, Kurzrock R) Am J Med 1995 Jun;98(6):551-8 PMID: 7539977 SCOPUS ID: 2-s2.0-0029065219 06/01/1995       62 Citations
  • Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. (Seymour JF, Estey EH, Keating MJ, Kurzrock R) Leukemia 1995 May;9(5):929-32 PMID: 7769859 SCOPUS ID: 2-s2.0-0029041516 05/01/1995       52 Citations
  • Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. (Cortes JE, Talpaz M, Cabanillas F, Seymour JF, Kurzrock R) Blood 1995 May 01;85(9):2516-20 PMID: 7537119 SCOPUS ID: 2-s2.0-0028933071 05/01/1995       54 Citations
  • Cell cycle-related shifts in subcellular localization of BCR: association with mitotic chromosomes and with heterochromatin. (Wetzler M, Talpaz M, Yee G, Stass SA, Van Etten RA, Andreeff M, Goodacre AM, Kleine HD, Mahadevia RK, Kurzrock R) Proc Natl Acad Sci U S A 1995 Apr 11;92(8):3488-92 PMID: 7724587 PMCID: PMC42192 SCOPUS ID: 2-s2.0-0028944996 04/11/1995       22 Citations
  • Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. (Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R) J Clin Oncol 1995 Mar;13(3):575-82 PMID: 7884418 SCOPUS ID: 2-s2.0-0028986492 03/01/1995       142 Citations
  • Erythema gyratum repens. (Kurzrock R, Cohen PR) JAMA 1995 Feb 15;273(7):594 PMID: 7837395 SCOPUS ID: 2-s2.0-0028852607 02/15/1995       10 Citations
  • Classification and diagnosis of erythromelalgia. (Kurzrock R, Cohen PR) Int J Dermatol 1995 Feb;34(2):146-7 PMID: 7794397 SCOPUS ID: 2-s2.0-0029243745 02/01/1995       7 Citations
  • Abnormalities in the PRAD1 (CYCLIN D1/BCL-1) oncogene are frequent in cervical and vulvar squamous cell carcinoma cell lines. (Kurzrock R, Ku S, Talpaz M) Cancer 1995 Jan 15;75(2):584-90 PMID: 7812927 SCOPUS ID: 2-s2.0-0028814615 01/15/1995       56 Citations
  • Interleukin-1 and its inhibitors: implications for disease biology and therapy. (Estrov Z, Kurzrock R, Talpaz M) Cancer Treat Res 1995;80:51-82 PMID: 8821574 SCOPUS ID: 2-s2.0-0029433806 01/01/1995       8 Citations
  • Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia. (Wetzler M, Kurzrock R, Estrov Z, Estey E, Talpaz M) Leuk Res 1995 Jan;19(1):23-34 PMID: 7837815 SCOPUS ID: 2-s2.0-0028852652 01/01/1995       46 Citations
  • Muir-Torre syndrome. (Cohen PR, Kohn SR, Davis DA, Kurzrock R) Dermatol Clin 1995 Jan;13(1):79-89 PMID: 7712655 SCOPUS ID: 2-s2.0-0028804415 01/01/1995       85 Citations
  • Miscellaneous genodermatoses: Beckwith-Wiedemann syndrome, Birt-Hogg-Dube syndrome, familial atypical multiple mole melanoma syndrome, hereditary tylosis, incontinentia pigmenti, and supernumerary nipples. (Cohen PR, Kurzrock R) Dermatol Clin 1995 Jan;13(1):211-29 PMID: 7712645 SCOPUS ID: 2-s2.0-0028833585 01/01/1995       45 Citations
  • KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts (Andersson BS, Collins VP, Kurzrock R, Larkin DW, Childs C, Öst A, Cork A, Trujillo JM, Freireich EJ, Siciliano MJ, Deisseroth AB) Leukemia December 1995;9(12):2100-2108 SCOPUS ID: 2-s2.0-0029417028 01/01/1995       29 Citations
  • Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. (Wetzler M, Kurzrock R, Estrov Z, Kantarjian H, Gisslinger H, Underbrink MP, Talpaz M) Blood 1994 Nov 01;84(9):3142-7 PMID: 7949186 SCOPUS ID: 2-s2.0-0028172866 11/01/1994       51 Citations
  • Interleukin 4 alters human bone marrow stroma and modulates its interaction with hematopoietic progenitors. (Ferrajoli A, Talpaz M, Ordonez NG, Stanley ER, Hirsch-Ginsberg C, Zipf TF, Wetzler M, Kurzrock R, Estrov Z) Stem Cells 1994 Nov;12(6):638-49 PMID: 7533582 SCOPUS ID: 2-s2.0-0028148254 11/01/1994       6 Citations
  • Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. (Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R) J Clin Invest 1994 Oct;94(4):1383-9 PMID: 7929813 PMCID: PMC295262 SCOPUS ID: 2-s2.0-0028018343 10/01/1994       98 Citations
  • Financial concerns prompt sponsoring pharmaceutical company to halt international phase I studies. (Stoter G, Arnold AA, Kurzrock R, Rustin GJ) J Natl Cancer Inst 1994 Sep 07;86(17):1353 PMID: 8064897 SCOPUS ID: 2-s2.0-0028767603 09/07/1994    
  • 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. (O'Brien S, Kurzrock R, Duvic M, Kantarjian H, Stass S, Robertson LE, Estey E, Pierce S, Keating MJ) Blood 1994 Aug 01;84(3):733-8 PMID: 7913841 SCOPUS ID: 2-s2.0-0028272475 08/01/1994       66 Citations
  • 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. (Seymour JF, Kurzrock R, Freireich EJ, Estey EH) Blood 1994 May 15;83(10):2906-11 PMID: 7910051 SCOPUS ID: 2-s2.0-0028289425 05/15/1994       192 Citations
  • Leukemia inhibitory factor in long-term adherent layer cultures: increased levels of bioactive protein in leukemia and modulation by IL-4, IL-1 beta, and TNF-alpha. (Wetzler M, Estrov Z, Talpaz M, Kim KJ, Alphonso M, Srinivasan R, Kurzrock R) Cancer Res 1994 Apr 01;54(7):1837-42 PMID: 8137298 SCOPUS ID: 2-s2.0-0028329958 04/01/1994       36 Citations
  • Clinical manifestations of vasculitis in patients with solid tumors. A case report and review of the literature. (Kurzrock R, Cohen PR, Markowitz A) Arch Intern Med 1994 Feb 14;154(3):334-40 PMID: 8297201 SCOPUS ID: 2-s2.0-0028069683 02/14/1994       95 Citations
  • What is the contribution of molecular studies to the diagnosis of BCR-ABL-positive disease in adult acute leukemia? (Kantarjian H, Talpaz M, Estey E, Ku S, Kurzrock R) Am J Med 1994 Feb;96(2):133-8 PMID: 8109597 SCOPUS ID: 2-s2.0-0028322988 02/01/1994       15 Citations
  • Sweet syndrome in patients with solid tumors. (Cohen PR, Holder WR, Tucker SB, Kono S, Kurzrock R) Cancer 1993 Nov 01;72(9):2723-31 PMID: 8402496 SCOPUS ID: 2-s2.0-0027422070 11/01/1993       132 Citations
  • Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. (Wetzler M, Talpaz M, Van Etten RA, Hirsh-Ginsberg C, Beran M, Kurzrock R) J Clin Invest 1993 Oct;92(4):1925-39 PMID: 8408645 PMCID: PMC288359 SCOPUS ID: 2-s2.0-0027367245 10/01/1993       173 Citations
  • Granulocyte-macrophage colony-stimulating factor as a cause of paraneoplastic leukaemoid reaction in advanced transitional cell carcinoma. (Wetzler M, Estrov Z, Talpaz M, Markowitz A, Gutterman JU, Kurzrock R) J Intern Med 1993 Oct;234(4):417-20 PMID: 7691980 SCOPUS ID: 2-s2.0-0027504471 10/01/1993       39 Citations
  • Benign rheumatoid nodules in a woman with chronic lymphocytic leukaemia and borderline lepromatous leprosy. (Cohen PR, Kurzrock R) Ann Rheum Dis 1993 Sep;52(9):685-8 PMID: 8239765 PMCID: PMC1005148 SCOPUS ID: 2-s2.0-0027268354 09/01/1993       7 Citations
  • Hematopoietic growth factors (Marlton P, Kurzrock R) Drugs of Today 1993;29(3):189-199 SCOPUS ID: 2-s2.0-0027260311 08/02/1993    
  • Role of interleukin-1 inhibitory molecules in therapy of acute and chronic myelogenous leukemia. (Estrov Z, Kurzrock R, Talpaz M) Leuk Lymphoma 1993 Aug;10(6):407-18 PMID: 8401177 SCOPUS ID: 2-s2.0-0027239639 08/01/1993       18 Citations
  • Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. (Beran M, Pisa P, O'Brien S, Kurzrock R, Siciliano M, Cork A, Andersson BS, Kohli V, Kantarjian H) Cancer Res 1993 Aug 01;53(15):3603-10 PMID: 8339266 SCOPUS ID: 2-s2.0-0027169552 08/01/1993       60 Citations
  • Chronic myelogenous leukemia: a concise update. (Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M) Blood 1993 Aug 01;82(3):691-703 PMID: 8338938 SCOPUS ID: 2-s2.0-0027204137 08/01/1993       450 Citations
  • All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome. (Kurzrock R, Estey E, Talpaz M) J Clin Oncol 1993 Aug;11(8):1489-95 PMID: 8336187 SCOPUS ID: 2-s2.0-0027227770 08/01/1993       55 Citations
  • Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190BCR-ABL or p210BCR-ABL: determination by analysis of individual colonies with the polymerase chain reaction. (Estrov Z, Talpaz M, Kantarjian HM, Zipf TF, McClain KL, Kurzrock R) Cancer Res 1993 Jul 15;53(14):3289-93 PMID: 8324740 SCOPUS ID: 2-s2.0-0027160624 07/15/1993       14 Citations
  • Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. (Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, Talpaz M) Cancer Res 1993 May 01;53(9):2118-22 PMID: 8481913 SCOPUS ID: 2-s2.0-0027278569 05/01/1993       158 Citations
  • Analysis of the effects of tumor necrosis factor inhibitors on human hematopoiesis. (Ferrajoli A, Talpaz M, Kurzrock R, Estrov Z) Stem Cells 1993 Mar;11(2):112-9 PMID: 8384506 SCOPUS ID: 2-s2.0-0027513476 03/01/1993       16 Citations
  • Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines. (Estrov Z, Kurzrock R, Pocsik E, Pathak S, Kantarjian HM, Zipf TF, Harris D, Talpaz M, Aggarwal BB) J Exp Med 1993 Mar 01;177(3):763-74 PMID: 8382256 PMCID: PMC2190931 SCOPUS ID: 2-s2.0-0027500666 03/01/1993       77 Citations
  • Suppression of chronic myelogenous leukemia colony growth by interleukin-4. (Estrov Z, Markowitz AB, Kurzrock R, Wetzler M, Kantarjian HM, Ferrajoli A, Gutterman JU, Talpaz M) Leukemia 1993 Feb;7(2):214-20 PMID: 8426475 SCOPUS ID: 2-s2.0-0027407487 02/01/1993       17 Citations
  • Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage. (Kurzrock R, Kantarjian H, Wetzler M, Estrov Z, Estey E, Troutman-Worden K, Gutterman JU, Talpaz M) Exp Hematol 1993 Jan;21(1):80-5 PMID: 8417962 SCOPUS ID: 2-s2.0-0027894179 01/01/1993       30 Citations
  • Paraneoplastic erythromelalgia. (Kurzrock R, Cohen PR) Clin Dermatol 1993 Jan-Mar;11(1):73-82 PMID: 8339204 SCOPUS ID: 2-s2.0-0027197187 01/01/1993       15 Citations
  • Vasculitis and cancer. (Kurzrock R, Cohen PR) Clin Dermatol 1993 Jan-Mar;11(1):175-87 PMID: 8339194 SCOPUS ID: 2-s2.0-0027319465 01/01/1993       75 Citations
  • Tripe palms and cancer. (Cohen PR, Grossman ME, Silvers DN, Kurzrock R) Clin Dermatol 1993 Jan-Mar;11(1):165-73 PMID: 8339193 SCOPUS ID: 2-s2.0-0027254008 01/01/1993       48 Citations
  • Sweet's syndrome and cancer. (Cohen PR, Kurzrock R) Clin Dermatol 1993 Jan-Mar;11(1):149-57 PMID: 8339190 SCOPUS ID: 2-s2.0-0027281155 01/01/1993       164 Citations
  • CML: mechanisms of disease initiation and progression. (Wetzler M, Talpaz M, Estrov Z, Kurzrock R) Leuk Lymphoma 1993;11 Suppl 1:47-50 PMID: 8251916 SCOPUS ID: 2-s2.0-0027181263 01/01/1993       27 Citations
  • Commentary (Cohen PR, Kurzrock R) Clinics in Dermatology January 1993/March 1993;11(1):1 SCOPUS ID: 2-s2.0-44949269383 01/01/1993    
  • Growth factor inhibitory molecules: A novel therapy of leukaemia (Estrov Z, Kurzrock R, Talpaz M) Interferons and Cytokines 1993(24):22-25 SCOPUS ID: 2-s2.0-0027451132 01/01/1993    
  • Interruption of endogenous growth regulatory networks: A novel approach to inhibition of leukaemia cell proliferation (Estrov Z, Kurzrock R, Talpaz M) FORUM - Trends in Experimental and Clinical Medicine 1993;3(3):306-318 SCOPUS ID: 2-s2.0-0027304277 01/01/1993       6 Citations
  • The modulatory hematopoietic activities of leukemia inhibitory factor. (Estrov Z, Talpaz M, Wetzler M, Kurzrock R) Leuk Lymphoma 1992 Sep;8(1-2):1-7 PMID: 1493463 SCOPUS ID: 2-s2.0-0026699346 09/01/1992       2 Citations
  • Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction. (Dhingra K, Kurzrock R, Kantarjian H, Baine R, Eastman PS, Ku S, Gutterman JU, Talpaz M) Leukemia 1992 Aug;6(8):754-60 PMID: 1640725 SCOPUS ID: 2-s2.0-0026799311 08/01/1992       41 Citations
  • The effect of granulocyte-macrophage colony-stimulating factor on undifferentiated and mature acute myelogenous leukemia blast progenitors. (Estrov Z, Park CH, Reading CL, Estey EH, Talpaz M, Kurzrock R, Deisseroth AB, Gutterman JU) Exp Hematol 1992 Aug;20(7):886-90 PMID: 1628706 SCOPUS ID: 2-s2.0-0026697354 08/01/1992       4 Citations
  • Malignancy-associated tripe palms. (Cohen PR, Kurzrock R) J Am Acad Dermatol 1992 Aug;27(2 Pt 1):271-2 PMID: 1430373 SCOPUS ID: 2-s2.0-0026647517 08/01/1992       16 Citations
  • Extracutaneous manifestations of Sweet's syndrome: steroid-responsive culture-negative pulmonary lesions. (Cohen PR, Kurzrock R) Am Rev Respir Dis 1992 Jul;146(1):269 PMID: 1626811 SCOPUS ID: 2-s2.0-0026739301 07/01/1992       26 Citations
  • Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia. (Kurzrock R, Talpaz M, Gutterman JU) Am J Med 1992 Jul;93(1):41-8 PMID: 1626572 SCOPUS ID: 2-s2.0-0026704147 07/01/1992       29 Citations
  • Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia. (Estrov Z, Estey EH, Andreeff M, Talpaz M, Kurzrock R, Reading CL, Deisseroth AB, Gutterman JU) Exp Hematol 1992 Jun;20(5):558-64 PMID: 1587302 SCOPUS ID: 2-s2.0-0026770536 06/01/1992       16 Citations
  • Myelokathexis: normalization of neutrophil counts and morphology by GM-CSF. (Wetzler M, Talpaz M, Kellagher MJ, Gutterman JU, Kurzrock R) JAMA 1992 Apr 22-29;267(16):2179-80 PMID: 1556785 SCOPUS ID: 2-s2.0-0026506339 04/22/1992       36 Citations
  • Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. (Estrov Z, Kurzrock R, Estey E, Wetzler M, Ferrajoli A, Harris D, Blake M, Gutterman JU, Talpaz M) Blood 1992 Apr 15;79(8):1938-45 PMID: 1373331 SCOPUS ID: 2-s2.0-0026732573 04/15/1992       76 Citations
  • Interferon-stimulated genes in interferon-sensitive and -resistant chronic myelogenous leukemia patients. (Talpaz M, Chernajovsky Y, Troutman-Worden K, Wetzler M, Kantarjian H, Gutterman JU, Kurzrock R) Cancer Res 1992 Mar 01;52(5):1087-90 PMID: 1737366 SCOPUS ID: 2-s2.0-0026516533 03/01/1992       24 Citations
  • Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). (Estey EH, Kurzrock R, Kantarjian HM, O'Brien SM, McCredie KB, Beran M, Koller C, Keating MJ, Hirsch-Ginsberg C, Huh YO) Blood 1992 Feb 15;79(4):882-7 PMID: 1346577 SCOPUS ID: 2-s2.0-0026513828 02/15/1992       175 Citations
  • Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia. (Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU) Cancer 1992 Jan 15;69(2):410-2 PMID: 1370212 SCOPUS ID: 2-s2.0-0026542063 01/15/1992       27 Citations
  • The reply (Kurzrock R, Cohen PR) The American Journal of Medicine July 1992;93(1):112-114 SCOPUS ID: 2-s2.0-44049115926 01/01/1992       1 Citation
  • Granulocyte-macrophage colony-stimulating factor and interleukin-3 in combination: a potent and consistent myelodysplastic syndrome bone marrow stimulant in vitro. (Estrov Z, Kurzrock R, Talpaz M, Blake M, Gutterman JU) Ann Hematol 1991 Dec;63(6):297-301 PMID: 1756190 SCOPUS ID: 2-s2.0-0026411065 12/01/1991       12 Citations
  • A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia. (Talpaz M, Kurzrock R, Kantarjian H, Rothberg J, Saks S, Evans L, Gutterman JU) Cancer 1991 Nov 15;68(10):2125-30 PMID: 1913450 SCOPUS ID: 2-s2.0-0025992507 11/15/1991       22 Citations
  • Erythropoietin treatment in patients with myelodysplastic syndrome and anemia. (Kurzrock R, Talpaz M, Estey E, O'Brien S, Estrov Z, Gutterman JU) Leukemia 1991 Nov;5(11):985-90 PMID: 1961041 SCOPUS ID: 2-s2.0-0026410636 11/01/1991       42 Citations
  • Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. (Kantarjian HM, Talpaz M, Dhingra K, Estey E, Keating MJ, Ku S, Trujillo J, Huh Y, Stass S, Kurzrock R) Blood 1991 Nov 01;78(9):2411-8 PMID: 1932753 SCOPUS ID: 2-s2.0-0026005505 11/01/1991       129 Citations
  • Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression. (Wetzler M, Kurzrock R, Lowe DG, Kantarjian H, Gutterman JU, Talpaz M) Blood 1991 Nov 01;78(9):2400-6 PMID: 1932751 SCOPUS ID: 2-s2.0-0025935843 11/01/1991       65 Citations
  • Erythromelalgia: review of clinical characteristics and pathophysiology. (Kurzrock R, Cohen PR) Am J Med 1991 Oct;91(4):416-22 PMID: 1951386 SCOPUS ID: 2-s2.0-0025999435 10/01/1991       65 Citations
  • Interferon alpha in the therapy of CML. (Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU) Br J Haematol 1991 Oct;79 Suppl 1:38-41 PMID: 1931707 SCOPUS ID: 2-s2.0-0026051441 10/01/1991       13 Citations
  • The molecular pathology of chronic myelogenous leukaemia. (Kurzrock R, Talpaz M) Br J Haematol 1991 Oct;79 Suppl 1:34-7 PMID: 1931706 SCOPUS ID: 2-s2.0-0026091624 10/01/1991       14 Citations
  • Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. (Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M) Cancer 1991 Oct 01;68(7):1536-7 PMID: 1893353 SCOPUS ID: 2-s2.0-0026349435 10/01/1991       113 Citations
  • The pathogenesis of Sweet's syndrome. (Cohen PR, Kurzrock R) J Am Acad Dermatol 1991 Oct;25(4):734 PMID: 1724249 SCOPUS ID: 2-s2.0-0026001016 10/01/1991       36 Citations
  • Hairy cell leukaemia: review of treatment. (Kurzrock R, Talpaz M, Gutterman JU) Br J Haematol 1991 Oct;79 Suppl 1:17-20 PMID: 1718389 SCOPUS ID: 2-s2.0-0025937961 10/01/1991       25 Citations
  • Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity. (Estrov Z, Kurzrock R, Wetzler M, Kantarjian H, Blake M, Harris D, Gutterman JU, Talpaz M) Blood 1991 Sep 15;78(6):1476-84 PMID: 1715791 SCOPUS ID: 2-s2.0-0025946285 09/15/1991       86 Citations
  • Treatment of cyclic neutropenia with very low doses of GM-CSF. (Kurzrock R, Talpaz M, Gutterman JU) Am J Med 1991 Sep;91(3):317-8 PMID: 1892155 SCOPUS ID: 2-s2.0-0026005271 09/01/1991       12 Citations
  • LIF: not just a leukemia inhibitory factor. (Kurzrock R, Estrov Z, Wetzler M, Gutterman JU, Talpaz M) Endocr Rev 1991 Aug;12(3):208-17 PMID: 1935819 SCOPUS ID: 2-s2.0-0026095995 08/01/1991       86 Citations
  • 2-Chlorodeoxyadenosine: A new anticancer agent in lymphoid malignancies (Estey EH, Kurzrock R, Kantarjian HM, Koller CA, O'Brien S, Beran M, Keating MJ, McCredie K, Freireich EJ) Cancer Bulletin 1991;43(3):253-258 SCOPUS ID: 2-s2.0-0025895341 08/01/1991       4 Citations
  • Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. (Kurzrock R, Talpaz M, Estrov Z, Rosenblum MG, Gutterman JU) J Clin Oncol 1991 Jul;9(7):1241-50 PMID: 2045865 SCOPUS ID: 2-s2.0-0025765633 07/01/1991       122 Citations
  • Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of low- over high-dose administration in selected patients. (Kurzrock R, Talpaz M, Gomez JA, Estey EH, O'Brien S, Hirsch-Ginsberg C, Koller C, Freireich EJ, Gutterman JU) Br J Haematol 1991 Jul;78(3):352-8 PMID: 1873220 SCOPUS ID: 2-s2.0-0025910278 07/01/1991       30 Citations
  • Constitutive expression of leukemia inhibitory factor RNA by human bone marrow stromal cells and modulation by IL-1, TNF-alpha, and TGF-beta. (Wetzler M, Talpaz M, Lowe DG, Baiocchi G, Gutterman JU, Kurzrock R) Exp Hematol 1991 Jun;19(5):347-51 PMID: 1709108 SCOPUS ID: 2-s2.0-0025908024 06/01/1991       76 Citations
  • Association of sebaceous gland tumors and internal malignancy: the Muir-Torre syndrome. (Cohen PR, Kohn SR, Kurzrock R) Am J Med 1991 May;90(5):606-13 PMID: 2029018 SCOPUS ID: 2-s2.0-0025755503 05/01/1991       250 Citations
  • Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. (Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU) Ann Intern Med 1991 Apr 01;114(7):532-8 PMID: 2001086 SCOPUS ID: 2-s2.0-0025854383 04/01/1991       404 Citations
  • Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression. (Dhingra K, Talpaz M, Kantarjian H, Ku S, Rothberg J, Gutterman JU, Kurzrock R) Leukemia 1991 Mar;5(3):191-5 PMID: 2013978 SCOPUS ID: 2-s2.0-0025728842 03/01/1991       45 Citations
  • Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. (Estey EH, Kurzrock R, Talpaz M, McCredie KB, O'Brien S, Kantarjian HM, Keating MJ, Deisseroth AB, Gutterman JU) Br J Haematol 1991 Mar;77(3):291-5 PMID: 2012752 SCOPUS ID: 2-s2.0-0025804122 03/01/1991       72 Citations
  • Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies. (Baiocchi G, Kavanagh JJ, Talpaz M, Wharton JT, Gutterman JU, Kurzrock R) Cancer 1991 Feb 15;67(4):990-6 PMID: 1825026 SCOPUS ID: 2-s2.0-0026015914 02/15/1991       101 Citations
  • Synergistic antiproliferative effect of interferon alpha and azidothymidine in chronic myelogenous leukemia. (Estrov Z, Talpaz M, Chou TC, Kurzrock R, Blake M, Gutterman JU) Leukemia 1991 Feb;5(2):101-7 PMID: 2020193 SCOPUS ID: 2-s2.0-0026049469 02/01/1991       7 Citations
  • Hybridization protection assay: a rapid, sensitive, and specific method for detection of Philadelphia chromosome-positive leukemias. (Dhingra K, Talpaz M, Riggs MG, Eastman PS, Zipf T, Ku S, Kurzrock R) Blood 1991 Jan 15;77(2):238-42 PMID: 1985690 SCOPUS ID: 2-s2.0-0025975208 01/15/1991       19 Citations
  • Cytokines in tumor therapy. Interleukin-3. (Kurzrock R, Estrov Z, Talpaz M, Gutterman JU) Am J Clin Oncol 1991;14 Suppl 1:S45-50 PMID: 2048564 SCOPUS ID: 2-s2.0-0026038061 01/01/1991       8 Citations
  • Hematopoietic growth factors in bone marrow failure states (Kurzrock R, Talpaz M, Estey EH, Gutterman JU) Cancer Bulletin 1991;43(3):215-223 SCOPUS ID: 2-s2.0-0025785640 01/01/1991       1 Citation
  • A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. (Wetzler M, Talpaz M, Kleinerman ES, King A, Huh YO, Gutterman JU, Kurzrock R) Am J Med 1990 Nov;89(5):663-72 PMID: 2239986 SCOPUS ID: 2-s2.0-0025123316 11/01/1990       96 Citations
  • Constitutive and induced expression of growth factors in normal and chronic phase chronic myelogenous leukemia Ph1 bone marrow stroma. (Wetzler M, Kurzrock R, Taylor K, Spitzer G, Kantarjian H, Baiocchi G, Ku S, Gutterman JU, Talpaz M) Cancer Res 1990 Sep 15;50(18):5801-5 PMID: 2203522 SCOPUS ID: 2-s2.0-0025147259 09/15/1990       25 Citations
  • Necrotizing vasculitis at granulocyte-macrophage-colony-stimulating factor injection sites. (Farmer KL, Kurzrock R, Gutterman JU, Duvic M) Arch Dermatol 1990 Sep;126(9):1243-4 PMID: 2204310 SCOPUS ID: 2-s2.0-85047690973 09/01/1990       16 Citations
  • Treatment of Sweet's syndrome. (Cohen PR, Kurzrock R) Am J Med 1990 Sep;89(3):396 PMID: 2203266 SCOPUS ID: 2-s2.0-0025146611 09/01/1990       22 Citations
  • Effects of granulocyte-macrophage colony-stimulating factor in iatrogenic myelosuppression, bone marrow failure, and regulation of host defense. (Gutterman J, Vadhan-Raj S, Logothetis C, Anaissle E, Estey E, Talpaz M, Kurzrock R) Semin Hematol 1990 Jul;27(3 Suppl 3):15-24 PMID: 2198660 SCOPUS ID: 2-s2.0-0025324546 07/01/1990       6 Citations
  • Update on therapeutic options for chronic myelogenous leukemia. (Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU) Semin Hematol 1990 Jul;27(3 Suppl 4):31-6 PMID: 2197731 SCOPUS ID: 2-s2.0-0025306552 07/01/1990       26 Citations
  • Fludarabine therapy in macroglobulinemic lymphoma. (Kantarjian HM, Alexanian R, Koller CA, Kurzrock R, Keating MJ) Blood 1990 May 15;75(10):1928-31 PMID: 1692487 SCOPUS ID: 2-s2.0-0025337074 05/15/1990       86 Citations
  • Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. (Estey EH, Dixon D, Kantarjian HM, Keating MJ, McCredie K, Bodey GP, Kurzrock R, Talpaz M, Freireich EJ, Deisseroth AB) Blood 1990 May 01;75(9):1766-9 PMID: 2184901 SCOPUS ID: 2-s2.0-11944252114 05/01/1990       66 Citations
  • Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. (Kantarjian HM, Kurzrock R, Talpaz M) Hematol Oncol Clin North Am 1990 Apr;4(2):389-404 PMID: 2182598 SCOPUS ID: 2-s2.0-0025253450 04/01/1990       43 Citations
  • Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course. (Kurzrock R, Kantarjian HM, Shtalrid M, Gutterman JU, Talpaz M) Blood 1990 Jan 15;75(2):445-52 PMID: 2403827 SCOPUS ID: 2-s2.0-0025020514 01/15/1990       76 Citations
  • Alpha interferon dose-dependent suppression of secondary clones in a patient with Philadelphia-positive chronic myelogenous leukemia. (Claxton D, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU, Talpaz M) Acta Haematol 1990;83(3):149-51 PMID: 2109455 SCOPUS ID: 2-s2.0-0025270769 01/01/1990       5 Citations
  • Treatment of acute myelogenous leukemia with chemotherapy and hematopoietic growth factors (Estey E, McCredie K, Keating MJ, Kantarjian HM, Kurzrock R, Talpaz M, Gutterman JU, Deisseroth AB) Cancer Bulletin 1990;42(3):156-161 SCOPUS ID: 2-s2.0-0024999464 01/01/1990       3 Citations
  • Chronic myelogenous leukemia and Sweet syndrome. (Cohen PR, Kurzrock R) Am J Hematol 1989 Oct;32(2):134-7 PMID: 2667344 SCOPUS ID: 2-s2.0-0024465997 10/01/1989       38 Citations
  • Phase I study of a combination of recombinant tumor necrosis factor-alpha and recombinant interferon-gamma in cancer patients. (Kurzrock R, Feinberg B, Talpaz M, Saks S, Gutterman JU) J Interferon Res 1989 Aug;9(4):435-44 PMID: 2502584 SCOPUS ID: 2-s2.0-0024412808 08/01/1989       20 Citations
  • Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis. (Talpaz M, Kurzrock R, Kantarjian H, O'Brien S, Gutterman JU) Am J Med 1989 May;86(5):554-8 PMID: 2712063 SCOPUS ID: 2-s2.0-0024521978 05/01/1989       34 Citations
  • Tripe palms and malignancy. (Cohen PR, Grossman ME, Almeida L, Kurzrock R) J Clin Oncol 1989 May;7(5):669-78 PMID: 2651581 SCOPUS ID: 2-s2.0-0024541880 05/01/1989       75 Citations
  • Diagnosing the Sweet syndrome. (Cohen PR, Kurzrock R) Ann Intern Med 1989 Apr 01;110(7):573-4 PMID: 2923392 SCOPUS ID: 2-s2.0-0024655252 04/01/1989       28 Citations
  • Acute febrile neutrophilic dermatosis. (Cohen PR, Almeida L, Kurzrock R) Am Fam Physician 1989 Mar;39(3):199-204 PMID: 2646883 SCOPUS ID: 2-s2.0-0024635015 03/01/1989       38 Citations
  • Biological molecules in the treatment of hematological disorders. (Kurzrock R, Talpaz M, Gutterman U) Sangre (Barc) 1989 Feb;34(1):53-8 PMID: 2469130 SCOPUS ID: 2-s2.0-0024550830 02/01/1989    
  • Therapy of chronic myelogenous leukaemia with interferons. (Talpaz M, Kurzrock R, Kantarjian H, Gutterman J) Cancer Surv 1989;8(4):793-8 PMID: 2701727 SCOPUS ID: 2-s2.0-0024956532 01/01/1989       4 Citations
  • Erythromelalgia and myeloproliferative disorders. (Kurzrock R, Cohen PR) Arch Intern Med 1989 Jan;149(1):105-9 PMID: 2643412 SCOPUS ID: 2-s2.0-0024569963 01/01/1989       62 Citations
  • Clinical studies with interferons in Philadelphia positive chronic myelogenous leukemia. (Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU) Bone Marrow Transplant 1989 Jan;4 Suppl 1:63 PMID: 2496883 SCOPUS ID: 2-s2.0-0024594521 01/01/1989       3 Citations
  • Therapy of chronic myelogenous leukemia with interferon. (Kurzrock R, Gutterman JU, Kantarjian H, Talpaz M) Cancer Invest 1989;7(1):83-91 PMID: 2472193 SCOPUS ID: 2-s2.0-0024349580 01/01/1989       5 Citations
  • The Sweet syndrome and malignant degeneration (Cohen PR, Kurzrock R) Ars Medici 1989;79(9):468-469 SCOPUS ID: 2-s2.0-0024436630 01/01/1989    
  • Malignancy-associated Sweet's syndrome: review of the world literature. (Cohen PR, Talpaz M, Kurzrock R) J Clin Oncol 1988 Dec;6(12):1887-97 PMID: 3058878 SCOPUS ID: 2-s2.0-0024247486 12/01/1988       303 Citations
  • Significance and correlations of molecular analysis results in patients with Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. (Kantarjian HM, Shtalrid M, Kurzrock R, Blick M, Dalton WT, LeMaistre A, Stass SA, McCredie KB, Gutterman J, Freireich EJ) Am J Med 1988 Nov;85(5):639-44 PMID: 3189367 SCOPUS ID: 2-s2.0-0024204183 11/01/1988       40 Citations
  • The molecular genetics of Philadelphia chromosome-positive leukemias. (Kurzrock R, Gutterman JU, Talpaz M) N Engl J Med 1988 Oct 13;319(15):990-8 PMID: 3047582 SCOPUS ID: 2-s2.0-0023753576 10/13/1988       714 Citations
  • Herpes simplex virus infections and cimetidine therapy. (Cohen PR, Kurzrock R) J Am Acad Dermatol 1988 Oct;19(4):762-3 PMID: 3183099 SCOPUS ID: 2-s2.0-0023695844 10/01/1988       7 Citations
  • Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: molecular analysis, clinical characteristics, and response to therapy. (Shtalrid M, Talpaz M, Blick M, Romero P, Kantarjian H, Taylor K, Trujillo J, Schachner J, Gutterman JU, Kurzrock R) J Clin Oncol 1988 Oct;6(10):1569-75 PMID: 3171624 SCOPUS ID: 2-s2.0-0024262142 10/01/1988       41 Citations
  • Effect of differentiation-inducing agents on oncogene expression in a chronic myelogenous leukemia cell line. (Eisbruch A, Blick M, Evinger-Hodges MJ, Beran M, Andersson B, Gutterman JU, Kurzrock R) Cancer 1988 Sep 15;62(6):1171-8 PMID: 3044574 SCOPUS ID: 2-s2.0-0023772690 09/15/1988       30 Citations
  • Recombinant interferon gamma in hairy cell leukemia, multiple myeloma, and Waldenstrom's macroglobulinemia. (Quesada JR, Alexanian R, Kurzrock R, Barlogie B, Saks S, Gutterman JU) Am J Hematol 1988 Sep;29(1):1-4 PMID: 3140655 SCOPUS ID: 2-s2.0-0023788106 09/01/1988       53 Citations
  • A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. (Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, Gutterman JU) J Clin Oncol 1988 Aug;6(8):1328-34 PMID: 3411344 SCOPUS ID: 2-s2.0-0023684531 08/01/1988       207 Citations
  • Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia. (Shtalrid M, Talpaz M, Kurzrock R, Kantarjian H, Trujillo J, Gutterman J, Yoffe G, Blick M) Blood 1988 Aug;72(2):485-90 PMID: 3165294 SCOPUS ID: 2-s2.0-0023749490 08/01/1988       101 Citations
  • Historical communication: Philadelphia-positive chronic myelogenous leukemia followed for 27 years. (Nowell PC, Jackson L, Weiss A, Kurzrock R) Cancer Genet Cytogenet 1988 Aug;34(1):57-61 PMID: 3165050 SCOPUS ID: 2-s2.0-0023805294 08/01/1988       23 Citations
  • Fusion of the bcr and the c-abl genes in Ph'-positive acute lymphocytic leukemia with no rearrangement in the breakpoint cluster region. (ar-Rushdi A, Negrini M, Kurzrock R, Huebner K, Croce CM) Oncogene 1988 Apr;2(4):353-7 PMID: 3283653 SCOPUS ID: 2-s2.0-0023915281 04/01/1988       14 Citations
  • Recent advances in the therapy of chronic myelogenous leukemia. (Talpaz M, Kurzrock R, Kantarjian HM, Gutterman JU) Important Adv Oncol 1988:297-321 PMID: 3042607 SCOPUS ID: 2-s2.0-0023674055 01/01/1988       13 Citations
  • Therapy of chronic myelogenous leukemia: chemotherapy and interferons. (Talpaz M, Kantarjian HM, Kurzrock R, Gutterman J) Semin Hematol 1988 Jan;25(1):62-73 PMID: 2450402 SCOPUS ID: 2-s2.0-0023705016 01/01/1988       67 Citations
  • Expression of c-abl in Philadelphia-positive acute myelogenous leukemia. (Kurzrock R, Shtalrid M, Talpaz M, Kloetzer WS, Gutterman JU) Blood 1987 Nov;70(5):1584-8 PMID: 3311207 SCOPUS ID: 2-s2.0-0023568324 11/01/1987       67 Citations
  • Therapy of chronic myelogenous leukemia with recombinant interferon-gamma. (Kurzrock R, Talpaz M, Kantarjian H, Walters R, Saks S, Trujillo JM, Gutterman JU) Blood 1987 Oct;70(4):943-7 PMID: 3115339 SCOPUS ID: 2-s2.0-0023611741 10/01/1987       77 Citations
  • Molecular analysis of chromosome 22 breakpoints in adult Philadelphia-positive acute lymphoblastic leukaemia. (Kurzrock R, Shtalrid M, Gutterman JU, Koller CA, Walters R, Trujillo JM, Talpaz M) Br J Haematol 1987 Sep;67(1):55-9 PMID: 3478080 SCOPUS ID: 2-s2.0-0023175233 09/01/1987       27 Citations
  • Cimetidine therapy of herpes simplex virus infections in immunocompromised patients. (Kurzrock R, Auber M, Mavligit GM) Clin Exp Dermatol 1987 Sep;12(5):326-31 PMID: 3446417 SCOPUS ID: 2-s2.0-0023183346 09/01/1987       24 Citations
  • Molecular characteristics of chronic myelogenous leukemia in blast crisis. (Blick M, Romero P, Talpaz M, Kurzrock R, Shtalrid M, Andersson B, Trujillo J, Beran M, Gutterman J) Cancer Genet Cytogenet 1987 Aug;27(2):349-56 PMID: 3474057 SCOPUS ID: 2-s2.0-0023217510 08/01/1987       30 Citations
  • Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia. (Kurzrock R, Kloetzer WS, Talpaz M, Blick M, Walters R, Arlinghaus RB, Gutterman JU) Blood 1987 Jul;70(1):233-6 PMID: 2885048 SCOPUS ID: 2-s2.0-0023234119 07/01/1987       51 Citations
  • Sweet's syndrome and malignancy. (Cohen PR, Kurzrock R) Am J Med 1987 Jun;82(6):1220-6 PMID: 3300306 SCOPUS ID: 2-s2.0-0023615187 06/01/1987       170 Citations
  • Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia--a pilot study. (Talpaz M, Rosenblum M, Kurzrock R, Reuben J, Kantarjian H, Gutterman J) Am J Hematol 1987 Apr;24(4):341-50 PMID: 3494396 SCOPUS ID: 2-s2.0-0023235045 04/01/1987       38 Citations
  • Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients. (Maxwell SA, Kurzrock R, Parsons SJ, Talpaz M, Gallick GE, Kloetzer WS, Arlinghaus RB, Kouttab NM, Keating MJ, Gutterman JU) Cancer Res 1987 Mar 15;47(6):1731-9 PMID: 2434223 SCOPUS ID: 2-s2.0-0023159991 03/15/1987       55 Citations
  • A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. (Kurzrock R, Shtalrid M, Romero P, Kloetzer WS, Talpas M, Trujillo JM, Blick M, Beran M, Gutterman JU) Nature 1987 Feb 12-18;325(6105):631-5 PMID: 3543692 SCOPUS ID: 2-s2.0-0023142769 02/12/1987       222 Citations
  • Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma. (Quesada JR, Kurzrock R, Sherwin SA, Gutterman JU) J Biol Response Mod 1987 Feb;6(1):20-7 PMID: 3104544 SCOPUS ID: 2-s2.0-0023156669 02/01/1987       77 Citations
  • Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia. (Kantarjian HM, Talpaz M, Kurzrock R, Keating MJ, McCredie KB, Gutterman J, Freireich EJ) Acta Haematol 1987;78 Suppl 1:70-4 PMID: 2449026 SCOPUS ID: 2-s2.0-0023543204 01/01/1987       8 Citations
  • Tongue lesions in the acquired immunodeficiency syndrome (Cohen PR, Kurzrock R) Cutis 1987;40(5):406-409 SCOPUS ID: 2-s2.0-0023628043 01/01/1987       21 Citations
  • Phase I study of i.v. administered recombinant gamma interferon in cancer patients. (Kurzrock R, Quesada JR, Rosenblum MG, Sherwin SA, Gutterman JU) Cancer Treat Rep 1986 Dec;70(12):1357-64 PMID: 3098417 SCOPUS ID: 2-s2.0-0022869216 12/01/1986       34 Citations
  • Phase I study of a combination of recombinant interferon-alpha and recombinant interferon-gamma in cancer patients. (Kurzrock R, Rosenblum MG, Quesada JR, Sherwin SA, Itri LM, Gutterman JU) J Clin Oncol 1986 Nov;4(11):1677-83 PMID: 3095504 SCOPUS ID: 2-s2.0-0023039353 11/01/1986       41 Citations
  • Rearrangement in the breakpoint cluster region and the clinical course in Philadelphia-negative chronic myelogenous leukemia. (Kurzrock R, Blick MB, Talpaz M, Velasquez WS, Trujillo JM, Kouttab NM, Kloetzer WS, Arlinghaus RB, Gutterman JU) Ann Intern Med 1986 Nov;105(5):673-9 PMID: 3094418 SCOPUS ID: 2-s2.0-0023002211 11/01/1986       58 Citations
  • Recombinant gamma interferon induces hypertriglyceridemia and inhibits post-heparin lipase activity in cancer patients. (Kurzrock R, Rohde MF, Quesada JR, Gianturco SH, Bradley WA, Sherwin SA, Gutterman JU) J Exp Med 1986 Oct 01;164(4):1093-101 PMID: 3093625 PMCID: PMC2188434 SCOPUS ID: 2-s2.0-0022474215 10/01/1986       68 Citations
  • Trisomy 12 correlates with elevated expression of p21 ras in a human adenosquamous carcinoma of the lung. (Liang JC, Kurzrock R, Gutterman JU, Gallick GE) Cancer Genet Cytogenet 1986 Oct;23(2):183-8 PMID: 3530433 SCOPUS ID: 2-s2.0-0022796349 10/01/1986       29 Citations
  • Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant gamma-interferon. (Kleinerman ES, Kurzrock R, Wyatt D, Quesada JR, Gutterman JU, Fidler IJ) Cancer Res 1986 Oct;46(10):5401-5 PMID: 3093063 SCOPUS ID: 2-s2.0-0022493572 10/01/1986       94 Citations
  • Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. (Kurzrock R, Quesada JR, Talpaz M, Hersh EM, Reuben JM, Sherwin SA, Gutterman JU) J Clin Oncol 1986 Jul;4(7):1101-9 PMID: 3088221 SCOPUS ID: 2-s2.0-0022542594 07/01/1986       75 Citations
  • Differential expression of p21ras gene products among histological subtypes of fresh primary human lung tumors. (Kurzrock R, Gallick GE, Gutterman JU) Cancer Res 1986 Mar;46(3):1530-4 PMID: 3002619 SCOPUS ID: 2-s2.0-0022559250 03/01/1986       55 Citations
  • Clinical toxicity of interferons in cancer patients: a review. (Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU) J Clin Oncol 1986 Feb;4(2):234-43 PMID: 2418169 SCOPUS ID: 2-s2.0-0022590832 02/01/1986       564 Citations
  • Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. (Kurzrock R, Rosenblum MG, Sherwin SA, Rios A, Talpaz M, Quesada JR, Gutterman JU) Cancer Res 1985 Jun;45(6):2866-72 PMID: 3921249 SCOPUS ID: 2-s2.0-0021969122 06/01/1985       180 Citations
  • Expression of p21ras in fresh primary and metastatic human colorectal tumors. (Gallick GE, Kurzrock R, Kloetzer WS, Arlinghaus RB, Gutterman JU) Proc Natl Acad Sci U S A 1985 Mar;82(6):1795-9 PMID: 3885218 PMCID: PMC397359 SCOPUS ID: 2-s2.0-0021875192 03/01/1985       167 Citations
  • The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. (Kloetzer W, Kurzrock R, Smith L, Talpaz M, Spiller M, Gutterman J, Arlinghaus R) Virology 1985 Jan 30;140(2):230-8 PMID: 2982232 SCOPUS ID: 2-s2.0-0021926819 01/30/1985       139 Citations
  • Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients (Kurzrock R, Rosenblum MG, Sherwin SA, Rios A, Talpaz M, Quesada JR, Gutterman JU) Oncology (Switzerland) 1985;42:41-50 SCOPUS ID: 2-s2.0-0022357537 01/01/1985       10 Citations
  • Expression of p21(ras) in fresh primary human lung tumors (Kurzrock R, Gallick G, Gutterman J) Proceedings of the American Association for Cancer Research 1985;VOL. 26 SCOPUS ID: 2-s2.0-0021808921 01/01/1985    
  • Phase II evaluation of PALA in patients with refractory metastatic sarcomas. (Kurzrock R, Yap BS, Plager C, Papdopoulos N, Benjamin RS, Valdivieso M, Bodey GP) Am J Clin Oncol 1984 Aug;7(4):305-7 PMID: 6741860 SCOPUS ID: 2-s2.0-0021238251 08/01/1984       9 Citations
  • Mycobacterial pulmonary infections after allogeneic bone marrow transplantation. (Kurzrock R, Zander A, Vellekoop L, Kanojia M, Luna M, Dicke K) Am J Med 1984 Jul;77(1):35-40 PMID: 6430082 SCOPUS ID: 2-s2.0-0021252125 07/01/1984       56 Citations
  • Obstructive lung disease after allogeneic bone marrow transplantation. (Kurzrock R, Zander A, Kanojia M, Vellekoop L, Spitzer G, Jagannath S, Schell S, Peters L, Dicke K) Transplantation 1984 Feb;37(2):156-60 PMID: 6364498 SCOPUS ID: 2-s2.0-0021322372 02/01/1984       25 Citations
  • Last update: 06/10/2022